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Zinc is a ubiquitous heavy metal that binds to proteins involved in critical cellular 
processes.  Apart from its necessary role, excessive release of intracellular free zinc 
(Zn2+) is neurotoxic under stressed conditions characteristic of ischemic or epileptic 
neuronal injury.   
Our earlier results indicated that Zn2+-induced cell death is exacerbated in neurons 
compared to supporting neuroglia, suggesting that astrocytes have means to upregulate 
Zn2+ buffering mechanisms, i.e. the Zn2+-binding protein metallothionein (MT).  The first 
aim of this dissertation sought to address whether MT can effectively maintain Zn2+ 
levels at a non-toxic minimum.  From these studies, we have identified a dichotomous 
role for MT – protective as a Zn2+ buffering agent and detrimental as an oxidant-labile 
source for toxic Zn2+. 
Previous studies demonstrated the role of Zn2+ as a mitochondrial toxin.  
Although it has been widely speculated that Zn2+ is taken up by the mitochondrial 
calcium uniporter, the evidence is not entirely convincing.  In the second specific aim, we 
addressed the specific hypothesis that mitochondrial Zn2+ uptake occurs though the  
 
 
 
                                                                                                     Ian J. Reynolds, Ph.D. 
 iv
 
uniporter.  Using a novel model involving isolated mitochondria pre-incubated with a 
Zn2+-selective fluorophore and attached to glass coverslips, we demonstrated for the first 
time direct visualization of mitochondrial Zn2+ transport.   
The third specific aim addresses the importance of mitochondria as dynamic 
intracellular ATP factories, whose intracellular trafficking is critical for neuronal 
viability.  We hypothesized that elevated Zn2+ would attenuate mitochondrial trafficking.  
Our results revealed that Zn2+ inhibited mitochondrial movement at pathophysiological 
levels.  Intriguingly, acute activation of phosphotidyl inositol 3- kinase was implicated in 
both Zn2+-mediated movement inhibition and toxicity, providing a novel role for this 
traditionally pro-survival signaling pathway. 
In summary, this dissertation identifies intracellular targets for Zn2+-mediated 
neurotoxicity.  We specifically emphasize the relevance of mitochondria as a Zn2+ target 
under two circumstances which are critically dependent on the Zn2+ concentrations 
established – direct mitochondrial interactions that may involve Zn2+ transport, and 
indirect mitochondrial interactions that affect intracellular mitochondrial trafficking.  
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 Chapter 1.  Introduction 
1.1 Preface 
Zinc is a heavy metal common to all tissues of the human body and is relevant as 
a nutritional requirement.  A large body of evidence attests to the critical role of zinc in 
the human diet, and zinc deficiency is associated with numerous pathologies, including 
cognitive dysfunction.  More recently however zinc has been studied because of its 
neurotoxic potential.  This perspective stands apart from traditional zinc biology, because 
it concerns the disruption of zinc homeostasis already present in the body, as opposed to 
zinc-related disorders that have as their root cause a nutritional excess or deficiency.  
Thus, the main focus of this dissertation concerns the neurotoxic properties of zinc. 
The introduction begins with a description of zinc in a neurophysiologic context: 
where it is found, what are the suspected functions, and how it is detected (Section 1.2).  
We then discuss the distribution (Section 1.2.1) and methods of measuring (Section 1.2.2) 
the three distinct pools of zinc in the brain.  Zinc is an essential component in zinc-
requiring proteins and enzymes (Section 1.2.3) and has been described as a 
neuromodulator of synaptic transmission (Sections 1.2.4. and 1.2.5).  Since intracellular 
zinc concentrations are so tightly and precisely regulated, the cell contains inherent 
homeostatic mechanisms to maintain the free zinc concentrations within cells, including 
the metallothionein family of zinc-binding proteins (Section 1.3.1) and the family of 
membrane-bound zinc transporters (Section 1.3.2).  In considering the different 
mechanisms for mobilization of intracellular free zinc, we re-explore the “zinc 
translocation hypothesis” (Section 1.4.1), which was once considered the primary 
mechanism for zinc mobilization between neurons inherent for proper cell-cell 
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 communication, but also which may exacerbate neuronal injury.  With emerging 
evidence against the zinc translocation hypothesis, we then discuss recent theories for 
zinc mobilization within cells in strong oxidizing environments (Section 1.4.2), which 
may contribute more importantly to zinc-mediated neurotoxicity compared to excessive 
zinc influx.  With respect to disease states, pathogenic roles for zinc have been proposed 
in the mechanisms of several pertinent neurodegenerative disorders (Sections 1.5.1-
1.5.6).  At the more cellular level, we discuss proposed mechanisms for zinc-mediated 
toxicity that may contribute to the overall neuropathogenesis (Sections 1.6.1-1.6.5).   
The introduction concludes with a general overview of the dissertation (Section 
1.7), describing each specific aim and the global conclusions reached in asking specific 
questions related to (1) determining the role of metallothionein as an intracellular zinc 
buffer under toxic conditions, (2) investigating the mechanisms of mitochondrial zinc 
transport during injury, and (3) exploring the mechanisms for zinc-mediated inhibition of 
mitochondrial trafficking.  Given the extensive literature on zinc-induced injury, this 
introduction will mostly concentrate on the existing evidence for the pathological role for 
zinc in the brain, whereas the more controversial topic of zinc actions on mitochondria 
and the more novel topics of mitochondrial trafficking and zinc-mediated cellular 
signaling pathways will be reserved for the discussion of the dissertation.                   
1.2 Physiological zinc in the nervous system 
In the brain, zinc is among the twenty most abundant elements and is second only 
to iron among the transition elements.  Bound to several proteins and enzymes, neural 
zinc is necessary for regulation of critical cellular processes and functions.  Nutritional 
zinc deficiency is documented to cause teratogenic and CNS disturbances in animals 
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 (O'Dell, 1993; Sandstead, 1994), specifically by reducing synaptic activity (Wensink et 
al., 1987) and causing hippocampal dysfunction (Hesse, 1979) upon chronic zinc 
deficiency.  Traditionally designated as a trace element, it was difficult to ascertain a 
significant and more precise concentration of zinc in the brain.  This is not reflected by its 
description as a “trace” element, but because available detection techniques 
underestimated physiological concentrations of zinc in the brain.  Newer generation 
methods for detecting neural zinc are now more sensitive and are capable of staining 
brain zinc pools that were previously inaccessible to dyes.  Indeed, estimated 
concentrations of total brain zinc far exceed that of classic neurotransmitters (10-100 
times higher) and neuropeptides (103 – 104 times higher) (Frederickson, 1989).  This 
emphasizes the pertinent role of zinc in the brain, and suggests its involvement in many 
critical cell functions. 
1.2.1 Neural zinc distribution 
The brain contains heterogeneous zinc distributions.  Evidence from the literature 
suggests that there are three disparate pools of zinc in the central nervous system: 
vesicular zinc, protein-bound zinc, and free ionic zinc.  Each of these pools of zinc will 
be separately discussed below in decreasing order of magnitude. 
Protein-bound zinc 
The majority of intracellular zinc is bound tightly to proteins and zinc-containing 
enzymes.  Zinc ions are thought to be incorporated into these proteins at the time of 
synthesis where they remain, with minimal transfer of zinc ions at a later point 
(Frederickson, 1989).  Therefore, the pool of protein-bound zinc is relatively stable and 
may only be involved in the specific function of the zinc-containing enzyme.  However, 
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 since protein-bound zinc accounts for nearly 85-95% of zinc in the brain, the array of 
zinc binding proteins is from a quantitative standpoint the most important in terms of 
regulating zinc levels in neural cells. 
Vesicular zinc 
 A special class of zinc-containing neurons, localized almost exclusively in the 
forebrain, sequesters zinc into presynaptic vesicles in some glutamatergic neurons.  
Within these presynaptic vesicles, ionic zinc is packaged along with glutamate at zinc 
concentrations estimated to be in excess of 1 mM (Frederickson et al., 1989).  The 
vesicles are accessible to zinc-specific permeable dyes and staining methods, and 
therefore the zinc residing within them can be histochemically stained (Szerdahelyi and 
Kasa, 1984; Frederickson, 1989).  Neurobiologists have been particularly interested in 
vesicular zinc because it is mobilized during synaptic activity.  Upon synaptic 
stimulation, the zinc is released along with glutamate, and traverses the synaptic cleft 
where it may have some impact on neurotransmission at the postsynaptic membrane 
(Choi and Koh, 1998).  Indeed much evidence suggests that this specific pool of zinc may 
affect the activities of several neurotransmitter receptors.  While it may have relevant 
consequences on neuronal function, vesicular zinc comprises scarcely 15% of total brain 
zinc (Frederickson, 1989).  In addition, it must be emphasized that the zinc-containing 
neuron is only a select subset of glutamatergic neurons and not all forebrain neurons 
contain histochemically-reactive zinc.  Apart from neuromodulatory activity, a second 
explanation for the function of vesicular zinc may involve a role in stabilizing stored 
glutamate and retaining the neurotransmitter within vesicles (Frederickson, 1989).  
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 However, the observation that not all glutamatergic neurons contain Zn2+ excludes this 
explanation.   
Free ionic zinc 
 Given the large number of intracellular zinc binding sites, intracellular free zinc 
([Zn2+]i ) is very small.  Limitations in detecting [Zn2+]i have made it particularly difficult 
to study Zn2+ dynamics in cells, but it is estimated that under normal conditions [Zn2+]i is 
roughly femtomolar to picomolar concentrations.  In fact, O’Halloran contends that there 
is no free zinc in the cell (Outten and O'Halloran, 2001).  It is conceivable that [Zn2+]i 
rises and declines as zinc is mobilized between storage sites, metal chaperones, and zinc-
requiring proteins.  [Zn2+]i may have functions similar to Ca2+ in that acute zinc pulses 
could also act as intra- and intercellular signals (Frederickson, 1989).  While the amount 
and function of this pool of zinc is still speculative, it is clear that relatively small 
increases in the amount of [Zn2+]i are lethal to neurons. 
1.2.2 Detecting neural zinc 
As mentioned above, the study of physiological zinc in the brain is limited by 
difficulties in measuring cellular zinc.  This is perhaps not surprising, given that most 
zinc is tightly bound to and perhaps masked by proteins.  Additionally, zinc biologists 
must face the obstacles that (1) the traditional detection techniques used to stain large and 
complex proteins cannot be applied for the zinc ion and (2) zinc is a common element 
that is found everywhere and therefore, contamination must be carefully avoided 
(Frederickson, 1989).  The method for detecting zinc in the brain depends on the nature 
of the sample, i.e. different techniques are applied for whole tissue vs. cells.  The 
differences in these procedures will be discussed below. 
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 In whole brain tissue 
 Wet human brain tissue contains approximately 10 µg/g of zinc, and total 
intracellular zinc is approximated at 150 µM (Wallwork, 1987; Frederickson, 1989).  
However, zinc in interstitial fluid contributes to the quantities detected in wet tissue and 
makes it difficult to precisely determine intracellular total zinc content (Frederickson, 
1989).  Investigating zinc distribution in the human central nervous system per weight of 
dry tissue (denoted in ppm; parts per million), cortical gray matter (69-82 ppm) typically 
contains more zinc than cortical white matter (33 ppm) (Smeyers-Verbeke and 
Verbeelen, 1985).  The highest concentrations of zinc were found in the hippocampus 
(108 ppm), with lower amounts (76 ppm) in the cerebellum (Frederickson, 1989).  Zinc 
contribution to tissue fluid may explain the large difference between white and gray 
matter, given that white matter has a lower extracellular fluid volume.  If so, zinc in the 
extracellular fluid would account for the ~2.5-fold difference (Frederickson, 1989).  
Factors that commonly contribute to analytical error may include loss of sample during 
its processing, zinc precipitation or fluid evaporation from samples.  Also, zinc can 
quickly bind glass and plastic surfaces of containers holding the sample (Frederickson, 
1989).  Such technical problems must be considered when quantifying precise zinc 
concentrations from whole brain tissue poses. 
In brain slices 
 In spite of quantitative limitations, qualitative data of zinc staining in brain 
sections gives some picture of regional zinc distribution in the brain.  Apparently the pool 
of zinc that is histochemically reactive, or most readily stained, is located in specific 
presynaptic zinc-containing neurons of the CNS.  This pool of zinc is not bound to 
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 proteins and is also highly concentrated within relatively small vesicles, making it easier 
to detect this stored pool compared to the much smaller Zn2+ pool that may transiently 
exist in the cytoplasm.   
 Early evidence for stored Zn2+ was observed when the colorimetric zinc-binding 
reagent dithizone was injected intraperitoneally, producing bright red staining in the rat 
hippocampus (Frederickson et al., 1981).  This suggested that histochemically-accessible 
Zn2+ is abundant in specific CNS neurons in situ.   Limitations of dithizone include 
contamination of signal by trace amounts of copper, weak signals (unless zinc is very 
high) and susceptibility to degradation upon light exposure (Choi and Koh, 1998).  
Therefore, although dithizone is sufficient for gross staining in brain regions where Zn2+ 
is heavily concentrated, it is not useful for detailed detection of [Zn2+]i.   
Other methods corroborated that stored Zn2+ was localized to presynaptic vesicles 
of a subset of CNS neurons.  The silver amplification method of Timm demonstrated 
metal precipitation in situ by forming metallic silver shells around weakly-bound metal in 
postmortem histologic brain sections (Frederickson, 1989).  Refined variants of the Timm 
method are used for selective detection of transition metals, such as copper, iron and zinc.  
The more recent utilized Timm-Danscher method specifically stains presynaptic vesicles 
of zinc-containing neurons in the mammalian CNS (Danscher, 1981; Danscher et al., 
1985).  The Zn2+ staining in presynaptic vesicles was confirmed by a second labeling 
method using 6-methoxy-8-quinolyl-p-toluenesulfonamide (TSQ), which brightly 
fluoresces when in complex with Zn2+.  This probe effectively traverses both the plasma 
and vesicular membranes where it can come into direct contact with Zn2+.  The 
observation that no fluorescence is produced when TSQ is in complex with other 
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 transition metals suggests that this indicator is selective for vesicular Zn2+ (Frederickson 
et al., 1987).  The combination of both silver amplification and fluorescent labeling 
further confirms the presence of this Zn2+ pool that may have important consequences for 
synaptic transmission.  TSQ and its derivatives (Zinquin and TFL-Zn) penetrate readily 
into synaptic vesicles and bind Zn2+ very well (Kd ~ nM) but do not remain within 
vesicles (Snitsarev et al., 2001), and therefore, may not be entirely useful apart from a 
qualitative standpoint.  The newer generation of fluorescent Zn2+ probes, Zinpyr-1 and its 
derivatives are more stable under physiological conditions, remain within vesicles and 
their fluorescence upon Zn2+ binding can be resolved in acute brain slices using standard 
confocal imaging (Burdette et al., 2001).  However, since Zinpyr-1 has low nanomolar 
affinity for Zn2+ and vesicles are estimated to contain millimolar levels of Zn2+, Zinpyr-1 
may not be the ideal indicator for detecting vesicular Zn2+.    
In cells   
 [Zn2+]i is detected with a variety of membrane-permeant fluorescent indicators.  
These indicators get trapped inside the cell where they can be used to monitor Zn2+ 
changes in living cells.  These include single wavelength excitation probes, such as 
Newport Green or FluoZin-3, or dual wavelength dyes, such as mag-fura-2 or FuraZin-1, 
which facilitate Zn2+ detection through ratiometric imaging compared to the former two.  
It is difficult to accurately convert fluorescence signals to actual [Zn2+]i values here 
because such calculations previously used in ratiometric imaging may be misleading 
(Dineley et al., 2002).  However, these probes do provide a semi-quantitative method to 
detect timing and magnitude of Zn2+ fluxes within neurons.  In addition, the membrane-
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 impermeant forms of these dyes are routinely used to detect extracellular Zn2+ that is 
released from presynaptic terminals (Li et al., 2001). 
 Tracking the migration of zinc within the cell can be difficult, given that cytosolic 
concentrations are putatively small and tightly regulated.  Recently, Sastry and Lastoskie 
(2004) used computer-based cellular models to predict how biosensors can be used to 
detect metals such as copper and zinc by determining the optimal placement of 
biosensors within the complex and heterogeneous cellular environment.  Biosensors are 
becoming more sophisticated tools for measuring both [Zn2+]i and extracellular Zn2+ 
release.  For the former, Pearce and colleagues (2000) developed a FRET-based construct 
to detect [Zn2+]i, whereby a conformational change in the construct indicates rapid and 
selective release of Zn2+ from metallothionein.  More recently, Hara and Aizenman 
(2004) demonstrated that a metal response element (MRE)-driven luciferase reporter 
gene can be used for detecting increases in intracellular Zn2+ concentrations in cultured 
neurons.  For detecting Zn2+ release from vesicles, Thompson and colleagues (2000) used 
the protein apocarbonic anhydrase (apoCA) tagged with a fluorescent indicator that 
increases in fluorescence when apoCA binds to Zn2+.  These probes, with the exception 
of the MRE-driven luciferase construct, allow real-time visualization of Zn2+ in living 
cells.   
1.2.3 Zinc requirements for protein and enzyme function 
 Zinc interacts with proteins in three conformations: zinc-containing proteins (also 
including zinc-containing enzymes), zinc-regulated proteins, and zinc-protein complexes.  
In each of these categories, the zinc ion plays a distinct role.  The zinc-containing 
proteins include metalloenzymes such as polymerases found in the nucleus, electron 
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 transport enzymes in the mitochondria, and phospholipases associated with the cell 
membrane (Frederickson, 1989).   These metalloenzymes bind zinc very stably and 
presumably would allow very little zinc exchange.  Evidence indicates that because of 
their firm stability, zinc metalloenzymes are relatively unaffected by acute changes in 
[Zn2+]i.  However, there is some evidence that high affinity metal chelators can affect 
zinc metalloenzyme stability by disrupting coordination of the zinc ions (Vallee and 
Galdes, 1984). 
 Zinc-containing proteins also include those in which zinc has a non-catalytic role, 
for example in stabilizing DNA or RNA structure (Vallee, 1988).  In addition, 1% of the 
human genome is estimated to encode for zinc finger proteins.  The observation that 
many of these zinc finger proteins are highly conserved implies that zinc plays a global 
role in control of gene expression in tissues where these proteins are expressed (Berg, 
1988).  Apart from playing structural roles, the zinc-containing protein can also play a 
scavenging role in the brain.  For example, the tripeptide protein glutathione is an 
important zinc-binding molecule in certain brain regions, such as the hippocampus and 
cerebellum.  Approximately 5-10% of total zinc in the brain is estimated to be associated 
with glutathione (Sato et al., 1984).  The observation that levels of zinc-glutathione 
complexes are region-specific and variable implies that glutathione may regulate zinc 
levels in areas where required. 
 Unlike zinc-containing proteins, zinc-regulated proteins have been demonstrated 
to change shape and activity in the presence of cytoplasm zinc.  For example, it has been 
reported in vitro that tubulin binds zinc with high affinity (Gaskin et al., 1978; Kress et 
al., 1981).  The bound zinc ions affect tubulin phosphorylation, whereby low zinc-tubulin 
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 association facilitates microtubule assembly, and high zinc-tubulin association deters 
microtubule assembly (Haskins et al., 1980; Hesketh, 1984a, b).  In addition to tubulin, 
there are reports of over a dozen enzymes shown to be activated (Parisi and Vallee, 1969) 
or inhibited (Zaslavsky, 1979; White et al., 1986) by zinc in vitro. 
 Like zinc-regulated proteins, the zinc–protein complex includes any protein 
loosely aggregated with zinc ions, where the metal is neither tightly nor 
stoichiometrically coordinated with the protein (Frederickson, 1989).  Examples of this 
include zinc-insulin (Gold and Grodsky, 1984) complexes, which may act as important 
storage complexes for CNS zinc. 
1.2.4 Zinc modulation of synaptic transmission 
With the observation that certain neurons can sequester zinc into synaptic 
vesicles, initial studies sought to determine the mechanism of zinc release.  Zinc release 
was detected in brain slices stimulated by depolarization with high K+ buffer, kainate 
(Assaf and Chung, 1984) or electrical stimulation (Howell et al., 1984).  This zinc release 
was determined to be calcium-dependent, strengthening the physiological relevance of 
the phenomenon.  Several lines of evidence suggest that once released zinc behaves as a 
neurotransmitter by acting on and modulating various ion channels and classic 
neurotransmitter receptors on the postsynaptic membrane.  The effects of Zn2+ on 
synaptic neurotransmission has been investigated with several approaches, for example 
by adding exogenous Zn2+ to cultured neurons and brain slices, chelating endogenous 
Zn2+ to understand the consequences of [Zn2+]i  release, or using knockout animals to 
interfere with physiological Zn2+ signaling pathways (Smart et al., 2004).  These 
approaches and their findings will be discussed in detail below.         
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 Glutamate receptors 
 Since zinc is co-localized and released with glutamate in a subpopulation of 
glutamatergic neurons, it is plausible that zinc is also a modulator of glutamate receptors.  
Indeed, evidence suggests that Zn2+ elicits subunit-dependent regulation of NMDA 
receptors, specifically that Zn2+ concentrations as low as several nanomolar can inhibit 
NMDA receptors (Smart et al., 1994; Paoletti et al., 2000).  This indicates that Zn2+ 
inhibits excitatory postsynaptic potentials (EPSPs) mediated by NMDA receptors.  Early 
evidence for EPSP inhibition by zinc was demonstrated by applying micromolar Zn2+ 
concentrations to cortical brain slices (Smart and Constanti, 1983).  Moreover, this 
inhibitory effect was prevented by Zn2+ chelation with TPEN (Ueno et al., 2002).  More 
recently, a low-affinity, modulatory Zn2+ binding site on the NMDA receptor subunit 
NR2B has been identified and raises the possibility that Zn2+ may mediate a 
concentration- and subunit-dependent inhibition of excitatory synaptic activity (Rachline 
et al., 2005).  On the other hand, low millimolar concentrations of Zn2+ significantly 
increased AMPA binding to its receptor and also potentiated whole cell current responses 
to AMPA in a concentration-dependent manner (Bresink et al., 1996), implying that Zn2+ 
may also modulate AMPA receptor properties.  
GABA receptors 
 Endogenous Zn2+ has also been shown to regulate many aspects of GABAergic 
synaptic activity.  Specifically, Xie and Smart (1991) demonstrated in adult hippocampal 
slices the ability of Zn2+ through interaction with GABAA receptors to increase GABA 
neurotransmitter release from presynaptic vesicles, thereby causing large depolarizing 
potentials.  In later studies, Zhou and Hablitz (1993) demonstrated that low micromolar 
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 applications of Zn2+ induced spontaneous large-amplitude inhibitory presynaptic 
potentials (IPSPs) mediated via GABA receptor activity.  Together, this suggested that 
Zn2+ released from presynaptic nerve terminals may facilitate GABA release and 
subsequent induction of GABA receptor-mediated potentiation of IPSPs. 
Glycine receptors 
 Zn2+ is thought to modulate glycine receptor activity in a concentration-dependent 
fashion.  Very low Zn2+ concentrations enhance glycine receptor activity by competing 
and displacing glycine from its receptor (Laube et al., 2000; Suwa et al., 2001). Higher 
concentrations of Zn2+ inhibit glycine receptor function (Bloomenthal et al., 1994; Laube 
et al., 1995), implying a concentration-dependent modulation of receptor activity.  It was 
recently demonstrated that Zn2+ mediates subtype selective inhibition of glycine transport 
by glycine transporter subtype 1b (Ju et al., 2004).   
 In summary, Zn2+ has been shown to modulate synaptic neurotransmission by 
both excitatory and inhibitory receptors at specific receptors in the nervous system.  
Given that histochemically-reactive Zn2+ is present in a minority of synaptic terminals in 
the brain and spinal cord, what remains questionable is the precise role of this Zn2+ pool 
in modulating synaptic activity under physiological conditions and its consequences on 
postsynaptic function.  The latter will be discussed in subsequent sections with respect to 
pathophysiological levels of [Zn2+]i .      
1.2.5 Zinc modulation of synaptic transmission 
 As mentioned above, zinc may be an important modulator of the NMDA subtype 
of glutamate receptors.  A recent study demonstrated that Zn2+ release upon synaptic 
excitation can modulate NMDA receptor-mediated changes in neighboring synapses, 
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 suggesting a heterosynaptic action of zinc on NMDA receptors (Ueno et al., 2002).  Since 
it is well recognized that NMDA receptors are involved in physiological processes such 
as learning and memory, it is possible that this Zn2+ mobilization could regulate cognitive 
processes as well.  The induction of long-term potentiation (LTP) is a form of synaptic 
plasticity critical in the cellular mechanism of learning.  Indeed, Li and colleagues (2001) 
claimed that [Zn2+]i accumulation in CA3 pyramidal neurons was mandatory for LTP 
induction.  Furthermore, they showed that the depletion of histochemically reactive Zn2+ 
impaired LTP.  However, there is increasing evidence against synaptic translocation of 
Zn2+ as knockout mice devoid of histochemically-reactive Zn2+ are not cognitively 
impaired (Cole et al., 2000; Lopantsev et al., 2003).   Therefore, this argues against the 
physiological role of vesicular Zn2+ or suggests an alternative Zn2+ source for LTP 
induction.  
1.3 Maintaining cellular zinc homeostasis 
[Zn2+]i is maintained at a minimum (< 10-12 M) by specific metal sensors, 
transporters and binding proteins (Outten and O'Halloran, 2001).  This extremely small 
free cytosolic concentration is a reflection of the abundance of metal-binding components 
in the intracellular environment.  In addition, the ability of these regulatory systems to act 
as switches that turn on or off under conditions of zinc excess or deficiency suggests that 
cells do not tolerate large fluctuations in cytoplasmic [Zn2+].  
1.3.1 Metallothioneins 
The most well characterized Zn2+-binding protein is metallothionein (MT), a low 
molecular weight protein (~7 kDa) that sequesters and distributes metal ions, regulates 
the biosynthesis and activity of zinc metalloproteins, and provides cytoprotection from 
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 free radical damage (Aschner et al., 1997).  First isolated by Vallee and colleagues in 
1966, the expression of MT in a plethora of organisms, including bacteria, plants, 
eukaryotic species, and all mammalian cells, suggests an important role in maintaining 
cellular metal homeostasis.  MT has high affinity for not only essential metals (zinc and 
copper), but also non-essential metals (cadmium and mercury).   
Since copper and zinc are physiologically relevant metals, it is plausible that MT 
may function as a cellular metal chaperone for zinc-requiring proteins and enzymes 
(Costello et al., 2004), while in addition to acting as a zinc reservoir to prevent its cellular 
accumulation.  Studies have demonstrated that both MT knockout cell and animal models 
exhibit increased susceptibility to oxidative damage (Palmiter, 1995; Kelly, 1996), 
whereas MT over expression in these systems confers resistance to heavy metal toxicity 
(Beach and Palmiter, 1981; Liu et al., 1995).  However, regardless of the extensive 
research that has been done on this family of proteins, a true physiological role for MT in 
zinc homeostasis still remains uncertain.  For example, genetic experiments reveal that 
mammalian cells that are MT-deficient grow as well as cells expressing MT (Hamer, 
1986; Palmiter, 1987).  In addition, specific MT isoform knockout mice develop, grow 
and reproduce normally (Palmiter, 1998), arguing against a critical role for MT as a metal 
chaperone delivering zinc to metalloproteins.  Together, these results imply that MT is 
protective during zinc toxicity, but may be unimportant during basal conditions.  Perhaps 
cells deficient in MT have alternative methods to remove toxic accumulations of [Zn2+]i, 
for example, with metal transporters that facilitate the efflux of zinc.  Or alternatively, 
perhaps cells do not experience elevated [Zn2+]i under normal conditions, thereby not 
requiring buffering capacity of MT.           
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 Biochemistry of metallothionein 
Zinc is redox inactive, but it can coordinate with proteins in different structural 
geometries.  With respect to MT, high resolution X-ray and NMR analyses have revealed 
the structural detail of the protein and its zinc binding sites.  Thionein, the apo-form of 
MT, is a cysteine-rich molecule that can bind up to seven zinc ions forming the metal-
bound form of the protein (Kd ~ 4 x 10-13 M), indicating that MT may be a key 
intracellular player in maintaining [Zn2+]i at a minimum (Maret, 2003).  Thionein consists 
of two metal clusters that selectively coordinate the metal, such that each metal atom is 
held tetrahedrally by four cysteine ligands.  The thiolate clusters of MT are of two types: 
the ß-domain contains cysteine ligands that coordinate 3 zinc ions in one site, whereas the 
α-domain consists of cysteine ligands that coordinate 4 zinc ions in two identical zinc 
sites.  The protein folds in such a manner to envelope the two clusters in a dumbbell 
shape (Maret and Vallee, 1998), thereby protecting the bound zinc ions from solvent 
exposure.  Despite this, the thiolate cluster coordination of zinc ions still allows the facile 
exchange of the metal with other metalloproteins and metalloenzymes.   
The two domains are significantly different with regard to zinc binding and 
release (Jiang et al., 2000).  For instance, the higher number of disulfide bridges that hold 
the zinc ions together in the α-domain correlate to the higher stability of this cluster and 
also the higher affinity for zinc ions.  There is some evidence that metals in the ß-domain 
exchange more readily and rapidly compared to those in the α-domain.  The α-domain is 
more thermodynamically stable, thereby making the ß-domain a better zinc donor.  
Although both the α- and ß-domains are unstable by themselves, mutual interactions 
between the two domains are responsible for stabilizing the entire protein and this 
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 determines the reactivity of MT (Maret and Vallee, 1998).  In this respect, MT may be a 
unique zinc-containing protein in that it controls the biological availability of zinc, which 
is different in other cases, where zinc controls the biological function of many 
metalloproteins.   
Although zinc binding to MT occurs with high affinity, this reaction is reversible 
in cell-free systems, as the multiple cysteine residues of MT can be oxidized, releasing 
bound metal in the process (Jacob et al., 1998; Jiang et al., 1998).  Although Zn2+ can be 
transferred to apo-proteins in both directions (from MT to apo-enzymes and enzymes to 
thionein), not all 7 zinc ions are transferred at once.  In addition, transfer is dependent on 
the modification of the thiol groups, such that some zinc ions are more susceptible to be 
transferred than others.  A study by Maret and Vallee (1998) demonstrated that exposure 
of MT protein to disulfide reagents, such as 2,2’-dithiodipyridine (2,2’-DTDP) in vitro 
enhanced the transfer of zinc from MT to apoenzymes.  The cycle of zinc binding and 
release is carefully orchestrated via redox reactions associated with glutathione, the 
principle free radical scavenger in the cytosol (Jiang et al., 1998).  Reduced glutathione 
(GSH) converts to oxidized glutathione (GSSG) as catalyzed by glutathione peroxidase.  
In other words, in a reduced environment MT remains metallated, whereas Zn2+ ions are 
released under more oxidizing conditions.  This strongly suggests that MT is not simply a 
metal detoxification mechanism, but part of a more complex system that mobilizes Zn2+ 
in response to the redox status of the cell.    
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Figure 1.1  Zinc binding and release by metallothionein is orchestrated by 
glutathione. 
 
Metallothionein isoforms 
The mouse genome possesses 4 MT genes located on chromosome 8, whereas in 
humans at least 16 MT genes are clustered on chromosome 16 (West et al., 1990; Quaife 
et al., 1994).  The idea of multiple MT genes suggests either redundancy in function or 
divergence of function dependent on cell-specific expression.  Four isoforms of 
mammalian MT protein have been identified.  MT-I and MT-II are expressed throughout 
development in all tissues; their expression is regulated in the presence of metals, 
glucocorticoids and inflammation (Palmiter, 1987).  The other two isoforms display more 
restricted expression, which might imply more specialized functions.  MT-III expression 
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 is localized to neurons and was found to inhibit growth in cultured cells (Uchida et al., 
2002).  Specifically, Palmiter (1995) demonstrated that under conditions of zinc 
deficiency, the persistent expression of MT-III (but not MT-I) inhibits growth of baby 
hamster kidney (BHK) cells, implying that this MT isoform competes with zinc binding 
proteins when the cells undergo zinc starvation.  These results are intriguing, because in 
vitro evidence shows that MT-III does not differ appreciably from MT-I in its Zn2+ 
binding dynamics.  In any case, the superior Zn2+ scavenging activity of MT-III 
presumably facilitates the degradation of other newly synthesized apo-proteins which 
require Zn2+ for proper structure and function.  This hypothesis is consistent with the 
results that MT-I protein levels diminish when zinc is depleted and only become induced 
when zinc is abundant, while MT-III expression is unaltered by metals or inflammatory 
stress.   
Initially identified as growth inhibitory factor (GIF) isolated from human brain 
extracts, MT-III was found to deficient in individuals with Alzheimer’s disease (Uchida 
et al., 1991).  However in a later study, Erickson et al. (1994) observed that although 
MT-III may inhibit neuronal growth, neither MT-III mRNA nor protein levels were 
significantly reduced in AD brain extracts.  A direct correlation between MT-III 
expression and the pathology of AD remains controversial.  Suggesting a physiological 
role for MT-III in the storage and transport of vesicular Zn2+, high levels of MT-III 
protein are found in the hippocampal neurons that sequester Zn2+ in vesicles (Masters et 
al., 1994).  However, mice deficient in MT-III do not display any behavioral or 
neurological abnormalities, and grow, develop and reproduce normally.  Yet they are 
more susceptible to increased neuronal death resulting from kainate-induced seizures 
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 (Erickson et al., 1997).  Together, this suggests that MT-III may regulate [Zn2+]i in 
pathological situations, but may not be as relevant under physiological conditions.     
The most recently identified isoform, MT-IV, is unique to epithelial cells, where 
its expression is restricted to stratified epithelium of the skin, tongue and upper 
alimentary canal (Quaife et al., 1994).  Although MT-IV has the conserved metal thiolate 
clusters that bind Zn2+, this is the least well characterized of the MT proteins.  Like the 
other MT isoforms, the functional significance of this protein remains unknown.   
The expression of certain MT isoforms are metal-induced: when [Zn2+]i 
accumulates, a metal response element-binding transcription factor (MTF-1) binds 
several metal response elements (MREs) located upstream of the promoter on the MT 
gene.  This binding, in turn, upregulates MT expression.  Richard Palmiter (1994) has 
demonstrated that MTF-1 is a metalloregulatory protein whose DNA-binding activity is 
reversibly activated in response to changes in [Zn2+]i.  
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 Although all MT isoforms may be somewhat protective, each is differentially 
regulated based on its cell-specific expression.  For example, it appears that both MT-I 
and MT-II are directly inducible in astrocytes, while the predominantly neuronal MT-III 
is relatively unresponsive to induction (Palmiter, 1998).  This cell-specific level of MT 
expression predisposes cells to certain fates or pathways.  Indeed, we have previously 
shown that astrocytes are more resistant than neurons to toxic levels of [Zn2+]i, perhaps 
due to glial-specific buffering mechanisms (Dineley et al., 2000).  In addition, the 
observation that astrocytes have ten times more basal MT-I than neurons and are able to 
up regulate expression considerably (Radtke et al., 1993) may explain why astrocytes are 
more resistant to zinc-mediated cell death than neurons (Dineley et al., 2000).  Whether 
MT-I and MT-II serve as glial-specific buffering mechanisms remains to be determined.  
Moreover, inducing MT expression in a zinc toxicity model may indicate a protective 
role in maintaining zinc homeostasis.   
With respect to MT protection in vivo, a study by van Lookeren Campagne and 
colleagues (1999) demonstrated that transgenic mice overexpressing MT-I displayed 
reduced infarct size and sensorimotor deficits after focal cerebral ischemia, supporting 
the contribution of free radicals and heavy metal toxicity to the pathogenesis of stroke.  
The same group (van Lookeren Campagne et al., 2000) showed that induction of MT-I 
expression immediately after cerebral ischemic insult was in response to an antioxidant 
electrophilic response element (ARE) binding to the MT-I promoter, suggesting that MT-
I is an early gene activated specifically in brain microvascular endothelial cells and 
astrocytes as a protective mechanism after stroke.  Also, Tredelenburg and colleagues 
(2002) used serial analysis of gene expression (SAGE) to show that MT-II mRNA is the 
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 most highly upregulated transcript after focal cerebral ischemia in mice, indicating that it 
is a neuroprotective gene that ameliorates stroke-induced neuronal damage.     
Zinc release from metallothionein 
  Extensive evidence also suggests that MT can protect against oxidative damage in 
a range of different cells and tissue.  Yeast which cannot synthesize MT and also which 
lack functional superoxide dismutase are more sensitive to oxidative stress (Tamai et al., 
1993).  It has been demonstrated in cells and in vivo that agents that induce oxidative 
stress, such as cytokines (De et al., 1990), paraquat and H2O2 (Min et al., 1991; Bauman 
et al., 1992; Dalton et al., 1994), induce MT-I and MT-II expression, and that this reflects 
a defense mechanism to protect the organism against oxidative damage. 
We previously stated that astrocytes are more resistant to zinc-mediated cell death 
than neurons (Dineley et al., 2000), perhaps due to the upregulated zinc-buffering 
capabilities of the glial-specific MT isoform.  However, it must also be recognized that 
there is the potential for  [Zn2+]i release from MT stores in response to an oxidative shift 
in the cellular environment (Aizenman et al., 2000), thereby making cells more prone to 
oxidant-mediated cell injury and death.  Perhaps the existence of more oxidative-sensitive 
Zn2+ pools in neurons compared to atsrocytes may explain their heightened vulnerability 
to elevated [Zn2+]i.  In addition, if oxidant-induced zinc release exacerbates cell injury in 
this model, MT may be viewed more as a cellular liability rather than as an advantage. 
1.3.2 Zinc transporters 
As mentioned above, organisms have evolved sophisticated homeostatic 
mechanisms to maintain [Zn2+]i at its required minimum.  In addition to intracellular 
binding proteins such as metallothionein, many prokaryotic and eukaryotic cells express 
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 two families of zinc transport proteins to allow Zn2+ influx with deficiency and to remove 
cytosolic Zn2+ with toxic accumulations.  (1) ZIP or Zrt-Irt like proteins, first identified in 
Saccharomyces cerevisiae (Zrt) and Arabidopsis thalina (Irt), have eight transmembrane-
spanning domains, and are proposed to be involved in cellular Zn2+ uptake, although 
precise mechanisms are not fully understood.  Currently 15 ZIP proteins have been 
identified (Liuzzi and Cousins, 2004).  (2) The CDF or cation diffusion facilitator family, 
containing proteins that confer resistance to heavy metal toxicity in many eukaryotic cell 
types, consists of six transmembrane domains (Gaither and Eide, 2001).   
The most familiar members of the CDF family are the zinc transporters (ZnT), of 
which at least nine proteins have been identified (Liuzzi and Cousins, 2004).  Expressed 
in the brain as well as many other tissues, these transporters are localized to both plasma 
and intracellular membranes of cells that express them.  Zinc transporters are involved in 
three basic maintenance functions: (i) cellular uptake to replenish [Zn2+]i, (ii) removal of 
excess [Zn2+]i and (iii) sequestration of [Zn2+]i into intracellular compartments when 
appropriate.  In summary, zinc transporters mediate the influx/efflux of Zn2+ and they 
also control the intracellular availability of Zn2+ for important proteins that modulate cell 
activity.  Although few are understood, mechanisms for how these transporters interact 
with other zinc-binding proteins and reasons for why they sequester Zn2+ are being 
identified.   
Cellular zinc uptake 
 The precise role of the ZIP family of Zn2+ transporters has not been well 
characterized in vivo.  There is limited evidence that cell lines treated acutely with 
elevated [Zn2+]i have reduced ZIP mRNA levels (Costello et al., 1999).  Others have 
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 demonstrated that Zn2+ deficiency in brain epithelial cells resulted in increased Zn2+ 
uptake (Lehmann et al., 2002), presumably through upregulation of ZIP proteins.  
Extensive studies in yeast more conclusively showed that ZIP transporters are 
constitutively expressed and are the primary means of Zn2+ uptake in the presence of 
physiological [Zn2+]i.  ZIP expression is induced as a result of zinc starvation, (Zhao and 
Eide, 1996; Zhao and Eide, 1997).  However, ZIP is altered by elevated [Zn2+]i, 
suggesting that under these conditions, the ZnT family more likely maintains [Zn2+]i.  
Removal of cytoplasmic zinc 
 One hypothesis for zinc efflux is under normal resting conditions, 
metallothioneins and other zinc-containing proteins are presumably saturated with Zn2+ 
(Colvin et al., 2003).  Under these conditions, the plasma membrane Zn2+ transporter, 
ZnT-1 plays a pertinent role in the removal of excess [Zn2+]i.  Studies have demonstrated 
that ZnT-1 expression in cultured cells counteracts increases in [Zn2+]i.  Reduced [Zn2+]i 
levels and subsequent resistance to Zn2+-mediated toxicity was observed in PC-12 cells 
overexpressing ZnT-1 (Kim AH et al., 2000).  More recent evidence indicates that ZnT-1 
expression in astrocytes protects against Zn2+-mediated toxicity by reducing toxic [Zn2+]i 
accumulation (Nolte et al., 2004).  Palmiter (2004) recently reported that baby hamster 
kidney (BHK) cells that have inactive ZnT-1 and MT genes, have high levels of [Zn2+]i.  
Restoration of MT expression moderately improved cell survival, but only slightly 
reduced [Zn2+]i.  Expression of both ZnT-1 and MT drastically improves cell survival and 
significantly lowers [Zn2+]i, suggesting the codependence between ZnT-1 and MT in 
regulating cellular Zn2+ homeostasis.  In any case, ZnT-1 must have some critical role, as 
mice lacking ZnT-1 die in utero (Andrews et al., 2001).  
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  Intracellular zinc compartmentalization 
 Several ZnTs are localized to intracellular membranes and mainly function in 
Zn2+ sequestration.  ZnT-2 was discovered on the membranes of acidic cytoplasmic 
vesicles that pump Zn2+ into these vesicles when extracellular Zn2+ is elevated.  Zn2+ 
stored in a subset of glutamatergic neurons are thought to be pumped into vesicles by 
ZnT-3, which lies on the vesicular membrane (Palmiter et al., 1996).   
Zn2+ concentrations within these synaptic vesicles are estimated to be up to 
millimolar levels (Frederickson et al., 1983) and could account for almost 15% of total 
brain Zn2+ (Cole et al., 1999).  The ability of this transiently-released Zn2+ (which may 
reach local concentrations of hundreds of micromolar in the synapse) to regulate ion 
channels and receptors on the postsynaptic neuronal membrane (Li et al., 2001; 
Thompson et al., 2002; Ueno et al., 2002) suggests a neuromodulatory role for Zn2+ in 
brain regions containing histochemically-visible Zn2+ pools.  However, the mechanism of 
how vesicles are replenished remains unknown; it is hypothesized that Zn2+ reservoirs 
like MT could release stores that are pumped into vesicles by ZnT-3 (Colvin et al., 2003).  
The importance of this transporter is questioned by data from knockout mice: while they 
presented with selective and complete depletion of vesicular Zn2+ in the brain (Cole et al., 
1999), the animals displayed no developmental or behavioral deficits.  Moreover, 
electrophysiological properties of the CA3 pyramidal neurons were unaltered (Cole, 
2000; Lopantsev et al., 2003).  ZnT-3 knockouts do experience more severe seizures and 
hippocampal cell death in response to kainate, suggesting that (1) vesicular Zn2+ pools 
may not be necessary to mediate toxicity, and (2) an alternative excitotoxic Zn2+ source 
may contribute more to neuronal death.    
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  Also expressed in the brain, ZnT-4 is mainly expressed in luminal cells of milk 
ducts (Michalczyk et al., 2002) and is involved in the transport of Zn2+ into milk during 
lactation (Kelleher and Lonnerdal, 2002).  Mice deficient in ZnT-4 have reduced 
quantities of Zn2+ in milk (Huang et al., 2002).  ZnT-5 is predominantly expressed in 
pancreatic ß cells and is specifically important for vesicular sequestration of Zn2+ in the 
pancreas (Kambe et al., 2002).  ZnT-6 and -7 are localized to the Golgi body and 
cytoplasmic vesicles, respectively, and are expressed in a range of tissues, including 
brain, lung and small intestine (Huang et al., 2002; Kirschke and Huang, 2003).  ZnT-8 
has been recently identified in pancreas and liver, ZnT-9 has been identified in both 
cytoplasmic and nuclear fractions of various tissues (Liuzzi and Cousins, 2004).  In fact, 
it is important to note that for the majority of these “transporters”, there is not yet hard 
evidence that they actually transport zinc.     
Table 1.1  CDF family of zinc transporters 
 
 Membrane localization Tissue specificity Function 
ZnT-1 Plasma membrane All cells Extrude cellular Zn2+
ZnT-2 Acidic cytoplasmic 
vesicles 
All cells Store Zn2+
ZnT-3 Synaptic vesicles Brain and testis Store Zn2+
ZnT-4 Luminal cell vesicles Mammary gland Induce lactation 
ZnT-5 Vesicles Pancreatic ß cells Sequestration of Zn2+
ZnT-6 Golgi body Brain, lung and small 
intestine 
Sequestration of Zn2+
ZnT-7 Cytoplasmic vesicles Brain, lung and small 
intestine 
Sequestration of Zn2+
ZnT-8 Vesicles Pancreas and liver Not yet known 
ZnT-9 Cytoplasmic and nuclear 
vesicles 
Various tissues Not yet known 
 
Adapted from Liuzzi and Cousins, 2004 
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 1.4 Mechanisms of zinc elevation 
 As mentioned above, cells contain sophisticated mechanisms to maintain [Zn2+]i at 
a minimum.  However, under pathophysiological conditions, [Zn2+]i can become elevated 
where these regulatory mechanisms are overcome, leading to Zn2+-mediated cellular 
disruptions and subsequent neuronal death.  The questions that arise are when most 
neural zinc is tightly coordinated to proteins and/or sequestered in intracellular 
compartments, (i) what is the source for elevations of [Zn2+]i and (ii) what factors or 
stimuli trigger its intracellular elevation ? 
1.4.1 Zinc translocation hypothesis 
It has been known for some time that toxic levels of Zn2+ induce neuronal death 
(Choi et al., 1988), presumably through translocation of elevated Zn2+ from presynaptic 
to postsynaptic neurons.  Based on observations that zinc is released from specific 
glutamatergic neurons and modulates the activities of postsynaptic receptors, it was 
hypothesized that large amounts of synaptically-released zinc could mediate neuronal 
pathogenesis.  This was demonstrated from evidence showing histochemically-reactive 
pools of zinc are readily depleted upon excessive neuronal stimulation and appear in 
dying CA3 and CA1 pyramidal neurons.  Furthermore, selective chelation of Zn2+ in the 
synapse with a membrane-impermeant chelator reduced postsynaptic Zn2+ accumulation 
and subsequent cell death (Koh et al., 1996).   
Zn2+ released into the synapse can enter postsynaptic cells through a number of 
Ca2+-permeable pathways.  Zn2+ permeates the NMDA receptor (Koh and Choi, 1994), 
which is ubiquitously present on most neuronal membranes and gate Ca2+-permable 
channels.  In addition, it is thought that Zn2+ can enter via Ca2+-permeable AMPA/kainate 
 27
 receptors (Ca2+-A/K), which are found on subpopulations of neurons (Weiss et al., 1993) 
and also through voltage-sensitive calcium channels (VSCC).  Studies by Sensi and 
Weiss (1997) in cultured neurons claim that Zn2+ in order of preference enters cells 
through Ca2+-A/K channels followed by VSCCs, and finally by NMDA receptor 
channels.  In addition to these three main routes mentioned above, it is also speculated 
that Zn2+ can permeate a unique Na+-Zn2+ exchanger, although it is entirely possible that 
it simply substitutes for Ca2+ in the known plasma membrane Na+-Ca2+ exchanger (Sensi 
et al., 1997; Cheng and Reynolds, 1998). 
The hypothesis that Ca2+-A/K channels are the predominant route for Zn2+ entry is 
supported by antagonists of these receptors providing protection against oxygen-glucose 
deprivation-induced Zn2+ accumulation and neuronal loss (Yin et al., 2002).  In addition, 
hippocampal pyramidal neurons that are susceptible to Zn2+-induced neurodegeneration 
preferentially express Ca2+-A/K receptors, suggesting that this specific type of channel 
may be upregulated in response to stress conditions involving toxic Zn2+ translocation 
(Weiss and Sensi, 2000).  Direct evidence for this has been provided by Liu et al. (2004), 
who recently demonstrated that selective blockade using genetic manipulations of Ca2+-
A/K receptors in adult rats rescues susceptible CA1 pyramidal neurons from forebrain 
ischemic injury.  With respect to the localization of Ca2+-A/K receptors, it must be noted 
with caution that not all electrophysiological studies have confirmed their presence in 
hippocampal regions (Weiss and Sensi, 2000).  In addition, not all neurons expressing 
high densities of Ca2+-A/K receptors are equally vulnerable or susceptible to excitoxicity, 
implying that additional factors contribute to the mechanism of neuronal injury. 
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 Because Zn2+ and Ca2+ are both prevalent intracellular divalent cations with 
neurotoxic capacities, it is perhaps useful to compare their physiological characteristics.  
However in practicality, the two ions are maintained by different gradients.  Zinc is 
mostly tethered to proteins, allowing [Zn2+]i to remain relatively small, whereas [Ca2+]i is 
bound to fewer proteins until it is released transiently between signaling as a second 
messenger.  Another important difference between the two cations is that whereas 
extracellular Ca2+ is mostly free and therefore Ca2+-regulated stimuli simply open 
membrane channels for its entry, hardly any extracellular Zn2+ is free, thereby requiring 
its release before Zn2+-induced signals can open membrane channels which the ion 
permeates.  The last disparity between calcium and zinc are the numbers of scavenging, 
sequestering and releasing proteins available in the intracellular environment:  there are 
over a dozen identified Ca2+-binding proteins, such as calbindin and calmodulin, 
however, metallothionein is the only known Zn2+-binding protein that regulates its 
intracellular availability (Frederickson and Bush, 2001). 
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 Table 1.2  Comparison of zinc and calcium signal properties 
 
Attribute Zinc (Zn2+) Calcium (Ca2+) 
~ Free ion extracellularly Not established, likely 1 pM  mM 
~ Free ion in cytosol Not established, ~ pM range ~ nM 
~ Ion in storage (releasable pool) ~ mM in presynaptic vesicles Low µM in SER 
Specific membrane-bound storage 
organelles ? 
YES; presynaptic vesicles and 
secretory granules 
YES; SER and neuronal synaptic 
vesicles 
Specific releasable pools YES; presynaptic vesicles and 
MT 
YES; SER 
Ion-sequestering proteins ? YES (few described, i.e. MT) YES (dozens described, ie 
cabining and calmodulin) 
Permeation thru ion channels ? YES (NMDA, AMPA/KA, 
VSCC) 
YES (NMDA, AMPA/KA, 
VSCC) 
Ion modulated enzymes YES YES 
Cytotoxicity? YES, nM fatal YES, µM fatal 
Number of ion-containing 
proteins 
Hundreds of zinc finger and other 
zinc-containing proteins 
Many calcium storage and 
calcium-modulated proteins 
 
Adapted from CJ Frederickson and AI Bush, 2001 
 
1.4.2 Oxidative stress-induced zinc release 
Since animals lacking vesicular zinc still exhibit neuronal injury due to toxic Zn2+ 
accumulation, this suggests that toxic [Zn2+]i can emanate from other sources.  The large 
reservoir of zinc bound to intracellular proteins within the cytosol represents a potential 
source of toxic zinc.  Indeed, it has been shown in vitro that modification of thiolate 
clusters of MT by disulfide agents is a mechanism to mobilize Zn2+ from an otherwise 
stable zinc-protein complex in a non-oxidizing environment (Maret and Vallee, 1998).  
This suggests that MT acts not only as a zinc buffer but also as a zinc donor, and that this 
cycle of zinc binding and release is carefully orchestrated by the intracellular redox 
status.  A shift in the redox balance towards a more oxidizing state may contribute to 
increased zinc release that leads to pathogenesis in many neurodegenerative diseases.   
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 To mimic oxidative stress, the sulfhydryl oxidizing agent, 2,2’-dithiodipyridine 
(2,2’-DTDP) has been used to show Zn2+ release from MT protein in cell-free systems.  
In addition, application of 2,2’-DTDP increased [Zn2+]i  in cultured cortical neurons, 
presumably by mobilizing metal bound to proteins.  Neuronal injury by 2,2’-DTDP was 
confirmed to be Zn2+-induced, since membrane-permeant Zn2+ removal significantly 
protected against toxicity (Aizenman et al., 2000).  Using another form of oxidative stress 
characteristic in stroke and ischemia, Zhang and colleagues (2004) recently showed that 
peroxynitrite-induced neuronal apoptosis is mediated by zinc release from intracellular 
stores, which in turn activated 12-lipoxygenase.  Peroxynitrite-mediated cell death was 
prevented by inhibitors of lipoxygenase and other downstream players in the apoptotic 
cascade.   
In addition to oxidative stress, nitrosylative stresses have also been shown to 
liberate zinc from metalloproteins.  After administration of nitric oxide (NO) donors to 
rats, brain tissue showed histochemically-reactive zinc in hippocampal neurons using 
Timm’s and TSQ fluorescence methods (Cuajungco and Lees, 1998).  A following study 
by Frederickson and colleagues (Frederickson et al., 2002), confirmed that NO caused 
zinc accumulation in hippocampal neurons, specifically from zinc depletion in 
presynaptic terminals.  However, the NO-sensitive Zn2+ pool could result from a general 
mobilization of intracellular stores, since Zn2+ accumulation was also observed in 
cerebellar neurons, where there is little to no vesicular zinc.    
Specific evidence for NO-mediated zinc released from MT was first demonstrated 
in cell-free systems, where the mechanism involves electrophilic attack of NO on thiolate 
clusters (Aravindakumar et al., 1999), and the production of these free radicals causes 
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 zinc release from MT.  Another study confirmed this mechanism, and moreover showed 
that NO released Zn2+ from the β-domain of the protein, while leaving the α-domain 
relatively untouched (Zangger et al., 2001).  Investigating the role of MT in NO signaling 
was facilitated in cells using a FRET-based green fluorescent fusion protein to study the 
direct interaction between MT and NO (Pearce et al., 2000).  NO caused conformation 
change of and subsequently released metal from the protein. Furthermore, enhanced 
expression of this FRET-MT construct in mouse lung fibroblasts prevented NO-induced 
conformational changes in MT and subsequent Zn2+ release (St. Croix et al., 2002), 
suggesting that MT content can regulate cellular Zn2+ homeostasis in response to 
nitrosylative stress.  With respect to in vivo data, mice deficient in MT-III exhibited 
reduced cytoplasmic zinc accumulation and neuronal death in the hippocampal CA1 
region after kainate-induced seizures compared to wild type mice (Lee et al., 2003).  This 
suggests that zinc release from MT may contribute to neuronal death following acute 
brain injury.   
Although MT is accepted as the predominant zinc-binding protein in the 
cytoplasm, there are other sources for oxidant-labile Zn2+.  For example, Knapp and 
Klann (2000) observed that superoxide exposure activates PKC in enzyme preparations 
by interaction with and thiol oxidation of the cysteine-rich, zinc finger motif of the 
enzyme.  In summary, their data showed that (1) Zn2+ chelation stimulated PKC activity, 
(2) superoxide induced PKC activity by promoting Zn2+ release from the enzyme, and (3) 
oxidized and active PKC contained less Zn2+ than reduced PKC.  A subsequent study by 
Korichneva et al. (2002) provided in vitro evidence that oxidation of PKC by reactive 
oxygen species triggers the release of zinc ions in NIH 3T3 cells.   
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 1.5 Zinc and neurodegeneration 
Evidence from a number of whole animal studies implicated zinc as a potent 
neurotoxin under acute neurological conditions, such as ischemia and epilepsy.  In 
addition, there is emerging evidence that Zn2+ may contribute to chronic and selective 
neurodegeneration associated with as Alzheimer’s and Parkinson’s.  The role(s) of Zn2+ 
in each of these disorders will be discussed in detail below. 
1.5.1 Cerebral ischemia 
A toxic role for Zn2+ in the pathology of cerebral ischemia or stroke was first 
identified by Tonder et al. (1990) and later confirmed by Koh and colleagues (1996), 
where toxic [Zn2+]i selectively accumulated in dying postsynaptic neurons in the CA1 
pyramidal region following transient global ischemia in rats.  The Zn2+ accumulation and 
subsequent neuronal death was prevented with a membrane-impermeable Zn2+ chelator, 
suggesting that Zn2+ translocated from presynaptic sites and subsequently accumulated 
specifically in postsynaptic neurons.  Similarly, Lee et al. (2003) claimed that transient 
focal ischemia in rats also causes Zn2+ translocation from pre- to postsynaptic neurons 
and subsequent cell death may accelerate cerebral infarct growth following the ischemic 
insult.   
1.5.2 Epileptic seizures 
Although extensive evidence portrayed Zn2+ as a seizure stimulant in animal 
models of epilepsy (Pei, 1983; Pei and Koyama, 1986), opposing studies claim that 
endogenous Zn2+ can have anticonvulsant properties as well.  For example, Mitchell and 
Barnes (1993) demonstrated that chelation of endogenous Zn2+ reduced the threshold for 
convulsions and augmented the severity of kainate-induced seizures, thereby implying 
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 that zinc release may be protective against epileptic seizures.  Other studies showed that 
Zn2+ chelation did not protect hippocampal neurons against accumulated Zn2+-mediated 
neuronal injury in seizure-induced mice (Cuajungco and Lees, 1997).  Therefore, it 
remains controversial whether the protection is mediated directly by zinc chelation or a 
side effect of the zinc-chelating agents.  Additionally, ZnT-3 knockout mice experience 
more intense seizures in response to kainate.  Whether or not zinc is involved in 
precipitating seizure events, there is extensive evidence that zinc accumulates in dying 
neurons after seizure.  The Zn2+ damage to CA3 neurons after seizures is exacerbated in 
MT-III knockout mice (Lee et al., 2003).  In addition, observations were made by Assaf 
and Chung (1984) where elevated K+-induced depolarization in rat hippocampal slices 
induced massive Zn2+ release producing extracellular levels up to 300 µM, which may be 
sufficient to cause neuronal cell death.  Other studies have shown that this Zn2+ 
accumulation generates neurotoxicity in cultured cells (Pollard et al., 1994b; Pollard et 
al., 1994a; Charriaut-Marlangue et al., 1996), it remains to be elucidated whether toxic 
doses of Zn2+ that are pro-convulsant are released from neurons to the same extent in 
vivo. 
1.5.3 Alzheimer’s disease 
One of the neuropathological hallmarks of Alzheimer’s disease (AD) is cortical 
tissue atrophy and the loss of functional neurons, especially in hippocampal regions 
(Cuajungco and Lees, 1997).  The tissue characteristically includes significant 
accumulation of plaques, mainly composed of amyloid-ß protein (Aß), which contributes 
to the neurodegenerative mechanisms associated with AD (Selkoe et al., 1990).  Aß 
originates from the cleavage of amyloid precursor protein (APP; Checler, 1995), and 
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 overexpression of APP is thought to contribute to the etiology of AD.  APP expression is 
tightly regulated by zinc-containing transcription factors, and itself contains a zinc-
binding site (Quitschke, 1994; Grilli et al., 2000).  The suspected role of Zn2+ in 
regulation of Aß accumulation stems from the interactions between Zn2+ and APP.  
Binding of Zn2+ to APP not only stimulates its synthesis, but also prevents its degradation 
to form potential toxic products, such as Aß (Bush et al., 1993; Bush et al., 1994a; Bush 
et al., 1994b; Bush et al., 1994c).  Thus, the binding of Zn2+ may be important for 
maintaining the stability of APP and preventing the subsequent accumulation of Aß.   
The accumulation of Aß has been shown to be cytotoxic to both cultured cells 
(Gschwind and Huber, 1995) and animal models (LaFerla et al., 1995), presumably 
through oxidative injury that can lead to nuclear and mitochondrial DNA damage and 
malfunctioning of mitochondrial respiration (Mecocci et al., 1994; Mutisya et al., 1994; 
Hutchin and Cortopassi, 1995), all of which may contribute to AD pathogenesis.  It is 
also well documented that oxidative stress can cause Zn2+ release from intracellular stores 
(Aizenman et al., 2000), and it is speculated that [Zn2+]i at toxic levels can in turn 
promote Aß aggregation (Bush et al., 1994a; Bush et al., 1994b; Bush et al., 1994c).  
However, whether Zn2+ prevents or enhances senile plaques remains to be further 
elucidated. 
1.5.4 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) primarily causes degeneration of motor 
neurons in the spinal cord, brain stem and cerebral cortex affecting motor function.  
Genetic mutations in the superoxide dismutase type 1 (SOD1) gene is thought to account 
for the 5-10% of familial ALS cases, where etiology is a gain of function in the mutant 
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 enzyme, as opposed to a loss of function (Cuajungco and Lees, 1997).  SOD1 encodes for 
the cytosolic antioxidant enzyme, copper/zinc-SOD, which catalyses the dismutation of 
superoxide free radicals to hydrogen peroxide and oxygen (Olanow, 1993).  The SOD 
protein contains binding sites for two zinc ions and two copper ions, all four of which are 
critical for proper SOD activity.  Although copper binding is essential for the catalytic 
activity, zinc is thought to be more important for maintaining structural integrity.  SOD 
binds Zn2+ with high affinity and the Zn2+ ions within the binding sites of the enzyme are 
not susceptible to removal with chelators (Cuajungco and Lees, 1997).  However, it has 
been demonstrated that mutations in SOD that affect Zn2+-binding sites could result in 
enzyme instability of (Lyons et al., 1996), which could substantially alter SOD ability to 
scavenge free radicals in highly oxidative environments.   
Another factor which could reduce Zn2+ binding to SOD is the formation of 
neurofilament (NF) aggregates in ALS pathology.  NF has high affinity for zinc and has 
been shown to compete for Zn2+ with both wild type and mutant SOD.  A study in 1997 
(Crow et al., 1997) demonstrated that decreased SOD-Zn2+ affinity led to enhanced SOD 
activity for damaging cellular proteins by peroxynitrite-mediated tyrosine nitration.  A 
subsequent study by Estevez and colleagues (1999) observed that overexpression of zinc-
deficient SOD encouraged NO-mediated apoptosis in motor neurons.  This neuronal 
injury was prevented when the enzyme was replete with Zn2+, suggesting that unstable 
structure led to improper enzyme function and subsequent accumulation of toxic free 
radicals.  Beyond this, further investigation needs to address how altering metal binding 
affects ALS disease progression in vivo. 
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 1.5.5 Parkinson’s disease 
Along with ALS, the etiologic mechanism leading to Parkinson’s disease (PD) 
also involves disruption of cellular redox balance (Jenner et al., 1992).  Postmortem 
studies identified lower levels of polyunsaturated fatty acids and elevated levels of 
malondialdehyde (which is indicative of increased lipid peroxidation) in substantia nigra 
tissue extracted from PD patients compared to controls (Dexter et al., 1989b).  Zinc levels 
were observed to be markedly increased in dopaminergic neurons of PD brains (Dexter et 
al., 1989a; Dexter et al., 1991; Jenner et al., 1992).  It has been demonstrated that 
overwhelming the redox status of the cell may cause Zn2+ release from metalloproteins 
(Aizenman et al., 2000), which may in turn generate more free radicals, increasing 
oxidation-induced neuronal injury.  A more definitive pathogenic role for Zn2+ in 
Parkinson’s disease is yet unidentified.  
1.5.6 Hyperzincemia  
A recently described metabolic syndrome associated with toxic Zn2+ overload has 
been defined as hyperzincemia, which is a condition that occurs in relation with copper 
deficiency.  Studies reveal that increased zinc absorption appears to be the primary 
defect, and decreased plasma copper presents as the secondary defect (Prodan et al., 
2002).  The high intake of zinc was speculated to be from either high intestinal absorption 
or reduced intestinal elimination of zinc.  This occurs presumably from induction of MT 
in the intestines, thereby blocking copper absorption and producing the secondary copper 
deficiency.  Previously, hypocupremia has been shown to cause neurological disorders in 
both humans and animals, but no known neurodegeneration has been associated with 
increased zinc ingestion.  The symptoms described in patients with hyperzincemia-
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 induced copper deficiency include severe CNS demyelination, axonal degeneration and 
widespread neuronal loss (Hedera et al., 2003).  Plasma copper levels can be restored 
with copper supplements, but this does not prevent the worsening of neurological 
conditions. 
1.6 Mechanisms of zinc-mediated toxicity 
Based on the evidence described above, [Zn2+]i accumulation contributes to 
neurodegeneration during excitotoxic conditions.  In vivo studies have shown that intense 
ZnCl2 treatments of rat hippocampus were detrimental to both neurons and glia and that 
this cell death was overcome by co-treatment with a zinc chelator (Lees et al., 1990; 
Cuajungco and Lees, 1996).  Moreover, there are extensive in vitro reports identifying 
[Zn2+]i as a potent neurotoxin to cells maintained in culture, suggesting that high 
extracellular Zn2+ exposure (300-600 µM) may disrupt neuronal homeostasis (Choi et al., 
1988; Koh and Choi, 1994).  Although an unambiguous mechanism for Zn2+-mediated 
neurotoxicity has not been delineated, several potential pathways have been identified.  
These mechanisms are only starting to be elucidated and many are analogous to Ca2+-
induced injury mechanisms.  It is highly improbable that one single mechanism mediates 
Zn2+-induced neurotoxicity.  It is more probable that Zn2+ overload involves multiple 
cellular disturbances that converge or act in parallel to cause cell death.  The specific 
circumstances under which these mechanisms are involved in Zn2+-induced cell death 
will be discussed below. 
1.6.1 Oxidative stress 
Regardless of the Zn2+-induced pathway to neuronal death, the convergence on 
oxidative stress is prominent in Zn2+-mediated neurodegeneration.  Likewise, oxidative 
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 stress can result in toxic zinc burden, and it is documented that oxidant exposure can 
trigger the release of Zn2+ from intracellular stores (Aizenman et al., 2000).  In turn, it is 
plausible that elevated [Zn2+]i  may produce further free radical accumulation.  Indeed, 
Kim et al. (1999) demonstrated that toxic Zn2+ entry in mouse cortical cells resulted in 
toxic free radical generation and produced neuronal degeneration.  The resulting cell 
death from Zn2+-induced free radical generation may be due to the downregulation of 
antioxidant mechanisms, such as glutathione.  A recent study by Chen and Liao (2003) 
demonstrated that Zn2+-induced neuronal injury depleted glutathione pools in neurons, 
while replenishment of glutathione significantly attenuated Zn2+ neurotoxicity.  More 
specific evidence for Zn2+-induced free radical generation was shown by Noh and 
colleagues (1999) where toxic exposure of mouse cortical cultures to Zn2+ activates 
membrane PKC, with subsequent free radical generation and neuronal death.  This 
neuronal injury was inhibited by application of PKC inhibitors or antioxidants, 
suggesting PKC-generated oxidative stress as one important mechanism in Zn2+-induced 
neuronal death.  Noh and Koh (2000) later confirmed that PKC activates the free radical-
generating enzyme NADPH oxidase, as one possible effector for oxidative stress in zinc-
overloaded cortical neurons.   
1.6.2 Zinc-induced apoptosis vs. necrosis 
Studies have elucidated a dose-dependent activation of cell death, where at high 
concentrations zinc-induced cell death reflects necrosis, characterized by rupturing of the 
plasma membrane and cell swelling (Yokoyama et al., 1986; Choi et al., 1988).  
Interactions of Zn2+ with plasma membrane-bound neurotransmitter receptors and ion 
channels present one mechanism for necrotic death.  As mentioned earlier, toxic Zn2+ 
 39
 translocation inhibits NMDA and GABA receptors, but potentiates both Ca2+-A/K and 
VSCC.  In addition to acting on the receptors themselves, Zn2+ is also thought to inhibit 
enzymes critical for synthesizing neurotransmitters (Frederickson, 1989).  Moreover, 
Zn2+ interaction with structural proteins may be characteristic of necrotic cell death.  One 
of the first direct evidence portraying neuronal functional disruptions came from earlier 
studies in the late 1970s investigating how Zn2+ influences cytoskeletal assembly (Gaskin 
and Kress, 1977).  Physiological Zn2+ levels in the brain coordinate assembly and 
disassembly of tubulin (Eagle et al., 1983) and other microtubule-associated proteins in 
vitro (Gaskin et al., 1978).  Toxic levels of Zn2+, on the other hand, interfere with 
microtubule structure and alter the cytoskeleton (Kress et al., 1981), thereby disrupting 
global neuronal function.   
On the other hand, lower zinc concentrations reflect a more apoptotic cell injury, 
characterized by cell body shrinkage, chromatin condensation and DNA fragmentation 
(Sunderman, 1995).  Neuronal apoptosis is associated with both acute neurodegeneration, 
described in traumatic brain injury or cerebral ischemia, but also is evident during the 
progression of chronic diseases, such as Alzheimer’s and Parkinson’s.  The mechanisms 
of Zn2+-mediated apoptosis is only recently being explored, but is considered relevant as 
many zinc-dependent transcription factors are required for normal cell functioning 
(O'Halloran, 1993), and therefore may be impaired during apoptotic injury.  Early 
evidence showing the specific Zn2+ translocation into dying postsynaptic neurons 
following cerebral ischemia or seizures, claim that the neurons die by apoptotic 
mechanisms (Koh et al., 1996).  Zn2+ activation of immediate early genes, such as c-jun 
and c-fos are known to play a role in the cascade of events leading to apoptosis in non-
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 neuronal cells (Xu et al., 1996).  In addition, toxic Zn2+ was shown to induce DNA 
laddering, a consequence of DNA fragmentation and a hallmark of apoptosis, which 
activates poly-[ADP-ribose] polymerase (PARP), an enzyme which recognizes and 
repairs damaged DNA strands (Shimizu et al., 1990).  Sheline and colleagues (2003) 
recently demonstrated that only acute, and not chronic, exposure of Zn2+ to cortical 
neurons activated PARP and furthermore, that Zn2+ neurotoxicity was diminished in 
mutant mice lacking the PARP gene.  In addition, Zn2+ mediation of apoptosis through 
caspase-dependent mechanisms appears to be favored.  For example, Aizenman and 
colleagues (2000) demonstrated that 2,2’-DTDP-induced neurotoxicity was prevented by 
pretreatment with a broad spectrum caspase inhibitor.  Further evidence for caspase-
dependent apoptosis in Zn2+ neurotoxicity comes from studies by Park and colleagues 
(2000) demonstrating that exposure of cortical neurons to elevated Zn2+ activated the 
p75NTR and p75NTR-associated death executor, which promote caspase-dependent 
apoptosis.  Zn2+ has been shown to activate the sphingomyelinase (Spence et al., 1989; 
Schissel et al., 1996), which leads to production of the known apoptogen, ceramide 
(Hannun, 1994; Brugg et al., 1996).   
1.6.3 Zinc activation of MAP kinases 
As mentioned above, generation of oxidative stress is induced by intracellular 
Zn2+ overloads.  Oxidative stress is one mechanism implicated in the cell death that 
occurs during neurodegenerative disorders and several studies have observed that oxidant 
radicals trigger cell death via activation of several signaling pathways, such as the 
mitogen-activated protein kinase (MAPK) pathways (Alessandrini et al., 1999; Bhat and 
Zhang, 1999; Stanciu et al., 2000; Wang et al., 2002).  The ubiquitous MAPK family 
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 consists of c-Jun N-terminal kinase (JNK), p38 MAPK, and the extracellular signal-
regulated kinases (ERK), all of which are protein kinases that activate their substrates 
through phosphorylation of serine or threonine residues, and are involved in maintenance 
of basic cell functions as well as induction of cell death.  JNK and p38 mediate cellular 
mechanisms in response to stress, whereas ERK is mainly activated by growth factors 
and mediates signaling relevant for cell proliferation and survival.   
However, growing evidence shows that ERK is also activated during, and may 
contribute to neuronal death caused by zinc overload.  Indeed, Seo and colleagues (2001) 
showed that [Zn2+]i elevations mediated cell death in differentiated PC12 cells involved 
JNK and ERK, but not p38 activation.  A separate study (Daniels et al., 2004) use a 
neuroblastoma cell line to show that high levels of extracellular Zn2+ rapidly activated 
p38, but downregulated ERK.  These opposing conclusions could reflect differences 
between the experimental model system and the concentrations and duration of Zn2+ 
exposure.  As opposed to models of direct Zn2+ exposure, Aizenman and colleagues have 
demonstrated through a series of studies that [Zn2+]i release upon oxidation in primary 
neurons activates MAPK members during the course of neuronal apoptosis.  In the first 
study (McLaughlin et al., 2001), they observed that Zn2+ release by sulfhydryl oxidation 
in neurons caused cell death by oxidative stress and p38 activation.  Only p38 inhibition 
blocked the 2,2’-DTDP-induced toxicity, implying that p38 is an early event, whereas 
energetic dysfunction, caspase activation or DNA damage are late events in oxidant-
induced apoptosis.  In a following study (Du et al., 2002), they applied the industrial 
biocide 2-methyl-4-isothiazolin-3-one (MIT) to enhance [Zn2+]i in cortical cultures 
through oxidative stress via the 12-lipoxygenase pathway.  MIT application induced early 
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 ERK activation, which led to NADPH oxidase activation, DNA damage, and PARP 
activation, all of which was independent of caspase activation. Taken together, these 
results suggest a role for MAPK in [Zn2+]i-induced neuronal death..  
1.6.4 Involvement of potassium channels 
Reports show that blocking K+ efflux by increasing extracellular K+ or inhibiting 
K+ channels could inhibit apoptotic processes and protect neurons from a wide variety of 
apoptotic stimuli (Hughes and Cidlowski, 1999).  Specifically, studies of oxidant-induced 
Zn2+ release in neurons suggest that 2,2’-DTDP-induced cell death can be prevented by 
high extracellular K+ or by inhibiting K+ channels using tetraethylammonium (TEA) 
(Aizenman et al., 2000).  With respect to specificity of the K+ channels that are activated 
during Zn2+-induced injury, recent work by Pal et al. (2003) identified Kv2.1 as the main 
K+ channel activated after toxic doses of 2,2’-DTDP or staurosporine in neurons.  This 
was shown by targeted disruption of the Kv2.1-encoded K+ channel, which prevented the 
enhanced K+ currents and also protected neurons against apoptogen-stimulated cell death.     
1.6.5 Inhibition of energy production 
The observation that mitochondria are the major cellular generators of free 
radicals suggests that these organelles are intracellular targets of toxic [Zn2+]i.  We and 
others have demonstrated that toxic Zn2+ exposure causes loss of mitochondrial 
membrane potential (∆Ψm), enhances reactive oxygen species (ROS) production, and 
inhibits mitochondrial respiration by blocking specific sites of electron transport.  Each of 
these direct effects of Zn2+ on mitochondrial respiration will be discussed more 
thoroughly in the discussion.   
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 1.7 The Dissertation 
 As an extension of previous work completed in the lab, this dissertation initially 
sought to further understand the neurotoxic properties of zinc, primarily by means of 
manipulating intracellular free zinc levels under toxic situations.  To accomplish this, the 
first aim investigated the zinc buffering properties of metallothionein (MT) in primary 
astrocytes.  Astrocytes were a convenient model to overexpress the zinc-binding protein, 
but the model also reiterated findings that only astrocytes, and not neurons, primarily 
have the ability to induce MT expression under elevated  [Zn2+]i.  From MT over 
expression in astrocytes, we observed that cells were more capable of buffering [Zn2+]i 
accumulation, implying a protective role of MT under toxic injury.  On the other hand, 
exposure to strong oxidizing agents enhanced zinc accumulation in MT-overexpressing 
cells, presumably as zinc is released from MT upon oxidation, thereby rendering 
intracellular MT populations as toxic sources of zinc.  This first study proposed a 
dichotomous nature of MT: as potentially protective and toxic under different toxic 
exposures.   
 We and others previously demonstrated that toxic zinc exposure to isolated brain 
mitochondria produces disturbances in mitochondrial function.  Methods used to show 
zinc uptake into mitochondria primarily through the calcium uniporter remain 
inconclusive.  In addition, we have demonstrated that removal of extramitochondrial zinc 
protects against zinc-mediated mitochondrial defects.  Therefore a fundamental question 
remains whether zinc is physically transported into mitochondria or does zinc act at an 
external site without requiring mitochondrial entry to generate its toxic consequences.  To 
address this very specific question, we used a novel method to fluorescently track zinc 
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 changes in glass coverslip-adherent isolated brain mitochondria using fluorescence 
microscopy.  We observed that mitochondria do indeed accumulate zinc when exposed to 
pathophysiological levels.  The ability of mitochondria to take up zinc was reduced, but 
not completely abolished, when the mitochondria were less polarized and when the 
calcium uniporter was blocked, suggesting a number of pathways for zinc action on 
mitochondria that are concentration-dependent. 
 The last aim of the thesis slightly deviates from the more traditional studies in 
zinc-induced neurotoxicity and is more closely associated with the mainstream interests 
of our lab.  Although still within the realm of zinc and mitochondria, it introduces the 
more novel concept that mitochondria are not simply static cellular energy-generating 
factories, but are quite dynamic entities that are constantly moving and changing shape.  
It is hypothesized that this so called “trafficking” of mitochondria is essential for proper 
energy distribution and functioning of neurons.  In recent years, our lab has become 
increasingly interested in the consequences of neuronal injury on the trafficking of 
mitochondria to appropriate region of neurons where needed.  We have been able to 
successfully visualize and track mitochondria within living neurons through methods of 
fluorescent labeling of mitochondrial proteins.  Our earlier studies have published results 
suggesting that glutamate excitotoxicity not only impairs mitochondrial movement in 
neurons, but also dramatically alters their morphology. Together, these two events may 
contribute to both mitochondrial dysfunction and their ability to deliver ATP and 
maintain calcium levels within various regions of the neuron and may overall contribute 
to cellular injury.   
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  We extended this study to investigate the effects of zinc, as an effective 
neurotoxin and mitochondrial toxin, on mitochondrial trafficking.  Toxic loads of zinc 
effectively impair mitochondrial movement, but unlike glutamate, do not cause any gross 
morphological changes.  In exploring the mechanism responsible for this zinc-mediated 
effect, we identified the transient activation of PI 3-kinase as necessary for movement 
inhibition.  Interestingly, blocking activation of this protein kinase prevented movement 
inhibition and neurotoxicity induced with toxic zinc elevations, suggesting a common 
pathway between changes in mitochondrial trafficking and zinc-induced injury.  Also 
notable is the rare evidence for PI 3-kinase activity involvement in cell death, whereas 
the major body of literature describes it as a mediator of cell survival.    
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 Chapter 2.  Divergent consequences arise from metallothionein 
overexpression in astrocytes: zinc buffering and oxidant-induced zinc 
release 
 
2.1 Abstract 
Excessive accumulation of the heavy metal zinc is cytotoxic.  As a consequence, 
cellular vulnerability to zinc-induced injury may be regulated by the abundance of 
proteins that maintain intracellular free zinc concentrations ([Zn2+]i).  In this study, we 
over expressed the zinc-binding protein  metallothionein-II (MT) in astrocytes to assess 
its impact as (i) an acute zinc buffering mechanism and (ii) an oxidant-releasable zinc 
pool.  Over expression of MT in primary astrocyte cultures was accomplished using an 
adenoviral vector.  Using the zinc-sensitive fluorescent indicator mag-fura-2, we 
monitored [Zn2+]i after stimulating zinc influx or oxidant treatment.  With MT over 
expression, we observed an acute buffering effect manifested as a dampening of 
stimulus-induced increases in [Zn2+]i.  Contrastingly, we also saw enhanced zinc release 
with application of the sulfhydryl oxidizing agent 2,2’-dithiodipyridine.  These results 
indicate that over expression of a zinc-binding protein can quickly diminish [Zn2+]i 
following zinc influx, but elevate [Zn2+]i under conditions of oxidative stress, providing 
protective yet potentially endangering effects. 
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 2.2 Introduction 
Intracellular free zinc ([Zn2+]i) is important for the activities of many cellular 
enzymes and proteins.  However, recent studies have identified it as a toxin to cells 
maintained in culture (Choi et al., 1988; Koh and Choi, 1988; Weiss et al., 1993; Koh and 
Choi, 1994; Manev et al., 1997).  In addition to in vitro paradigms, studies using animal 
models suggest that elevated [Zn2+]i may contribute to neurodegeneration in conditions 
such as ischemia (Koh et al., 1996), epilepsy (Frederickson et al., 1988) and head trauma 
(Suh et al., 2000).  It has been demonstrated that zinc differentially affects neural cell 
types.  The finding that astrocytes require much higher concentrations for zinc-mediated 
injury compared to neurons (Dineley et al., 2000) suggests unique characteristics of this 
cell type, such as glial-specific zinc buffering mechanisms (Choi et al., 1988).   
It is likely that cells have intrinsic mechanisms for controlling and preventing 
accumulation of [Zn2+]i.  For example, the total intracellular zinc concentration is 
approximately 150 µM, whereas the free zinc concentration is much lower, in the pM 
range (Outten and O'Halloran, 2001).  This presumably reflects the abundance of 
intracellular zinc binding components in the cytoplasmic milieu.  Several candidate 
homeostatic mechanisms for maintaining [Zn2+]i have been identified.  These include zinc 
transporters as well as the zinc-binding protein metallothionein (MT).   Certain members 
of these two families are thought to be regulated by the metal response element-binding 
transcription factor (MTF-1), so that the expression levels of these proteins are increased 
in response to increases in [Zn2+]i  (Palmiter, 1994; Langmade et al., 2000).  
The most well characterized example of a zinc-binding protein is metallothionein 
(MT), a low molecular weight (6-7 kDa) protein that binds and sequesters metal ions, 
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 such as copper, zinc and cadmium (Shaw et al., 1991).  MT is a cysteine-rich molecule, 
which can bind up to seven zinc ions with high affinity, KD ~ 1.4 x 10-13 M, (Maret and 
Vallee, 1998) forming metal thiolate clusters (Arseniev et al., 1988).  Four isoforms of 
mammalian MT have been identified, designated I-IV: MT-I and MT-II are expressed 
ubiquitously (Palmiter, 1987), MT-III is found primarily in neurons (Masters et al., 
1994), and MT-IV is expressed in differentiated squamous epithelial cells (Quaife et al., 
1994).  Endogenous MT-I and MT-II mRNA are directly inducible in cells by various 
stimuli (i.e. metals, glucocorticoids and oxidative stress) while the primarily neuronal 
MT-III mRNA is relatively unresponsive to induction (Kramer et al., 1996).  In addition 
to behaving as a heavy metal scavenger, other functions of MT include regulating the 
biosynthesis and activities of zinc metalloproteins and metalloenzymes (Cherian, 1977) 
and providing cytoprotection from free radical damage (Schwarz et al., 1994).   
The over expression of MT both in cell culture and animal models results in 
resistance to heavy metal toxicity (Hidalgo et al., 2001).  This suggests that MT may be 
an important player in protecting cells from elevated levels of heavy metals.  
Interestingly, a recent study demonstrated induction of the MT-II transcript in mice 
following transient focal cerebral ischemia (Trendelenburg et al., 2002), supporting the 
idea of a more neuroprotective role for MT-II.  However, despite available evidence on 
this family of proteins, an explicit physiological role for MT in zinc homeostasis still 
remains unknown. 
  Aside from its intrinsic ability to bind zinc, MT also functions dynamically by 
releasing zinc ions under certain conditions. Specifically, the multiple cysteine residues 
of the protein are susceptible to oxidation, thereby releasing bound metal in the process.  
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 Indeed, the oxidant-induced release of zinc ions from MT has been demonstrated in cell-
free systems (Maret and Vallee, 1998).  In addition, previous studies have suggested the 
release of zinc ions from metalloproteins in neuronal cultures under oxidative conditions 
(Aizenman et al., 2000).  Furthermore, it has been shown that nitric oxide can liberate 
zinc ions presumably from metalloproteins in the brain in vivo (Cuajungco and Lees, 
1998).  These lines of evidence oppose a protective role, but rather suggest a detrimental 
function for MT under an oxidative burden. 
In this study, we investigated the role of MT in zinc homeostasis in primary 
astrocyte cultures to identify an explicit buffering effect of MT on [Zn2+]i.  We 
demonstrate the novel effect of MT-over expressing cells to maintain lower [Zn2+]i 
compared to wild-type cells following an equivalent zinc load.  On the other hand, we 
also demonstrate that MT-over expressing cells exhibit increased oxidant-induced [Zn2+]i 
release compared to control cells, implicating MT as a deleterious source of [Zn2+]i.  This 
study thus identifies a dual role for MT in regulating [Zn2+]i. 
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 2.3 Materials & Methods 
 
Cell Culture 
 Procedures involving animals were in agreement with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the Institutional Animal Care and 
Use Committee of the University of Pittsburgh.  Primary cultures of Type I astrocytes 
were prepared as previously described (Kress et al., 2002) from cortices removed from 
one day-old Sprague-Dawley rats and plated on 75 mm2 flasks in Basal Medium Eagle’s 
(BME) supplemented with 15% fetal bovine serum (FBS), 0.1% glutamine, 0.6% 
glucose, 100 U/mL penicillin and 100 µg/mL streptomycin.  Medium was changed every 
other day for ten consecutive days after plating.  The flasks were then shaken for 15-18 
hours at 37˚C to remove other glial types.  The remaining astroglial cells were removed 
by trypsin and plated on poly-D-lysine-coated 31 mm glass coverslips placed in 6-well 
plates in supplemented BME.  All experiments were done on cells 1-7 days after being 
plated on coverslips.  
 
Infections 
 Astroglial cultures were infected with an MT replication deficient adenovirus, 
constructed from an E1a-deleted replication-deficient adenoviral vector expressing the 
human metallothionein-IIA using a kit from Microbix Biosystems, Inc. and a bacterial 
plasmid containing the MT insert (Sciavolino et al., 1992).  Media were aspirated from 
the wells of the culture plates and 250-400 µL of infected media (diluted appropriately 
from a stock concentration of 1.8 x 1011 PFUs/mL) were added per well and incubated for 
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 one hour at 37˚C, during which the plates were shaken every ten minutes.  After one 
hour, the virus was diluted with 1.5 mL fresh media per well and plates were incubated 
for an additional 16-24 hours before performing experiments.  
 
Immunocytochemistry 
 MT-infected astrocyte cultures were fixed in 4% paraformaldehyde for 30 
minutes at room temperature prior to blocking in 10% BSA (in PBS) for an additional 30 
minutes.  Cells were then incubated in a mouse monoclonal MT antibody (Dako Corp, 
Carpinteria, CA) overnight at 4˚C at a 1:500 dilution (in 3% BSA/0.4% Triton-X in 
PBS).  Following a series of 1X PBS washes, cells were then placed in a goat anti-rat 
secondary antibody conjugated with Cy3 (1:1000 in 3% BSA/0.4% Triton-X in PBS) for 
2 hours at room temperature.  Plates were rinsed in 1X PBS again before viewing under 
the microscope.  
 
Reagents and solutions  
 During microfluorimetric [Zn2+]i recordings, cells cultured on coverslips were 
perfused at a constant rate with HEPES-buffered salt solution (HBSS), containing 140 
mM NaCl, 5 mM KCl, 0.9 mM MgSO4, 1.4 mM CaCl2, 10 mM NaHCO3, 0.6 mM 
Na2HPO4, 0.4 mM KH3PO4, 20 mM HEPES and 5.5 mM glucose, adjusted to pH 7.4 
with NaOH.  Amounts of zinc were diluted from 1000X stocks of ZnCl2 made in 25 mM 
HCl.  The zinc-specific ionophore sodium pyrithione (Sigma, St. Louis, MO) was added 
at a concentration of 20 µM from a stock of 20 mM in DMSO.  The membrane-permeant 
heavy metal chelator N,N,N’,N’-tetrakis(2-pyridalmethyl)ethylenediamine (TPEN) 
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 (Molecular Probes, Eugene, OR) was added at a concentration of 25 µM from a 25 mM 
stock in DMSO.  The sulfhydryl oxidizing agent 2,2’-dithiodipyridine was added at a 
concentration of 100 µM from a stock of 100 mM, prepared fresh each time in DMSO. 
 
Fluorescence Microscopy 
 [Zn2+]i measurements were recorded from control, LacZ-infected and MT-
infected cells using the zinc-sensitive fluorophore mag-fura-2 (Molecular Probes, OR).  
Coverslips were loaded at room temperature for 20 minutes with mag-fura-2 diluted in 5 
mg/mL BSA/HBSS loading buffer for a final concentration of 5 µM before being 
mounted in a recording chamber with constant perfusion at a rate of 20 mL/min.  The 
fluorophore was alternatively illuminated at wavelengths 335 and 375 nm.  Emitted light 
passed through a 400 nm dichroic and a 510/80-wideband emission filter.  The PC-based 
imaging system consisted of a monochromator-driven xenon light source (ASI, OR), 
Nikon Diaphot 300 microscope with a 40X oil immersion objective, a CCD camera 
(Hamamatsu Photonics, Japan) and a PC-based acquisition program (SimplePCI, 
Compix, PA).  All microfluorimetric measurements were performed at room temperature.  
 
Data Analysis 
 Data were represented as a comparison of the mag-fura-2 ratio changes that 
occurred prior and subsequent to an added stimulus.  This ratio change was generated by 
subtracting the baseline ratio value from the ratio value achieved at the end of the 
stimulus.  Each experiment averaged 5-10 cells in a single field of a coverslip, and 
experiments were repeated in cultures from 3-5 independent infections.  Values were 
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 analyzed with the appropriate statistical tests using the software package GraphPad Prism 
3.0 (GraphPad Software, Inc., San Diego, CA). 
 
2.4  Results 
 
MT over expression in astrocytes 
Previous studies have investigated zinc homeostasis by over expressing human 
metallothionein-IIA in epithelial cells using a replication-deficient adenoviral vector (St 
Croix et al., 2002).  Here, we employed this viral construct to over express MT in 
primary astrocyte cultures.  To determine optimal infection efficiency, cells were infected 
with an adenovirus containing the β-galactosidase gene using a range of viral 
concentrations from 106-109 plaque forming units/mL (PFUs/mL).  The extent of 
infection was visualized through β-galactosidase staining.  From this preliminary 
experiment, an optimal viral titer of 107-108 PFUs/mL, which typically infected 
approximately 60% of cells on any given coverslip, was established for all subsequent 
infections involving the MT adenovirus.  To confirm MT over expression in infected 
cultures, immunocytochemistry was performed using a mouse monoclonal anti-MT 
antibody along with a Cy3-conjugated goat anti-rat secondary antibody.  Protein 
expression was detected using fluorescence microscopy (Figure 2.1).  Comparing non-
infected (A) to infected (B) cells, we showed that marked MT immunofluorescence was 
detected only in infected cultures, consistent with virus-induced MT over-expression.  It 
is not reasonable to conclude an absence of endogenous MT in our astrocyte cultures.  
Indeed, similar cultures stained with the same antibody did reveal MT in wild-type cells 
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 using Western techniques (Rising et al., 1995).  However, under these 
immunocytochemical conditions endogenous MT was not detected in non-infected cells.  
The inability to detect MT-II in non-infected cells precludes estimating the extent of over 
expression through the immunocytochemical procedures we used.  
 
 
 
 
 
 
 
 
A B
 
Figure 2.1  Adenoviral infection induces MT protein expression in astrocytes. 
Primary astrocyte cultures were infected with the MT-II adenovirus at a viral titer of 107-108 
plaque forming units/mL (PFUs/mL) and stained with a monoclonal mouse anti-MT antibody.  
Fluorescent images from (A) control and (B) MT-infected cells confirm that expression is 
detected only in infected cultures.  Results are representative of 3 individual experiments.  
Magnification 40X. 
 
Ionophore-induced [Zn2+]i changes  
Having established over expression of MT in primary astrocytes, we then 
measured [Zn2+]i.  For monitoring [Zn2+]i, we employed a member of the fura-2 dye 
family, mag-fura-2 (Cheng and Reynolds, 1998), which is commonly used to measure 
changes in [Ca2+]i and [Mg2+]i, but has a much higher affinity for Zn2+, KD ~ 20 nM 
(Molecular Probes, Inc., Eugene, OR).  To examine the buffering ability of MT in 
 55
 response to acute changes in [Zn2+]i (Figure 2.2), a brief stimulus of ZnCl2 (1µM) in the 
presence of the zinc ionophore sodium pyrithione (20 µM) was applied to cells (Dineley 
et al., 2000).  As seen in the representative traces shown in Figure 2.2A, ionophore-
induced [Zn2+]i increases are smaller in MT-infected cells compared to controls.  The 
signal remains elevated during the washing out of zinc and pyrithione, indicating that 
[Zn2+]i levels also prevail until the addition of the membrane-permeant heavy metal 
chelator TPEN (25 µM). The reversal of mag-fura-2 fluorescence back to baseline levels 
suggests that the signal reflects [Zn2+]i and not increases in [Ca2+]i or [Mg2+]i.  
Fluorescence signals were not converted to actual [Zn2+]i values here because we have 
recently demonstrated that such calculations previously used in ratiometric imaging may 
be misleading (Dineley et al., 2002).  Cells infected with the LacZ virus were included in 
this paradigm as a negative control to show that the effects seen were not due to the 
induction of endogenous zinc buffering components as a stress response to the virus 
itself.  These results, summarized in Figure 2.2B, demonstrate the significantly reduced 
responses to ionophore-induced [Zn2+]i changes in MT-infected cells compared to both 
control and LacZ-infected cells.  Since we generate a sub-maximal efficiency for each 
infection, these results actually underestimate the true magnitude of the effect.  
Regardless, these observations suggest that MT can act as a rapid buffering mechanism in 
the presence of [Zn2+]i accumulation.   
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Figure 2.2  MT overexpression reduces ionophore-induced [Zn2+]i elevations. 
(A) Representative traces are shown from [Zn2+]i recordings using mag-fura-2, where cells were 
stimulated for 5 minutes with 1 µM ZnCl2 in the presence of 20 µM sodium pyrithione.  
Following a brief HBSS rinse, fluorescence levels were returned to baseline values with a 5-
minute exposure to 25 µM TPEN.  Control cells (as indicated by the solid line) are distinguished 
from those cells infected with the MT adenovirus (indicated by the dotted line).  Each trace 
represents the mean of approximately 5-10 astrocytes from a single coverslip.  (B) The graph 
represents a compilation of all experiments from control, LacZ-infected and MT-infected cells.  
The values above each column indicate the number of coverslips included in each condition.  Bars 
represent means ± S.E.  * P<0.05, one-way ANOVA, Tukey’s multiple comparison test, F = 
1.981. 
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 Oxidant-induced [Zn2+]i release 
 Previous studies in cell free systems have shown that zinc ions are released from 
MT upon oxidative stimuli (Maret and Vallee, 1998).  In addition, Aizenman et al. have 
demonstrated that zinc-induced neurotoxicity can occur upon exposure to a sulfhydryl 
oxidizing agent, presumably from metalloproteins releasing zinc (Aizenman et al., 2000).  
This led us to investigate whether MT over expression in astrocytes affects the pools of 
oxidant-releasable [Zn2+]i (Figure 2.3).  In this experimental paradigm, cells were initially 
exposed to 25 µM TPEN to chelate any unbound or loosely-bound [Zn2+]i, followed by a 
10-minute perfusion with the sulfhydryl oxidizing agent 2,2’-dithiodipyridine (2,2’-
DTDP, 100 µM).  As seen in the sample traces in Figure 2.3A, the response to 2,2’-
DTDP is larger in MT-infected cells compared to non-infected controls.  These results are 
compiled in Figure 2.3B, where the change in mag-fura-2 ratio upon 2,2’-DTDP 
treatment is significantly greater in MT-over expressing cells compared to control cells.  
These data confirm the ability of MT to release [Zn2+]i, as was suggested by previous 
studies in cell-free systems.  In addition, these effects suggest that MT can be a 
significant intracellular source of oxidant-releasable zinc.  
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Figure 2.3  Overexpression of MT enhances oxidant-induced [Zn2+]i release. 
(A) Representative traces of [Zn2+]i recordings from both non-infected (solid line) and MT-
infected (dotted line) astrocytes.  Following a 5-minute perfusion with 25 µM TPEN to chelate 
unbound or loosely-bound [Zn2+]i, 100 µM 2,2’-DTDP was administered for 10 minutes.  (B) The 
graph represents a summary of the 2,2’-2,2’-DTDP-induced [Zn2+]i changes in control and MT-
infected cell populations as indicated by changes in mag-fura-2 ratio values.  Values above each 
column represent the number of experiments done under each condition. Bars represent means ± 
S.E.  * P<0.05, t = 3.375. 
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 Acute zinc pre-loading of cellular thionein 
The ability of MT-infected cells to buffer [Zn2+]i implies that the MT adenovirus 
generates a significant pool of the apo-form of MT, or thionein (St Croix et al., 2002).  
We next investigated whether altering the cellular MT: thionein ratio in infected 
astrocytes would have any consequences on the potential amounts of oxidant-releasable 
[Zn2+]i (Figure 2.4).  Larger quantities of zinc loaded MT would presumably (i) decrease 
the buffering capability of MT and (ii) increase the amounts of oxidant-releasable zinc 
from MT-over expressing cells.  To acutely increase the proportion of zinc-bound MT, 
control and infected cells were pre-loaded with an initial zinc stimulus as described above 
(Figure 2.2), after which the oxidant 2,2’-DTDP was introduced (Figure 2.4A).  As a 
control for pre-loading, cells were perfused with sodium pyrithione alone for the same 
period of time (Figure 2.4B).  With pyrithione treatment alone, we occasionally observed 
increases in signal, which reflect ambient zinc in the buffer, and such responses did not 
vary between control and infected cells.  As anticipated, MT over expression increased 
the response to 2,2’-DTDP. However, the pre-loading treatment with zinc and sodium 
pyrithione did not significantly enhance the subsequent response to 2,2’-DTDP in either 
of the conditions tested (Figure 2.4C).  These series of experiments conclude that acute 
zinc pre-loading of MT does not enhance oxidant-releasable zinc. 
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Figure 2.4  [Zn2+]i release is not enhanced in zinc pre-loaded MT-infected cells.  
Oxidant-induced [Zn2+]i was recorded from control (solid line) and MT-infected (dotted line) 
cells in the (A) presence or (B) absence of an initial 1 µM ZnCl2 stimulus facilitated by 20 µM 
sodium pyrithione.  Following this 5-minute stimulus and a brief HBSS wash, 25 µM TPEN was 
administered to chelate any free [Zn2+]i.  After a subsequent HBSS rinse, 100 µM 2,2’-DTDP was 
applied for approximately 10 minutes as described in Figure 3.  (C) The graph represents a 
summary of all experiments done using this paradigm under control, LacZ-infected and MT-
infected conditions, where open bars represent those coverslips pre-loaded with sodium 
pyrithione alone and solid bars represent those coverslips pre-loaded with sodium pyrithione in 
the presence of ZnCl2.  Numbers above columns represent the number of times experiments were 
repeated.  Bars represent ± S.E.  * P<0.05, t = 1.666. 
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2.5 Discussion 
The findings from this study demonstrate that MT over expression in cultured 
cells results in enhanced [Zn2+]i buffering following an acute zinc load.  On the contrary, 
MT over expression also enhanced [Zn2+]i release in response to an oxidative stimulus, 
thus revealing potentially endangering effects of increasing the levels of this protein in 
cells.  Earlier studies found associations between MT expression and neuroprotection in 
both cells and animals that over express MT (Durnam and Palmiter, 1987; van Lookeren 
Campagne et al., 1999), presumably through buffering of [Zn2+]i.   However, we are not 
aware of any studies that have explicitly demonstrated that up regulating MT expression 
can actually alter [Zn2+]i.  Thus, the findings presented here provide a direct 
demonstration that over expression of MT can decrease [Zn2+]i. 
 
Comparison to cytosolic calcium-binding proteins 
Although these findings are novel with respect to [Zn2+]i buffering, our findings 
are analogous to previous studies that had over expressed cytosolic calcium binding 
proteins.  For example, Lledo and colleagues showed that overexpressing calbindin-D28k 
in GH3 cells decreased the magnitude of intracellular calcium transients (Lledo et al., 
1992).  Similar results have been reported in PC12 cells (McMahon et al., 1998) and 
HEK293 cells (Rintoul et al., 2001).  The overexpression of calcium binding proteins 
therefore provides a model that is quite analogous to the results reported here. 
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Cellular redox environment modulates zinc binding and release 
Several lines of evidence suggest that the cellular redox environment mediates 
zinc binding and release.  When MT is oxidized in the presence of glutathione, it releases 
free zinc ions, while under reducing conditions the protein remains metallated (Maret and 
Vallee, 1998).  Therefore, changes in cellular redox status can modulate zinc release.  It 
is likely that the modification of the thiol ligands in the MT clusters that house the zinc 
ions ultimately determines the extent of zinc mobilization (Jacob et al., 1998).  It was 
previously shown that under conditions of oxidative stress in cultured neurons, the zinc 
released from intracellular stores can contribute to neuronal injury via an apoptotic 
cascade (Aizenman et al., 2000).  This was accomplished with the sulfhydryl oxidizing 
agent, 2,2’-dithiodipyridine (2,2’-DTDP), which we also used in our experiments.  
Although 2,2’-DTDP produced significantly and consistently larger increases in 
fluorescence signal in MT-overexpressing cells compared to those containing basal levels 
of expression, 2,2’-DTDP is far removed from a true physiological stimulus.  Nitric oxide 
(NO), on the contrary, has been demonstrated to mobilize [Zn2+]i both in vivo (Cuajungco 
and Lees, 1998) and in vitro (St Croix et al., 2002), presumably through its release from 
metalloproteins.  It is also conceivable that a protein other than MT contributes to the 
oxidant-induced release of zinc in cells since there are many other zinc-bound cellular 
proteins and enzymes.  For example, it has been suggested that protein kinase C (PKC), 
an abundant intracellular protein, can release zinc in the presence of oxidants (Knapp and 
Klann, 2000).  Thus, even though we were unable to identify neither the endogenous 
oxidant nor the metalloprotein species responsible for zinc release in wild-type cells, this 
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 study provides an interesting observation that enhanced oxidant-sensitive release of zinc 
is a possible outcome if MT protein expression is altered. 
 
Regulating zinc loading of thionein 
A previous study by St. Croix et al. has specifically demonstrated NO-induced 
zinc release from MT in epithelial cells (St Croix et al., 2002).  They concluded that the 
overall cellular ratio of MT to non-metal bound thionein is the critical factor that 
determines the buffering power of the system.  The authors observed an NO-induced zinc 
release from MT with adenoviral infection alone, which was then enhanced when cells 
were grown overnight in zinc-supplemented media.  This implies that infected cells 
contain mainly the apo-form of MT, or thionein.  In our experiments we applied a 
strategy for potentially converting thionein to MT by acutely exposing cells to a zinc pre-
loading stimulus prior to assessing the effects of oxidants.  However, we did not observe 
enhanced oxidant-induced zinc release when astrocytes were pre-loaded with a brief zinc 
stimulus regardless of MT over expression.  This suggests that our astrocyte cultures, 
when infected with virus, contain mostly metallated protein, as opposed to thionein.  
However, the profound buffering effect that we observed in our MT-over expressing cells 
argues against this hypothesis.  In addition, the limited time frame of the pre-loading 
experiments suggests that saturating MT may not occur as rapidly or efficiently.  Perhaps 
a more chronic or prolonged zinc exposure of MT-infected cells would more efficiently 
load zinc onto MT.  It is also possible that there are essentially two pools of sulfhydryl 
groups that can bind and buffer zinc, but that only one of the two pools is oxidant 
sensitive.  If this oxidant-sensitive pool is fully metallated, while the second pool is not 
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 saturated and thus available to bind zinc, this would generate conditions where the zinc 
buffering was enhanced while the oxidant-releasable zinc pool was not increased by zinc 
loading.  This could explain the findings we report here, although further experiments 
would be required to fully evaluate this hypothesis.  One could also speculate that MT 
acts as a metal chaperone to deliver zinc to an undetermined oxidant-sensitive zinc pool.  
It is conceivable that because the timed nature of these experiments, an acute zinc pre-
loading followed by application of the oxidant is too rapid for MT to deliver metal to this 
unknown zinc-binding protein.   However, we cannot conclude this based on the results 
presented here since little is known about the dynamics of the mechanisms that regulate 
zinc loading of thionein in astrocytes. 
 
Are astrocytes more resistant to zinc-mediated injury compared to neurons ? 
We have previously demonstrated that astrocytes are less vulnerable to both zinc- 
and iron-induced injury when compared to neurons (Dineley et al., 2000; Kress et al., 
2002).  Astrocytes are also relatively resistant to the toxic effects of DTDP (Aizenman et 
al., 2000).  Therefore, the primary astrocyte cultures used here was a sub-optimal system 
for studying zinc-induced cytotoxicity.  However, unlike neurons, which are synaptically 
excitable cells, astrocytes lack the various neurotransmitter receptors that act as potential 
entry routes for zinc.  This benefits our aim of primarily studying the cytosolic binding 
and release of zinc without the added burden of considering its cytotoxic influences.  
Unlike primary neuronal cultures, astrocytes are also more easily manipulated for 
biochemical purposes.  We have demonstrated previously that astrocytes are more 
resistant to the toxic consequences of elevated [Zn2+]i compared to neurons (Dineley et 
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 al., 2000).  It is possible that either the elevated endogenous levels of MT-I or MT-II or 
else the induction of MT-I and MT-II in astrocytes may explain this zinc resistance.  
However, it is also possible that the targets of zinc-mediated injury are relatively resistant 
in astrocytes compared to neurons. Unfortunately, we cannot make this distinction from 
the present study.  Regardless, we present an interesting dichotomous nature of MT 
during ischemic conditions: in one aspect behaving as an important [Zn2+]i buffering 
agent, but on the other hand existing as an intracellular source for toxic amounts of zinc 
during oxidative stress. 
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 Chapter 3.  Direct visualization of mitochondrial zinc accumulation 
reveals uniporter dependent and –independent transport mechanisms 
 
3.1 Abstract 
Current evidence suggests that zinc may kill neurons by disrupting energy 
production, specifically by inhibiting mitochondrial function.  However it is unclear if the 
inhibitory effect requires zinc accumulation, and if so, precisely how zinc enters 
mitochondria.  Here, using fluorescence microscopy to visualize individual rat brain 
mitochondria, we detected matrix zinc uptake using the fluorophore FluoZin-3.  
Fluorescence increased rapidly in mitochondria treated with micromolar free zinc, and 
was quickly returned to baseline by membrane permeant chelation.  Zinc uptake occurred 
through the calcium uniporter, because depolarization or uniporter blockade reduced 
fluorescence changes.  However, increased fluorescence under these conditions suggests 
that zinc can enter through a uniporter-independent pathway.  Fluorescence steadily 
declined over time and was unaffected by acidification or phosphate depletion, 
suggesting that zinc precipitation is not a mechanism for reducing matrix zinc.  Uniporter 
blockade with ruthenium red also did not change the rate of zinc loss.  Instead, zinc 
appears to exit the matrix through a novel efflux pathway not yet identified.  
Interestingly, dye-loaded mitochondria showed no fluorescence increase after treatment 
with strong oxidants, arguing against oxidant-labile intramitochondrial zinc pools.  This 
study is the first to directly demonstrate zinc accumulation in individual mitochondria 
and provides insight about mechanisms mediating mitochondrial zinc uptake and efflux. 
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 3.2 Introduction 
 Mitochondria are semi-autonomous organelles that play a critical role in 
maintaining energy gradients required for neuronal survival through control of ATP 
production, calcium (Ca2+) mobilization, and reactive oxygen species (ROS) 
accumulation.  During glutamate excitotoxicity, which is most commonly used to model 
ischemic injury, intracellular Ca2+ reaches pathophysiological levels.  This in turn leads to 
mitochondrial perturbations such as Ca2+ overload, dissipation of mitochondrial 
membrane potential (∆Ψm), and decreased ATP production.  Consequently, the impaired 
mitochondria may initiate a cell death cascade involving the release of pro-apoptotic 
molecules and further ROS accumulation (Nicholls and Budd, 2000). 
 In vivo evidence suggests that intracellular free zinc ([Zn2+]i) contributes to 
neurodegeneration in transient global (Koh et al., 1996) and focal (Lee et al., 2002) 
cerebral ischemia.  Moreover, there are extensive in vitro reports identifying exogenous 
Zn2+ as a potent neurotoxin to cells in culture (Choi et al., 1988; Koh and Choi, 1994).  
Other evidence suggests that neurotoxic [Zn2+]i can be mobilized from intracellular stores 
in response to oxidative stress (Aizenman et al., 2000).  Precisely how Zn2+ kills neurons 
remains unclear, but a growing body of evidence suggests that Zn2+ may impair neuronal 
energy production, specifically by inhibiting mitochondria (Dineley et al., 2003).  Indeed, 
as early as 1967, Skulachev suggested that Zn2+ blocks complexes of the electron 
transport chain, findings that were generally supported by subsequent studies (Skulachev 
et al., 1967; Nicholls and Malviya, 1968; Kleiner, 1972, 1974; Lorusso et al., 1991; Link 
and von Jagow, 1995; Mills et al., 2002).  Other possible sites of Zn2+ action include the 
TCA cycle (Brown et al., 2000; Gazaryan et al., 2002).  The consequences of Zn2+ 
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 inhibition are potentially numerous, including swelling and cytochrome c release (Jiang et 
al., 2001), loss of ∆ψm, and increased ROS production (Sensi et al., 1999; Sensi et al., 
2000; Dineley et al., 2005). 
 While it is obvious that Zn2+ can disrupt mitochondrial function, it unclear 
whether Zn2+ acts externally or if mitochondria import Zn2+ into the matrix.  Several 
studies show that the Ca2+ uniporter blocker ruthenium red partially protects against Zn2+ 
effects on mitochondria (Brierley and Knight, 1967; Saris and Niva, 1994; Jiang, 2001), 
implying that Zn2+ enters via a pathway that normally accommodates Ca2+.  However 
these studies provide no direct evidence that Zn2+ is actually imported into the matrix. 
 In this report, we have used a novel mitochondrial preparation technique (Vergun 
et al., 2003b) to study Zn2+ transport in individual mitochondria.  This approach is 
superior to previous experiments using mitochondrial suspensions because it employs 
fluorescent indicators to detect matrix Zn2+, allows substrates and solutions to be perfused 
onto mitochondria when desired, and removes the ambiguity of signals arising from dye 
leakage.  Using the high affinity Zn2+ indicator FluoZin-3, we provide evidence for two 
distinct mechanisms for Zn2+ import.  The first was consistent with a uniporter-like 
mechanism because it required ∆ψm, was inhibited by ruthenium red, and was relatively 
high capacity.  A second mode of Zn2+ import occurred in the absence of ∆ψm, was 
insensitive to uniporter blockade, and was relatively low capacity.  Additionally, the 
results and methods presented here provide a new practical and conceptual framework for 
investigating mitochondrial Zn2+ homeostasis. 
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 3.3 Experimental Procedures 
 
Materials   
All reagents were purchased from Sigma (St. Louis, MO) unless otherwise specified.  
 
Isolation of brain mitochondria   
All procedures using animals were in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by the Institutional 
Animal Care and Use Committee at the University of Pittsburgh.  Rat brain mitochondria 
were isolated from the cortex of adult Sprague Dawley rats as previously described by 
Vergun et al. (2003b).  Briefly, mitochondria were isolated using a Percoll gradient 
method described by Sims (1991) with minor modifications.  Isolation buffer contained 
(in mM) 225 mannitol, 75 sucrose, 0.5 EDTA, 5 HEPES, and 1 mg/ml fatty acid free 
BSA, pH adjusted to 7.4 with KOH.  All isolation procedures were carried out at 0-2oC.  
Mitochondria in isolation medium were stored on ice until use.   
 
Fluorescence Microscopy 
All imaging experiments were performed at room temperature in KCl-based buffer 
containing (in mM) 125 KCl, 2 K2HPO4, 5 HEPES, 5 MgCl2, 0.02 EDTA, 5 malate, 5 
glutamate and 0.05 ATP, pH adjusted to 7.0 with KOH.  Mitochondria were added to this 
buffer at a final concentration of 0.75-1 mg protein/ml immediately before each 
experiment.  For phosphate-free experiments, K2HPO4 was replaced with 2 mM 
KC2H3O2.  Thirty-one mm glass coverslips were washed with 70% ethanol, then with 
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 H2O and dried prior to use.  A 20 µl drop of mitochondrial suspension was placed in the 
middle of the coverslip for 5-7 min.  Coverslips were then placed into a 700-µl perfusion 
chamber and mounted onto a microscope fitted for fluorescence imaging as described 
below. The coverslip was superfused with KCl buffer at 5 ml/min; after 1 min of 
perfusion unattached mitochondria were effectively washed out of the recording chamber.  
Typically, mitochondria remained attached at a density of 400,000 – 500,000 per square 
millimeter.  Thus, approximately 2,000 mitochondria were present in a field observed 
with a 100x objective. 
For ∆Ψm measurements we used the potentiometric probes rhodamine 123 
(Rh123) and tetramethylrhodamine methyl ester (TMRM) (Molecular Probes, Eugene, 
OR) at nonquenching concentrations.  Rh123 (200 nM) or TMRM (40 nM) was present 
in the perfusion medium during the experiment (no preloading was necessary).  To 
monitor Zn2+ uptake, the mitochondria were loaded with 50 µM FluoZin-3 AM 
(Molecular Probes Eugene, OR) in substrate-free KCl buffer containing 200 µM EGTA 
for 20 min at 37°C, and then placed onto the coverslip as described above.  Polarized 
FluoZin-3 loaded mitochondria were pre-selected by transiently adding TMRM to the 
perfusate.  After preselection, TMRM was no longer included in the buffer.  Under such 
conditions TMRM is completely gone from the matrix in 1 to 2 minutes, allowing us to 
measure “pure” FluoZin-3 changes.  Treatments of ZnCl2 and other reagents were diluted 
in KCl buffer from stock concentrations and perfused onto mitochondria at 5 ml/min.   
For the fluorescence recording we used a BX50WI Olympus Optical (Tokyo, 
Japan) microscope fitted with an Olympus Optical LUM PlanFI 100x water immersion 
quartz objective.  The fluorescence was monitored using excitation light provided by a 
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 75W xenon lamp-based monochromator (T.I.L.L. Photonics GmbH, Martinsried, 
Germany), and emitted light was detected using a CCD camera (Orca; Hamamatsu, 
Shizouka, Japan).  Rh123 or FluoZin-3 was illuminated at 490 nm, and light passed 
through a 500 nm long pass dichromatic mirror and a 535/25 nm band pass filter (Omega 
Optical, Brattleboro, VT).  TMRM was excited at 550 nm, light passed through a 570 nm 
long-pass dichromatic mirror and a 605/55 nm band pass filter.  Fluorescence data was 
acquired and analyzed using Simple PCI software (Compix Inc, Cranberry PA).  
Fluorescence was measured in 50-100 individual mitochondria for each coverslip.  
Objects smaller than 0.3 µm in diameter were not analyzed.  Background fluorescence 
was collected from 3-4 mitochondrion-free regions and subtracted from all the signals.  
All experiments were repeated 4-6 times using mitochondria from at least three different 
animals. 
 
Statistics   
Statistical analysis was performed using Prism 4.01 (Graph Pad Software, San Diego, 
CA).  All the data are presented as mean ± S.E.  Comparisons were made using Student’s 
t test and one-way ANOVA with Dunnett posttest to compare all conditions to control, 
with p values of less than 0.05 regarded as significant. 
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 3.4 Results 
 
Visualization of Zn2+ uptake into single mitochondria   
We visualized mitochondrial Zn2+ uptake using the high affinity Zn2+ indicator 
FluoZin-3 AM (KD ~ 15 nM), which was loaded into isolated rat brain mitochondria prior 
to attachment onto glass coverslips (Vergun et al., 2003b).  FluoZin-3 signal was dim in 
unstimulated mitochondria (Figure 3.1A), but increased greatly upon addition of 30 µM 
ZnCl2 to the perfusate (Figure 3.1B).  We used the potentiometric probe TMRM in these 
same mitochondria to show that most were polarized at the outset as indicated by a bright 
TMRM signal (Figure 3.1C), but depolarized in response to Zn2+ (Figure 3.1D).  A 
representative FluoZin-3 trace (Figure 3.1E) shows that an acute Zn2+ stimulus produced a 
rapid and robust increase in FluoZin-3 signal in mitochondria that was quickly reversed to 
baseline by the membrane-permeant heavy metal chelator TPEN (25 µM).  As noted in 
materials and methods, TMRM was used transiently at the beginning of the experiment to 
allow pre-selection of healthy, polarized, FluoZin-3 loaded mitochondria.  In a typical 
experiment, >90% of attached mitochondria were polarized; mitochondria depolarized at 
the outset were not selected for analysis.   
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Figure 3.1  FluoZin-3 detects Zn2+ uptake in single mitochondria.  Isolated 
mitochondria loaded with FluoZin-3 AM were perfused with 30 µM added ZnCl2 to stimulate 
mitochondrial Zn2+ accumulation.  FluoZin-3 images were captured before (A) and after (B) Zn2+ 
exposure.  Corresponding TMRM images were taken before the start of the experiment (C) to 
select polarized mitochondria, and after Zn2+ exposure (D) to demonstrate Zn2+-induced 
mitochondrial depolarization.  A representative trace (E) shows that Zn2+ produces a rapid and 
robust increase in FluoZin-3 signal which is reversed by 25 µM TPEN.  Data from (E) represent 
the mean ± S.E. from approximately 50-100 mitochondria within a given field.   
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 FluoZin-3 detects matrix Zn2+ in a concentration-dependent manner 
To determine the lowest concentration of Zn2+ that produces an increase in 
FluoZin-3 fluorescence, we perfused mitochondria with a range of added ZnCl2 
concentrations (0, 21, 25, 30 and 100 µM).  Using the web-based program 
MAXCHELATOR (http://www.stanford.edu/~cpatton/maxc.html), we estimated 
approximate free Zn2+ concentrations of 0, 1, 5, 10, and 80 µM given the chelator present 
in the KCl buffer (20 µM EDTA) and the binding affinity of EDTA for Zn2+ (KD ~ 7.6 x 
10-14 M).  This is likely an overestimation of free [Zn2+] as it only takes into consideration 
the added [Zn2+] and [EDTA], but not other buffering components in the medium.  From 
this approximation, concentrations of Zn2+ from here on will be described as free Zn2+ 
values.  As the representative traces in Figure 3.2A show, this range of free Zn2+ produced 
concentration-dependent FluoZin-3 responses, which reached maximum levels at 10 µM 
free Zn2+.  Perfusion with TPEN alone (25 µM) did not significantly decrease the basal 
signal, indicating that the endogenous mitochondrial free Zn2+ pool is small and 
contributes minimally to background fluorescence (Figure 3.2B).   
We observed fluorescence increases in response to Zn2+ stimuli within distinct, 
single mitochondria.  A recent study used membrane-impermeant Ca2+ indicators to detect 
free Ca2+ in the intermembrane space (Chalmers and Nicholls, 2003).  To be convinced 
that FluoZin-3 was detecting matrix Zn2+ and not Zn2+ trapped in the intermembrane 
space, we incubated mitochondria with the membrane impermeant salt form of FluoZin-3 
(Figure 3.2B) that would be expected to enter the intermembrane space.  Exposure to 10 
µM free Zn2+ did not increase fluorescence.  This data suggests that FluoZin-3 AM is 
indeed detecting matrix free Zn2+.  To be certain that FluoZin-3 was selective for Zn2+ in 
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 this context, we perfused dye-loaded mitochondria with 200 µM CaCl2 (Figure 3.2B).  
Consistent with cell-free dye measurements, high Ca2+ caused no FluoZin-3 increase 
(Devinney et al., 2005).  This additionally demonstrated that large Ca2+ loads did not 
elevate matrix free Zn2+. 
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Figure 3.2  Mitochondria accumulate matrix Zn2+ in a concentration-dependent 
manner.  (A) Representative traces from mitochondria exposed to increasing concentrations of 
added ZnCl2 (0, 21, 25, 30 and 100 µM) display increasing FluoZin-3 responses.  In considering 
the concentration of chelator present during experiments (20 µM EDTA), we have estimated free 
Zn2+ concentrations of 0, 1, 5, 10 and 80 µM, respectively.  (B) Summary of FluoZin-3 responses 
indicate that the signal reaches maximal levels at approximately10 µM free Zn2+.  Controls: (1) 
mitochondria incubated with the membrane impermeant salt form of FluoZin-3 and perfused with 
10 µM free ZnCl2 (“salt”), (2) perfused with 25 µM TPEN alone (“TPEN”), and (3) perfused with 
200 µM CaCl2 alone (“Ca2+”).  Data from (A) represent the means ± S.E. from approximately 50-
100 mitochondria within a given field.  Data from (B) represent the mean ± S.E. of 4-6 
experiments from at least three different mitochondrial preparations.   
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 Loss of ∆Ψm, uniporter blockade, or co-application of Ca2+ reduces mitochondrial Zn2+ 
uptake 
Next, we examined if ∆Ψm drives Zn2+ uptake into mitochondria (Figure 3.3).  
Through TMRM fluorescence we have established that approximately 90% of attached 
mitochondria are polarized at the start of the experiment prior to addition of Zn2+ (Figure 
3.1C), and only these mitochondria were selected for analysis.  Mitochondria were 
depolarized prior to Zn2+ with a 5-pre-treatment with (i) the uncoupler FCCP (250 nM) or 
(ii) high Ca2+ (200 µM) (Figure 3.3A).  Both of these maneuvers reduced Zn2+ uptake by 
as much as much as 80% suggesting that ∆Ψm drives matrix Zn2+ import. 
Several studies suggested that mitochondrial Zn2+ uptake occurs through the Ca2+ 
uniporter (Brierley and Knight, 1967; Saris and Niva, 1994; Jiang et al., 2001).  To 
determine if the Ca2+ uniporter may be a route for Zn2+ uptake, we applied the uniporter 
blocker ruthenium red (2 µM) prior to and during Zn2+ exposure in one set of 
experiments, and in another we co-applied high Ca2+ with Zn2+ (Figure 3.3B).  Both 
maneuvers significantly reduced Zn2+ uptake, which is compatible with a uniporter 
mechanism that is responsible for large capacity Zn2+ uptake.  However, it is important to 
note that in all these conditions Zn2+ still increased FluoZin-3 fluorescence.  This suggests 
that some Zn2+ uptake occurs through a relatively low capacity, high affinity 
mechanism(s) independent of ∆Ψm and the uniporter. 
 
 
 
 
 78
 0
10
20
30
40
Zn
2+
FC
CP
   C
a
2+
Ru
Re
d
Ca
2+ /Z
n
2+
5 µM
80 µM
Free [Zn2+]
∆  F
lu
oZ
in
-3
 S
ig
na
l
B
5 10 15
30
40
50
60
70
5 µM free Zn2+
FCCP
 Ca2+
control
Time (min)
Fl
uo
Zi
n-
3 
Si
gn
al
A
 
Figure 3.3  Mitochondrial Zn2+ uptake is partially mediated by the Ca2+ uniporter 
and depends on ∆Ψm.  (A) Representative traces of FluoZin-3 responses in mitochondria 
exposed to 5 µM free Zn2+ in the presence or absence of two depolarizing conditions: (i) 250 nM 
FCCP was perfused for an additional 5 minutes prior to co-perfusing 5 µM free Zn2+ or (ii) 200 
µM CaCl2 was perfused for 5 minutes prior to 5 µM free Zn2+.  (B) Summary graph of FluoZin-3 
responses produced by 5 µM (open bars) or 80 µM (solid bars) free Zn2+.  These control (Zn2+ 
alone) values were compared to Zn2+ uptake after depolarization (with FCCP or high Ca2+), 
treatment with the Ca2+ uniporter blocker ruthenium red (RuRed, 2 µM), or in the presence of 
competing Ca2+ (200 µM).  Data from (A) represent the mean ± S.E. from approximately 50-100 
mitochondria within a given field.  Data from (B) represent the mean ± S.E. of 4-6 experiments 
from at least three different mitochondrial preparations.  All treatments were significantly 
different when compared to both control (Zn2+ alone) treatments.  p < 0.0001 for one-way 
ANOVA. 
 79
 Uniporter blockade partially protects against Zn2+-induced depolarization 
     
Our previous observations suggest that Zn2+ depolarizes isolated mitochondria in 
suspension, which is partially protected by blocking the Ca2+ uniporter with ruthenium red 
(Dineley et al., 2005).  However, this partial protection is overcome with higher Zn2+ 
concentrations, suggesting that Zn2+-induced depolarization does not require Zn2+ entry.  
Here, we were able to distinguish between intra- and extramitochondrial Zn2+-induced 
depolarizations using the potentiometric dye Rhodamine 123 (Rh123) (Figure 3.4).   
 As demonstrated in Figure 3.4A, 10 µM free Zn2+ partially depolarized 
mitochondria, as indicated by decreased Rh123 fluorescence.  It is important to note that 
these mean traces represent incomplete depolarizations throughout the entire 
mitochondria population, as opposed to an effect that produces two distinct subsets, i.e. 
one completely depolarized and another fully polarized.  Depolarization by 10 µM free 
Zn (~50% decrease in fluorescence) was partially blocked by ruthenium red.  2+ In Figure 
3.4B, however, mitochondria exposed to higher free Zn2+ (80 µM) depolarized to a 
greater extent (~80% decrease in fluorescence) and were not protected with ruthenium 
red.  These findings are consistent with the suggestion that the predominant effect of Zn2+ 
on ∆Ψm is mediated by a site outside of the mitochondrial matrix.   
 In panel 3.4D, we show Ca -induced depolarization, which was completely 
blocked with ruthenium red.  While the data serves as a positive control supporting the 
feasibility of this particular approach, it also reveals interesting differences between the 
effects of Zn  and Ca :  depolarization by high Zn  was slower, partially reversible, 
and insensitive to ruthenium red, whereas depolarization by high Ca  during the brief 
2+
2+ 2+ 2+
2+
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 time frame was immediate, not rapidly reversible and completely sensitive to ruthenium 
red.
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Figure 3.4  Ruthenium red partially protects against Zn2+-induced mitochondrial 
depolarization.  Using the ∆Ψm-sensitive dye Rhodamine 123 (Rh123), the extent of 
depolarization (determined by decreased fluorescence) was measured in mitochondria perfused 
with two different Zn2+ concentrations.  (A) Representative trace of mitochondria exposed to 10 
µM free Zn2+ depolarized (solid line), and was partially blocked by ruthenium red (RuRed, 2 
µM). (B)  Representative traces showing mitochondria exposed to 80 µM free Zn2+ fully 
depolarized (solid line) and are not protected by ruthenium red (dotted line).  (C) Graph 
summarizing mitochondrial depolarization with 0, 10 or 80 µM free Zn2+ without (open bars) or 
with (closed bars) ruthenium red.  (D) Positive control to demonstrate that mitochondria rapidly 
depolarized in the presence of 200 µM Ca2+ (solid line), which is completely inhibited in the 
presence of ruthenium red (dotted line).  Data from (A), (B), and (D) represent the mean ± S.E. 
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 from approximately 50-100 mitochondria within a given field.  Data from (C) represent the mean 
± S.E. of 4-6 experiments from at least three different mitochondrial preparations.      
 
Zn2+-induced FluoZin-3 fluorescence slowly decreases over time 
 Following Zn  treatment, the FluoZin-3 signal did not remain elevated and 
stable, but instead declined slowly over several minutes (Figure 3.5A).  To rule out dye 
leakage or photobleaching, we did control experiments where mitochondria were given 
two pulses of Zn  separated by ~ 5 minutes (Figure 3.5B).  The second pulse of 80 µM 
free Zn  did not re-elevate fluorescence levels, which is unsurprising given that 
mitochondria were depolarized by the first pulse (as in Figure 3.4B).  However, when the 
ionophore sodium pyrithione was used to deliver the second pulse, maximum 
fluorescence was roughly equal to that achieved by the first pulse (Figure 3.5C).  These 
data suggest that there is no substantial FluoZin-3 leakage or photobleaching in this 
paradigm. 
2+
2+
2+
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Figure 3.5  FluoZin-3 fluorescence slowly decreases over time, but is not a result of 
dye leakage or photobleaching.  (A) Representative trace of mitochondria perfused with 10 
µM free Zn2+ followed by 10-washout period with KCl buffer demonstrates slow decline of 
FluoZin-3 fluorescence over minutes.  For summary data, uptake was calculated as the difference 
from baseline to maximum fluorescence, while efflux was calculated as the difference between 
maximal fluorescence to fluorescence values at the end of the washout period.  (B) To determine 
if decreasing signal resulted from dye leakage or photobleaching, mitochondria were challenged 
with consecutive free Zn2+ (80 µM) stimuli separated by 2-3 minutes.  (C) When the second pulse 
was delivered in the presence of sodium pyrithione, FluoZin-3 change was equivalent to the first 
response, arguing that dye leakage from mitochondria is not contributing to the decreasing signal.  
Data represent mean traces from approximately 50-100 mitochondria within a given field and are 
representative of 3-4 additional experiments. 
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 Slow decline of matrix Zn2+ is unaffected by phosphate removal, decreased matrix pH, 
or uniporter blockade 
A second possibility for the declining signal may be Zn2+-phosphate 
precipitatation within the matrix, which would decrease the amount of Zn2+ available to 
bind FluoZin-3.  In previous studies of mitochondrial Ca2+ homeostasis, acetate was 
substituted for buffer phosphate as a means of decreasing Ca2+-phosphate precipitation in 
the matrix (Zoccarato and Nicholls, 1982; Chalmers and Nicholls, 2003).  We used the 
same maneuver here to determine if phosphate depletion would affect the FluoZin-3 
recovery.  However, neither the apparent uptake nor removal of Zn2+ was altered when 
phosphate was replaced with acetate (Figure 3.6A).  Furthermore, matrix acidification 
with FCCP, which should promote the dissolution of metal-phosphate complexes, also did 
not alter FluoZin-3 recovery (Figure 3.6B).  Taken together, these data suggest that 
phosphate does not significantly participate in controlling matrix Zn2+. 
  Lastly, we tested for uniporter-mediated Zn2+ efflux by following the Zn2+ 
stimulus with 2 µM ruthenium red (Figure 3.6C).  Ruthenium red did not affect the rate of 
signal decline, arguing against uniporter-mediated Zn2+ efflux.  The only effective method 
for significantly altering the Zn2+ efflux was with TPEN (25 µM).  This reversal in signal 
depends on membrane permeation, as the impermeant chelator EDTA did not accelerate 
Zn2+ removal compared to control (Figures 3.6B and 3.6C).  
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Figure 3.6  Matrix Zn2+ declines slowly and is unaffected by phosphate removal, 
matrix acidification or uniporter blockade.  (A) Summary graph of experiments as shown 
in Figure 5A compare the uptake and efflux changes in mitochondria stimulated with Zn2+ in 
either phosphate buffer or phosphate-free (acetate) buffer.  (B) Representative traces of 
mitochondria exposed to 10 µM free Zn2+ followed by washout (control), 250 nM FCCP, 100 µM 
EDTA or 25 µM TPEN.  (C) Summary graph of mitochondria exposed to 10 µM free Zn2+ 
followed by washout, TPEN, or FCCP as shown in (B).  Similar experiments were done with Zn2+ 
exposure followed by 100 µM EDTA or 2 µM ruthenium red.  Only TPEN was significantly 
different from washout with control buffer.  p < 0.0015 by one-way ANOVA.  Data from (B) 
represent the mean ± S.E. from approximately 50-100 mitochondria within a given field.  Data 
from (A) and (C) represent the mean ± S.E. of 4-6 experiments from at least three different 
mitochondrial preparations.   
 
 
 
 85
 Strong oxidant exposure does not increase matrix Zn2+  
 Previous reports suggested that mitochondria possess oxidant-sensitive sources of 
Zn2+ (Sensi et al., 2003b), including metallothionein (Ye et al., 2001), and Zn2+-sensitive 
fluorophores have been used to detect oxidant-mobilized free Zn2+ in cells (Aizenman et 
al., 2000).  We used FluoZin-3 here to determine if mitochondria possess oxidant labile 
Zn2+.  However, mitochondria treated with high concentrations of either 2,2’-DTDP (300 
µM) or H2O2 (1 mM) showed no fluorescence increase (Figure 3.7).  Additionally, 2,2’-
DTDP did not further elevate FluoZin-3 fluorescence in Zn2+-loaded mitochondria (data 
not shown).  Together, these results suggest that the pool of oxidant-sensitive Zn2+ 
binding proteins in the mitochondrial matrix is minimal. 
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Figure 3.7  Strong oxidation does not increase matrix free Zn2+.  (A) Representative 
mean traces of mitochondria exposed to 10 µM free Zn2+, 300 µM 2,2’-DTDP, or 1 mM H2O2.  
(B) Summary data show that the oxidative stimuli did not increase FluoZin-3 fluorescence.  Data 
from (A) represent the mean ± S.E. from approximately 50-100 mitochondria within a given 
field.  Data from (B) represent the mean ± S.E. of 4-6 experiments from at least three different 
mitochondrial preparations. 
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 3.5 Discussion  
 
Advantages of experimental system for studying Zn2+ transport 
In this study we provide direct evidence for mitochondrial Zn2+ uptake.  FluoZin-
3-loaded mitochondria allowed the detection of robust and reproducible increases in free 
Zn2+ within the mitochondrial matrix.  The ability to perfuse solutions directly onto 
adherent mitochondria is an advantage over previous reports using isolated mitochondrial 
suspensions, because solution exchange is feasible.  In addition, the use of superfused 
mitochondria eliminates contributions of extra-matrix dye to the overall dye signal, which 
would otherwise be hard to avoid.  Our prior study shows that the preparation is 
bioenergetically functional and fully capable of maintaining a membrane potential over 
the duration of these experiments (Vergun et al., 2003b).  Thus, isolated attached 
mitochondria provide a useful model system in which to characterize Zn2+ transport.  Our 
mitochondrial preparation probably generates a mixture of both neuronal and glial 
mitochondria.  Unfortunately it is currently not feasible to separate or distinguish 
between neuronal and non-neuronal mitochondria from a whole-brain preparation.  
However, our observations show that mitochondria respond uniformly to the stimuli used 
here.  The absence of any subpopulations suggests that neural mitochondria, regardless of 
cellular origin, are more similar than different with respect to zinc handling mechanisms.   
 
Uniporter-dependent and –independent mechanisms for mitochondrial Zn2+ uptake 
There appear to be two mechanisms of Zn2+ accumulation, one of which appears 
to be the calcium uniporter while the other is a novel pathway.  Mitochondrial Zn2+ 
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 uptake occurs partially via a ∆Ψm- and Ca2+ uniporter-sensitive pathway because the 
accumulation of Zn2+ was partially inhibited by ruthenium red and by mitochondrial 
depolarization with FCCP.  This is consistent with previous reports that Zn2+ uptake is 
mediated by the uniporter in isolated bovine heart and rat liver mitochondria.  Brierley 
and Knight (1967) reported that Zn2+ uptake could be detected in bovine heart 
mitochondria using atomic absorption at supraphysiological levels and only in the 
absence of other permeant ions.  Saris and Niva (1994) demonstrated that Zn2+-induced 
mitochondrial swelling in rat liver was inhibited by ruthenium red, which implies a 
uniporter-mediated Zn2+ accumulation.  However, these studies used considerably higher 
concentrations of Zn2+, which are likely to greatly exceed free Zn2+ concentrations found 
within cells under any reasonable circumstance.  On the contrary, between 20 and 40% of 
the accumulation of Zn2+ was insensitive to uniporter inhibition, uncoupling or the 
addition of Ca2+ (Figure 3.3).  This accumulation presumably occurs through a separate 
and as yet unidentified pathway.  In the presence of ruthenium red or in the absence of a 
membrane potential, the amount of Zn2+ accumulated through this ∆Ψm- and uniporter-
independent pathway is the same in the presence of 5 or 80 µM free Zn2+.  This suggests 
that this mechanism is already saturated by Zn2+ at the lower concentration.  However, 
the driving force for this Zn2+ accumulation remains unclear. 
 
Identification of a novel mitochondrial Zn2+ efflux pathway 
Along with Zn2+ import, this method is useful for monitoring Zn2+ efflux.  These 
studies reveal that Zn2+ efflux occurs in a uniporter-independent fashion.  It is notable, 
too, that neither the accumulation nor efflux of Zn2+ is altered when phosphate was 
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 replaced by acetate in the superfusion solution.  Additionally, FCCP did not affect efflux.  
When calcium is transported by mitochondria it accumulates in an insoluble phosphate 
precipitate (Zoccarato and Nicholls, 1982).  Addition of uncouplers alters the pH of the 
matrix allowing solubilization of the precipitate and subsequent efflux of calcium 
(Nicholls and Chalmers, 2004).  The absence of effect of phosphate substitution or FCCP 
on efflux rate argues that Zn2+ does not form insoluble phosphate salts after 
accumulation.  Since Zn2+ is a critical ion necessary for many cellular processes, cells 
have evolved specific membrane-bound Zn2+ transport proteins to supply free Zn2+ to the 
various subcellular compartments.  Evidence accumulated to date has identified at least 
14 specific Zn2+ transporters in mammalian cells that are localized to the plasma 
membrane and intracellular vesicles (Liuzzi and Cousins, 2004).  Thus far there is no 
evidence that any member of this family is associated with mitochondria, and a recent 
report on the human heart mitochondrial proteome (Taylor et al., 2003) did not identify 
any of the known Zn2+ transporters.  Thus, the mechanism of Zn2+ efflux remains unclear.  
 
Are there oxidant-labile intramitochondrial Zn2+ pools ? 
Approximately 80% of intracellular Zn2+ is thought to be protein bound, and it 
plausible that Zn2+-protein complexes may regulate cellular and subcellular Zn2+ 
homeostasis (Frederickson, 1989).  Ye et al. demonstrated that isolated liver 
mitochondria import exogenously added metallothionein, raising the possibility that 
metalloproteins can regulate respiration by controlling Zn2+ availability (Ye et al., 2001).  
Unfortunately this intriguing hypothesis is not yet supported by studies in intact cells.  It 
is known that mice lacking MT-I and -II show no bioenergetic abnormalities (Palmiter, 
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 1998), and no MT isoforms were identified in the heart mitochondrion proteome (Taylor 
et al., 2003).  In any case, we were unable to detect oxidant-labile zinc in the preparation 
used in this study.  Ostensibly then our data argues that mitochondria contribute little to 
the oxidant-induced [Zn2+]i loads observed in several different cell types (Cuajungco and 
Lees, 1998; Aizenman et al., 2000; St. Croix et al., 2002; Bossy-Wetzel et al., 2004). 
The ability to monitor subcellular zinc transport in intact cells would present 
obvious advantages, and in fact this work was preceded by a number of reports claiming 
evidence for mitochondrial zinc transport in cultured neurons (Sensi et al., 2000; Sensi et 
al., 2003b; Sensi et al., 2003a; Bossy-Wetzel et al., 2004).  These studies relied solely on 
live cell fluorescent indicator that purportedly localize to mitochondria.  The approach 
however is fraught with a number of confounds including dye labeling of subcellular 
structures inconsistent with mitochondrial morphology, labeling that does not or only 
partially co-localizes with other established mitochondrial markers, and dye responses to 
zinc that occur not just within mitochondria, but throughout the entire cell body.  Given 
these complications, it is premature to conclude that mitochondria have a substantial role 
in accumulating or releasing zinc in the intact cell, and definitive proof of such requires 
the development of a zinc sensor that is unambiguously specific for mitochondria. 
 
Zn2+ concentrations allow the study of different effects in cells vs. in mitochondria 
Studies of Zn2+ transport by brain mitochondria are relevant to the role of Zn2+ in 
neuronal injury.  As a neurotoxin, Zn2+ appears to have an important impact on neuronal 
energy metabolism (Choi and Koh, 1998; Koh, 2001; Dineley et al., 2003; Sensi and 
Jeng, 2004), and this appears to be due at least partly to an interaction with mitochondria.  
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 However, it is much less clear whether the impact of Zn2+ on mitochondrial function 
depends on Zn2+ accumulation into the matrix, or whether actions of Zn2+ on the exterior 
of the mitochondrion could suffice.  The present studies clearly reveal evidence for the 
ability of Zn2+ to impair mitochondrial function.  Thus, Zn2+ diminishes ∆Ψm quite 
effectively (Figure 3.4), an effect that is partly sensitive to ruthenium red at low ion 
concentrations.  This impairment of ∆Ψm can then account for the failure of mitochondria 
to accumulate Zn2+ from a second exposure (Figure 3.5), even though the dye is clearly 
capable of reporting more Zn2+ under these circumstances.  The limited sensitivity of the 
mitochondrial depolarization to ruthenium red suggests that ∆Ψm loss is due to an 
external effect of Zn2+.  This conclusion is consistent with other findings showing that 
Zn2+ mediated mitochondrial impairment can be reversed by membrane-impermeant 
chelators (Dineley et al., 2005).  However, this argues against the notion that 
mitochondrial transport of Zn2+ is necessary for neurotoxicity (Jiang et al., 2001; Sensi et 
al., 2003b).  The relevance of this transport phenomenon may also depend on the 
concentrations of cytoplasmic Zn2+ that are achieved during injury to neurons, a 
parameter that is difficult to determine quantitatively (Dineley et al., 2002).  Although 
mitochondrial depolarization can clearly occur as the result of Zn2+ exposure (Sensi et al., 
2003b), it is clearly also possible to kill neurons without causing overt mitochondrial 
dysfunction (Dineley et al., 2000).  It seems likely that there are multiple mechanisms of 
Zn2+ -mediated injury that can be expressed according to the magnitude of the 
intracellular Zn2+ load.  Whether mitochondrial depolarization and bioenergetic failure 
represent the primary effects of Zn2+ at the lowest concentrations remain to be 
determined. 
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 Chapter 4.  Zinc inhibits mitochondrial movement in neurons by PI 3-
kinase activation 
 
4.1 Abstract 
 Mitochondria have been identified as targets of the neurotoxic actions of zinc, 
possibly through decreased mitochondrial energy production and increased reactive 
oxygen species accumulation.  It has been hypothesized that impairment of mitochondrial 
trafficking may be a mechanism of neuronal injury.  Here, we report that elevated 
intraneuronal zinc impairs mitochondrial trafficking.  At concentrations just sufficient to 
cause injury, zinc rapidly inhibited mitochondrial movement without altering 
morphology.  Zinc chelation initially restored movement, but the actions of zinc became 
insensitive to chelator in less than 10 minutes.  A search for downstream signaling events 
revealed that inhibitors of PI 3-kinase prevented this zinc effect on movement.  
Moreover, transient inhibition of PI 3-kinase afforded neuroprotection against zinc-
mediated toxicity.  These data illustrate a novel mechanism that regulates mitochondrial 
trafficking in neurons, and also suggests that mitochondrial trafficking may be closely 
coupled to neuronal viability.            
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 4.2 Introduction 
 Neural zinc is a highly regulated ion, much of which is tightly coordinated to 
proteins, leaving a small pool of zinc that remains free and mobile (Frederickson, 1989).  
Elevated intracellular free zinc ([Zn2+]i) results from entry through several Ca2+-
permeable pathways (Weiss et al., 1993; Koh and Choi, 1994; Yin and Weiss, 1995; 
Sensi et al., 1997; Cheng and Reynolds, 1998) and also from oxidant-mediated release 
from intracellular stores (Aizenman et al., 2000).  Elevated [Zn2+]i results in neuronal 
injury in vitro (Choi et al., 1988; Koh and Choi, 1994), and it has been suggested that its 
accumulation may contribute to neurodegeneration associated with ischemia (Koh et al., 
1996; Lee et al., 2002), epileptic seizures (Frederickson et al., 1988), and head trauma 
(Suh et al., 2000).  
 Although an unambiguous mechanism for Zn2+-mediated neurotoxicity has not 
been identified, several lines of evidence suggest mitochondria and energy metabolism as 
subcellular targets for the toxic actions of [Zn2+]i (Dineley et al., 2003; Sensi and Jeng, 
2004).  Zinc can inhibit glycolysis (Sheline et al., 2000), the tricarboxylic acid cycle 
(Brown et al., 2000) and complexes in the electron transport chain (Skulachev et al., 
1967; Kleiner, 1972; Kleiner, 1974; Link and von Jagow, 1995; Mills et al., 2002).  It has 
also been shown that Zn2+ dissipates mitochondrial membrane potential (∆Ψm), decreases 
oxygen consumption, and enhances reactive oxygen species (ROS) accumulation 
(Dineley et al., 2005).  However, it remains unclear which, if any, of these processes 
represent the critical target for the neurotoxic actions of zinc.       
 It has long been appreciated that mitochondria constantly move, divide and fuse 
throughout the cell (Bereiter-Hahn and Voth, 1994).  It is reasonable to suggest that 
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 mitochondrial trafficking in neurons serves to position mitochondria to deliver ATP to 
regions of high energy demand (van Blerkom, 1991) and to aid in the regulation of local 
Ca2+ homeostasis (Spira et al., 2001; Yi et al., 2004), although direct evidence that 
mitochondrial trafficking is driven by energy demand remains sparse.  Nevertheless, 
recent studies suggest that interruption of trafficking is one consequence of excessive 
activation of N-methyl-D-aspartate (NMDA) receptors and the subsequent calcium entry 
(Rintoul et al., 2003).  Other potential neurotoxins, such as nitric oxide (Rintoul et al. 
2004, SFN Abstract) and ATP depletion (Rintoul et al., 2003) also inhibit mitochondrial 
movement, suggesting that impaired delivery of mitochondria could be an important 
contributor to neuronal injury.  
 In this report, we have investigated the effects of [Zn2+]i on mitochondrial 
trafficking.  Using a mitochondrially-targeted enhanced yellow fluorescent protein (mt-
eYFP), we observed that movement is substantially diminished with ionophore-induced 
elevations of [Zn2+]i, that are just sufficient to cause injury.  We further show that these 
actions of zinc are mediated by a signaling cascade that involves activation of PI 3-kinase, 
and that transient inhibition of PI 3-kinase prevents both the impairment of trafficking and 
zinc-induced neuronal injury. 
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 4.3 Materials & Methods 
 
Materials   
All reagents were purchased from Sigma (St. Louis, MO) unless otherwise specified.   
 
Cell Culture  
All procedures using animals were in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals and were approved by the 
Institutional Animal Care and Use Committee at the University of Pittsburgh.  Primary 
cultures of rat forebrain neurons were prepared from embryonic Sprague Dawley rat pups 
(17 days in gestation) and grown in a 37˚C incubator containing 5% CO2.  Cortices were 
removed, trypsinized at 37˚C for 30 minutes, and plated on poly-D-lysine-coated 31 mm 
glass cover slips.  Cells were plated in medium containing Dulbecco’s Modified Essential 
Medium (DMEM) with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin.  
Cultures contain less than 5% glia in total cell population.  Five hours after initial plating, 
plating medium was completely removed and replaced with N2-NB media (Neurobasal 
media with 0.5% penicillin/streptomycin and 1% N2 supplement).  Cells were re-fed with 
N2-NB media 4 days after plating, whereby approximately half of the volume was 
removed and replaced with an equal volume of fresh N2-NB media.  Cells were fed 8 and 
11 days after plating with B27-NB media (Neurobasal media with 0.5% 
penicillin/streptomycin and 2% B27 Supplement Minus AO) using the same feeding 
protocol described above.  For preparation of the insulin-depleted cells, cultures were fed 
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 only with B27-NB media beginning at 5 hours after initial plating.  All experiments were 
performed on neurons after 13-15 days in culture. 
 
Transfection using DNA constructs 
The mitochondrial-targeted enhanced yellow fluorescent protein (mt-eYFP) construct 
(Llopis et al., 1998) consists of eYFP fused to the mitochondrial targeting sequence from 
subunit IV of human cytochrome c oxidase.  The luciferase reporter plasmid consists of 
the luciferase gene placed in a mammalian expression vector under the control of a CMV 
promoter (Gossen and Bujard, 1992).  After 10-12 days in vitro, neurons were transiently 
transfected using a modified calcium phosphate transfection technique (Xia et al., 1996).  
This procedure typically generates 1-2% efficiency; with maximal protein expression 24-
72 hours post transfection. 
 
Fluorescence microscopy   
All experiments were performed using a Hepes-buffered salt solution (HBSS) of the 
following composition: 137 mM NaCl, 5 mM KCl, 10 mM NaHCO3, 0.6 mM KH2PO4, 
0.6 mM Na2HPO4, 0.9 mM MgSO4, 1.4 mM CaCl2, 20 mM Hepes and 5.5 mM glucose 
(pH adjusted to 7.4 with NaOH).  Neurons were perfused for 5 ml/min during the course 
of each experiment and the chamber temperature was maintained at 37˚C with heated 
buffer.  The PC-based system for data acquisition is as previously described (Dineley et 
al., 2002) using SimplePCI imaging software (Compix Inc, Cranberry, PA).  Using a 40X 
water immersion objective, mitochondrial movement in a field containing a single cell 
were observed by illuminating at 490 nm and acquiring images every 6 seconds.  
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 Following a brief 3 to 5-minute rinse in HBSS buffer, cells were perfused with the 
appropriate stimulus (diluted in buffer from stock concentrations).   
 For [Zn2+]i measurements, we used the Zn2+-sensitive fluorophore mag-fura-2-AM 
(Molecular Probes, Eugene, OR).  Coverslips were incubated with 5 µM mag-fura-2 for 
20 minutes at 37˚C.  With constant perfusion at 10 ml/min, fluorescence was measure by 
illuminating the indicator alternatively at 335 and 375 nm.  For ∆Ψm experiments, 
neurons were incubated with 5 µM Rhodamine 123 (Molecular Probes, Eugene, OR) for 
10 minutes at 37 ˚C (Vergun et al., 2003a).  Cells were excited at 490 nm and 
fluorescence was measured in 10-20 individual neurons for each coverslip.  For nucleic 
acid staining, coverslips were incubated in HBSS containing 1.5 µM Hoechst-33342 for 
15 minutes at room temperature (Dineley et al., 2000).  Cells were illuminated at 340 nm 
and fluorescent images were obtained randomly from 3-6 cell-containing regions per 
coverslip.      
 
Quantification of mitochondrial movement   
Mitochondrial movement was analyzed using a macro-based analysis program as 
previously described (Rintoul et al., 2003).  Briefly, a 255 x 255 pixel subfield containing 
mitochondria was selected where pixel images in successive images are subtracted.  A 
movement event for each pixel was registered if the change in fluorescence between 
successive fields exceeds 20 fluorescence units and a quantitative measurement of 
movement was obtained by combining pixel events in a field over 2 minutes.  Movement 
was represented as average event counts/ pixel, which are normalized to pre-stimulus 
movement values.     
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 Toxicity   
For the simplicity of assaying only cells that express mt-eYFP, we transfected neurons 
with the luciferase construct to measure neuronal injury.  For toxicity experiments, 
coverslips of luciferase-transfected neurons were washed three times with HBSS.  
Reagents were diluted in HBSS at the desired concentration, and 1 ml of solution was 
applied to the coverslips for the desired time at room temperature.  Stimuli were 
terminated by washing at least 3 times with excess HBSS.  The wash buffer was then 
replaced with conditioned media and returned to the incubator.  Twenty four hours later, 
cells were rinsed and lysed in PBS.  Lysates were used to measure luciferase enzyme 
activity using the BriteLite Ultra-High Sensitivity Luminescence Reporter Gene Assay 
System (Perkin Elmer Life Sciences, Boston, MA) according to manufacturer’s 
instructions.  Arbitrary luminescence units were normalized to control, non-treated cells. 
 
Western blotting   
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1.5 mM 
MgCl2, 1 % Triton X-100, 5 mM EGTA, 20 µM Leupeptin, 1 mM AEBSF, 1 mM 
NaVO3, 10 mM NaF, and 1 tablet of protease inhibitor).  Protein concentration was 
determined by a micro-protein assay using the BCA protein assay kit according to 
manufacture’s instruction (Pierce Biotechnology, Rockford, IL).  Approximately 30 µg of 
lysates were mixed with equal volumes of 2 x SDS sample loading buffer (60 mM Tris-
HCl, pH 7.5, 2 mM EDTA, 10 mM 2-mercaptoethanol, 20% glycerol, and 2% SDS) and 
size-fractionated by electrophoresis on 4-15% Tris-HCl Ready Gels (Bio-Rad Labs, 
Hercules, CA) at 30 mA for 1 hour followed by electrotransfer onto a nitrocellulose 
 99
 membrane at 80 volts for 2 hours.  The membrane was pre-blotted with 5% dry milk in 
PBS-Tween (1X PBS, 0.1% Tween 20) at room temperature for 1 hour.  The blots were 
probed with rabbit antiserum raised against Akt, and phosphosphorylated-Akt (Cell 
Signaling Technology, Beverly, MA) antibodies.  Goat anti-rabbit IgG coupled to 
horseradish peroxidase (1:1000, Pierce Biotechnology, Rockford, IL), was used as the 
secondary antibodies.  Bands were visualized by the SuperSignal West Dura Extended 
Duration Substrate (Pierce Biotechnology, Rockford, IL). 
 
Statistical Analyses   
Statistical analysis was performed using Prism 4.01 (Graph Pad Software, San Diego 
CA).  All the data are presented as mean ± S.E. consisting of 4-6 experiments for each 
condition from at least three different cell culture preparations.  Comparisons were made 
using Student’s t test and one-way ANOVA with Dunnett post test to compare all 
conditions to control, with p values of less than 0.05 regarded as significant. 
 
4.4 Results 
 
Concentrations of Zn2+ that inhibit mitochondrial movement parallel Zn2+ 
concentrations that are neurotoxic. 
 We fluorescently labeled neuronal mitochondria using a mitochondrially-targeted 
enhanced yellow fluorescent protein (mt-eYFP).  The ionophore sodium pyrithione was 
used to increase [Zn2+]i (Dineley et al., 2000).  As shown in Figure 4.1a, buffer, sodium 
pyrithione alone (20 µM), or 0.3 µM Zn2+/Pyr did not affect mitochondrial movement.  
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 However, higher concentrations of Zn2+ significantly inhibited mitochondrial movement, 
with concentrations as low as 1 µM resulting in a significant decrease in movement.  
Notably, this stimulus consistently stopped movement of all mitochondria in a given field 
and did not preferentially alter the movement of retrogradely vs. anterogradely moving 
mitochondria.  This Zn2+-mediated effect was irreversible up to 20 minutes after the 
stimulus was washed out.  Interestingly, this concentration-dependent movement 
inhibition corresponded to the concentration-dependence of Zn2+ toxicity (inset).   
 To establish that this was not a Ca2+-induced phenomenon, we perfused cells with 
Zn2+/Pyr under Ca2+ free conditions to confirm that the stimulus was still effectively 
inhibiting movement (Figure 4.1b).  There is evidence that under depolarizing conditions, 
cellular Zn2+ entry occurs through plasma membrane Ca2+-permeable pathways (Sensi et 
al., 1999).  As a more physiological approach to elevate [Zn2+]i, we observed that 
mitochondrial movement was significantly inhibited with elevated Zn2+ (300 µM) in the 
presence of high K+ buffer (Figure 4.1b).  Evidence that exposure to strong oxidizing 
agents can generate [Zn2+]i fluxes in neurons is indicative of Zn2+ release from cytosolic 
reservoirs, including metallothionein (Aizenman et al., 2000).  Application of the 
sulfhydryl oxidizing agent, 2,2’-DTDP (10 µM) significantly inhibited mitochondrial 
movement, suggesting that [Zn2+]i release in addition to Zn2+ entry is sufficient to induce 
the effect (Figure 4.1b).  Our previous study showed that Ca2+-induced cessation of 
movement was also associated with a substantial change in mitochondrial morphology 
(Rintoul et al., 2003).  However, the representative fluorescent images taken before 
(Figure 4.1c) and after (Figure 4.1d) Zn2+ exposure demonstrated that there are no gross 
morphological changes that occur with Zn2+ exposure.  
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Figure 4.1  [Zn2+]i inhibits mitochondrial movement at cytotoxic concentrations.  (a) 
Neurons expressing mito-eYFP were perfused with buffer, pyrithione (20 µM) alone or in the 
presence of a range of [ZnCl2] (0.3-10 µM) for 10 minutes.  Bars represent mitochondrial 
movement measured at the end of the stimulus.  Inset demonstrates that neurons undergo Zn2+-
mediated toxicity at parallel concentrations that affect mitochondrial movement.  (b) 
Mitochondrial movement is inhibited when neurons are perfused with (i) 3 µM Zn2+(Pyr) in Ca2+-
free buffer, (ii) 300 µM Zn2+ in an elevated K+ buffer, or (iii) 10 µM 2,2’-DTDP.  Fluorescent 
images were taken prior to (c) and after (d) 3 µM Zn2+ (Pyr) to show that there are no gross 
morphological changes with acute Zn2+ treatment.  Treatments were significantly different when 
compared to control (buffer alone).  p < 0.01 for one-way ANOVA with Dunnett’s post test. 
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 Zn2+ inhibition of mitochondrial movement is partially sensitive to chelation.   
 To determine whether chelation can restore Zn2+-mediated movement inhibition, 
we applied membrane-permeant heavy metal chelator TPEN (50 µM) immediately 
following Zn2+/Pyr exposure (Figure 4.2a).  Notably, TPEN partially restored movement 
when applied after 1 µM Zn2+, but was ineffective at restoring movement when applied 
ten minutes after 3 µM Zn2+.  Additionally, Figure 4.2b shows that TPEN restored 
movement when applied after shorter exposures to 3 µM Zn2+, but became ineffective 
after treatments longer than 6 minutes.  We also observed that TPEN rescued neurons 
from injury when applied 5 minutes after Zn2+/Pyr exposure, but did not protect against 
toxicity after a 10-Zn2+ treatment (Figure 4.2c and 4.2d).  Together, these results indicate 
that the TPEN effects are concentration- and time sensitive-dependent.  The insensitivity 
to TPEN after longer or larger Zn2+ exposures suggested the initiation of a signaling 
cascade, which is irreversible upon simple Zn2+ chelation and therefore becomes 
independent of Zn2+. 
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Figure 4.2  Zn2+ removal restores movement inhibition in a concentration- and time-
sensitive manner.  (a) Neurons were perfused with Zn2+/Pyr (0-10 µM) for 10 minutes 
followed by 50 µM TPEN for 10 minutes.  Mitochondrial movement was measured both after the 
Zn2+ (gray bars) and TPEN stimuli (black bars).  (b) Neurons were perfused with 3 µM Zn2+(Pyr) 
for varying times (0-10 minutes) followed immediately by TPEN.  Zn2+-induced toxicity was 
assayed in neurons exposed to 0-10 µM Zn2+ (Pyr) for 5 minutes (c) or 10 minutes (d) 
immediately followed by TPEN treatment.  p < 0.05 by paired Student’s t test. 
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 Inhibitors of PI 3-kinase prevent Zn2+-induced movement inhibition. 
 To identify the Zn2+-activated signaling cascade involved in the movement effect, 
we investigated several agents that selectively inhibit protein kinases.  Of all the 
compounds which we tested in our movement paradigm, only the PI 3-kinase inhibitors, 
wortmannin (1 µM) and LY294002 (30 µM), were effective in that they (i) did not affect 
mitochondrial movement by themselves, and (ii) blocked the Zn2+-mediated effect at the 
concentration (3 µM Zn2+/Pyr) and time (10 minutes) which was TPEN insensitive 
(Figure 4.3a).  One concern was that perhaps wortmannin was preventing ionophore-
induced [Zn2+]i accumulation by blocking its cellular entry or chelating the [Zn2+]i before 
it can mediate any effects on movement.  We excluded this possibility by monitoring 
[Zn2+]i in mag-fura-2-loaded neurons which were perfused with 3 µM Zn2+/Pyr, either 
with or without wortmannin (1 µM) pretreatment (Figure 4.3b).  Both conditions 
produced equal mag-fura-2 responses that were TPEN-reversible, confirming that 
wortmannin was not preventing entry or binding [Zn2+]i.   
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Figure 4.3  PI 3-kinase inhibitors prevent Zn2+-induced movement inhibition.  (a) 
Neurons were perfused with either wortmannin (1 µM) or LY294002 (30 µM) for 10 minutes 
prior to and during 3 µM Zn2+(Pyr) treatment and mitochondrial movement was analyzed after 
application of inhibitors (gray bars) and Zn2+ in the presence of inhibitors (black bars).  (b) 
Neurons loaded with mag-fura-2 were exposed to 3 µM Zn2+(Pyr) for 5 minutes either without 
(solid line) or pre-treated with 1 µM wortmannin (dotted line).  In both conditions, TPEN (50 
µM) was applied after the Zn2+ stimulus.   
 
Preventing Akt phosphorylation does not prevent Zn2+-induced movement inhibition. 
 As a possible downstream effector of PI 3-kinase, we investigated the role of Akt 
phosphorylation in Zn2+-induced movement inhibition.  We monitored phosphorylated 
Akt levels in neurons treated with 3 µM Zn2+/Pyr for 10 minutes, either in the presence or 
absence of wortmannin (1 µM) or a putative Akt inhibitor (1L-6-Hydroxymethyl-chiro-
inositol-2-(R)-2-O-methyl-3-O-octadecykcarbonate) (10 µM; Calbiochem, San Diego, 
CA) (Figure 4.4a).  This phosphatidylinositol ether analog has been reported to selectively 
inhibit Akt phosphorylation and prevent growth of HT-29, MCF, HeLa and PC-3 cancer 
cell lines.  This novel class of Akt inhibitors selectively blocks Akt activation and 
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 downstream substrates without affecting upstream kinases or other kinase pathways.  We 
used insulin (100 nM) as a positive control in these experiments.  As demonstrated in 
Figure 4.4a, both insulin and Zn2+ rapidly induced Akt phosphorylation within 10 minutes 
in a wortmannin-sensitive manner.  Interestingly, treatment with Akt inhibitor alone 
increased phosphorylation from control levels, and this compound did not significantly 
reduce phosphorylation in neurons compared to either insulin or Zn2+ by themselves.      
We also monitored the effects of these treatments on mitochondrial movement. As 
shown in Figure 4.4b, perfusion with 100 nM insulin for 10 minutes did not significantly 
decrease mitochondrial movement compared untreated cells, even though a ten-stimulus 
of 100 nM insulin is sufficient for Akt phosphorylation in primary neurons. Treatment 
with the Akt inhibitor itself slightly decreased mitochondrial movement and also did not 
prevent the Zn2+-induced movement effect.  Although previous studies have used this 
inhibitor to prevent Akt phosphorylation in cell lines (Kozikowski et al., 2003), it appears 
to be less effective in neurons. 
 As an alternative to the Akt inhibitor, we transiently co-transfected an HA-tagged 
dominant negative Akt (K179M) plasmid along with the mitochondrially-targeted eYFP 
plasmid.  Over expression of DN-Akt did not prevent the Zn2+-mediated movement 
inhibition (data not shown), arguing against Akt activation by PI 3-kinase as a 
downstream event.  We additionally tested other targets of PI 3-kinase that are of Akt-
independent pathways.  Blocking ARF6 phosphorylation using a dominant negative 
construct (Langille et al., 1999) or inhibiting TOR phosphorylation using rapamycin 
(Lynch et al., 2001) did not prevent the Zn2+-mediated inhibition (data not shown), 
indicating that these protein kinases are not directly involved in the movement paradigm.  
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 Thus, although PI 3-kinase activation appears to be an essential component of the effect 
of zinc, it is apparently not sufficient to account for the actions of zinc on mitochondrial 
movement. 
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Figure 4.4  Akt inhibitor does not prevent Zn2+-induced mitochondrial movement 
inhibition.  (a) Representative western blot for phosphorylated Akt from neurons treated for 10 
minutes with 3 µM Zn2+(Pyr) or 15 minutes with 100 nM insulin, either in the presence or 
absence of wortmannin (1 µM) or Akt inhibitor (10 µM) pretreatment for 10 minutes.  The lane 
numbers correspond to the bar conditions depicted in the graph directly below.  Relative protein 
levels were normalized to total Akt protein levels as shown in the graph, which is a compilation 
of results from at least 3 different culture preparations.  (b) Neurons were exposed to 3 µM 
Zn2+(Pyr), 100 nM insulin or pretreated for 10 minutes with Akt inhibitor (10 µM) prior to Zn2+.  
Movement was measured after insulin (hatched bar), inhibitor (gray bar) and Zn2+ (black bar) 
treatments.     
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 Zn2+ effects on mitochondrial movement do not result from compromised mitochondrial 
function. 
 We have previously shown that acute application of the mitochondrial uncoupler 
FCCP, which rapidly dissipates ∆Ψm, decreased mitochondrial movement in primary 
neurons (Rintoul et al., 2003).  Zinc at some concentrations can also impair mitochondrial 
function (Sensi et al., 1999; Dineley et al., 2000).  However, an examination of the effects 
of these zinc treatments on mitochondrial membrane potential showed that zinc only 
produced a significant depolarization at relatively high concentrations (Figures 4.5a and 
4.5b).  In addition, pretreating neurons with wortmannin (1 µM) did not prevent the 
inhibition of mitochondrial movement produced by FCCP (750 nM) exposure (Figure 
4.5c).  Together, these results argue against mitochondrial dysfunction as the key 
mechanism in Zn2+-mediated movement inhibition. 
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Figure 4.5  Zn2+-induced movement inhibition does not grossly affect mitochondrial 
function.  (a) Representative traces of ∆Ψm changes in neurons using Rhodamine 123 exposed to 
pyrithione (20 µM) alone or in the presence of Zn2+ (0.3-10 µM) for 5 minutes.  FCCP (750 nM) 
was applied at the end of each experiment.  (b) Summary graph of Rhodamine 123 changes in 
neurons exposed to Zn2+(Pyr). (c) Mitochondrial movement in neurons was measured after FCCP 
(750 nM) exposure for 5 minutes, either without or with 10-minute wortmannin (1 µM) 
pretreatment.   p < 0.01 by ANOVA with Dunnett’s post test. 
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 Wortmannin protects against Zn2+-induced  neurotoxicity. 
 As shown in figure 3a, pre-perfusion with wortmannin prevented Zn2+-mediated 
inhibition of mitochondrial movement.  However, the effectiveness of wortmannin was 
decreased when Zn2+ was increased from 3 to 10 µM (Figure 4.6a).  Interestingly, 
wortmannin protected against Zn2+-induced neurotoxicity with concentrations at or less 
than 3 µM Zn2+/Pyr, but not with 10 µM (Figures 4.6b and 4.6c), suggesting a correlation 
between PI 3-kinase activation in Zn2+-mediated movement inhibition and kinase activity 
during neurotoxicity.    
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Figure 4.6  Wortmannin prevents both Zn2+-mediated movement inhibition and 
neurotoxicity in a concentration-sensitive manner.  (a) Movement was analyzed in 
neurons following 3 or 10 µM Zn2+(Pyr) stimuli pretreated with 1 µM wortmannin.  (b) Extent of 
cell death was measured in neurons pretreated with wortmannin (1 µM) prior to Zn2+ (0-10 µM) 
exposure.  (c) Representative Hoechst staining in neurons exposed to varying Zn2+ (Pyr), either 
with or without wortmannin, where cell death is represented by extensive nuclear condensation 
(bright blue staining) compared to more healthier-looking cells (diffuse blue staining).  p < 0.005 
by Student’s t test. 
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 Transient, as opposed to sustained, PI 3-kinase activation prevents Zn2+-mediated 
neurotoxicity. 
 Although PI 3-kinase is generally considered to be a pro-survival signaling 
mechanism, a recent study demonstrated that transient PI 3-kinase inhibition protects 
primary neurons from oxidative stress (Levinthal and DeFranco, 2004).  As described 
above, our data suggests that wortmannin protected against Zn2+-induced neurotoxicity at 
concentrations that inhibited mitochondrial movement.  Although wortmannin is a fast-
acting inhibitor (half-life of 90 minutes), it is also relatively unstable in aqueous solution.  
The other selective PI 3-kinase inhibitor LY294002 has a longer half-life (3.5 hours) and 
produces a more sustained kinase inhibition (Jones et al., 1999).  Since we were unable to 
prevent Zn2+-induced neurotoxicity with LY294002 (Figure 4.7a), we speculated that the 
neuroprotection that we observed with wortmannin could be explained by a transient 
inhibition of the kinase.  To explore this possibility, neurons were repeatedly exposed to 
wortmannin during the course of Zn2+ toxicity.  Sustained kinase inhibition with 
wortmannin no longer prevented neurons against elevated [Zn2+]i (Figure 4.7b), in 
agreement with the hypothesis that only transient inhibition of PI 3-kinase affords 
protection against Zn2+ toxicity.         
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Figure 4.7  Transient inhibition of PI 3-kinase affords protection against Zn2+-
mediated toxicity.  (a) Extent of cell death was measured in neurons pretreated with LY294002 
(30 µM) prior to Zn2+ (0-10 µM) exposure.  (b) Toxicity assayed in neurons pretreated with 
wortmannin (1 µM) followed by 0-10 µM Zn2+ (Pyr) were given additional wortmannin pulses 3 
and 6 hours after Zn2+ application.    
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 4.5 Discussion 
 The main finding from this study is that elevated [Zn2+]i modulates mitochondrial 
movement through a signaling mechanism that is most commonly portrayed as a pro-
survival pathway.  In our experiments, acute application of pathophysiological [Zn2+]i 
consistently stopped mitochondrial movement in cortical neurons.  This effect was 
reversible only with early Zn2+ chelation, indicating that a Zn2+-induced signaling 
cascade had been initiated which subsequently mediated movement inhibition.  
Interestingly, both Zn2+-induced movement changes and neurotoxicity were prevented 
with inhibitors of the PI 3-kinase pathway.  Thus, we have demonstrated a signaling 
mechanism that regulates both mitochondrial trafficking and neuronal viability in 
parallel.   
  
Comparison to NGF modulation of mitochondrial movement in neurons  
 Recent studies have identified several modulators of mitochondrial trafficking in 
central neurons.  In particular, elevated intracellular Ca2+ is an effective inhibitor of 
movement, an effect that is likely to be mediated by inhibition of ATP synthesis as well 
as potentially disruption of the cytoskeleton (Rintoul et al., 2003).  Nitric oxide also 
inhibits movement (Rintoul et al. 2004, SFN Abstract), probably as a result of inhibition 
of the electron transport chain.  However, the mechanism by which Zn2+ inhibits 
movement is distinct in that it appears to occur without clear disruption of mitochondrial 
function.  Our findings of a role for PI 3-kinase are consistent with a recent report by 
Chada and Hollenbeck, which reported that focal stimulation of NGF receptors in 
sympathetic neurons causes mitochondria to “dock” or stop in the region of NGF 
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 application via a mechanism sensitive to inhibition by wortmannin (Chada and 
Hollenbeck, 2003), and likely by undergoing docking interactions with the actin 
cytoskeleton (Chada and Hollenbeck, 2004).  Interestingly, this phenomenon did not 
occur with global application of NGF, which would more closely parallel the conditions 
used here.  Nevertheless, the basic concept of a PI 3-kinase-mediated control of 
mitochondrial trafficking is clearly similar between the two model systems.  From our 
experiments, it is appears that PI 3-kinase is involved in the actions of zinc described 
here, but the downstream target of the signaling cascade is less obvious.  Although the 
conditions used here result in Akt phosphorylation, agents like insulin that mimic this 
action of zinc do not recapitulate the effects on trafficking.  Also, neither Akt inhibitors 
nor dominant negative Akt prevent the effects of zinc.  Likewise, neither TOR nor ARF6 
inhibition interrupted the actions of zinc.  Thus, the step between PI 3-kinase activation 
and the mitochondrial target remains unidentified.  Moreover, recent studies have 
highlighted the role of other signaling cascades in the regulation of mitochondrial 
trafficking, including interactions with phosphatidylinositol (4,5) bisphosphate species 
(De Vos et al., 2003), activation of protein kinase A (Okada et al., 1995) and tumor 
necrosis factor-induced p38 activation (De Vos et al., 2000).  In addition to mitochondria, 
others have implicated the regulation of synaptic vesicular transport by kinesin motor 
proteins (Zhao et al., 2001; Okada et al., 1995).  With regard to the current study, we 
have also demonstrated that mitochondrial trafficking is regulated by a signaling 
mechanism critical for cell survival. 
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 What effects are mediated at the lowest, most physiologically relevant Zn2+ levels ? 
 A number of different mechanisms for zinc-mediated toxicity have been 
suggested.  The data shown here illustrate the point that there are multiple effects of Zn2+ 
which occur over a range of concentrations.  We observed that low concentrations of 
Zn2+ that inhibit movement and produce injury have no effect on ∆Ψm.  Higher 
concentrations of zinc produce a form of injury that is not prevented by wortmannin, and 
is also associated with mitochondrial depolarization.  Zinc mediated mitochondrial 
depolarization has been reported in a number of studies, both in intact cells (Sensi et al., 
1999) as well as in isolated mitochondria (Dineley et al., 2005).  However, these results 
suggest that while mitochondria are clearly a target for zinc action, the most sensitive 
mechanisms associated with cytotoxicity do not involve gross disruption of mitochondrial 
function.   
 
Secondary effects of oxidants in inhibiting mitochondrial movement  
 Evidently, this movement phenomenon is not strictly dependent on the source of 
zinc.  To mimic oxidant-labile [Zn2+]i, we applied 2,2’-DTDP to neurons and observed 
that mitochondrial movement significantly decreased with concentrations as low as 10 
µM.  This was surprisingly low, given that 100 µM 2,2’-DTDP was applied to cells in 
order to see mag-fura-2 responses in neurons (Aizenman et al., 2000).  In addition, we 
also observed movement inhibition with 100 µM H2O2 (unpublished observations), which 
was used to mimic ROS exposure.  Interestingly, TPEN did not restore mitochondrial 
movement when applied after either 2,2’-DTDP or H2O2.  Together, these results raise 
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 the possibility that apart from a direct Zn2+ effect, a secondary ROS-induced mechanism 
may also modulate mitochondrial movement.      
  
PI 3-kinase activation by zinc in different cell types 
 Indirect PI 3-kinase activation by Zn2+ has been reported in other studies.  Eom et 
al. (2001) found that Zn2+-induced stimulation of JNK through the PI 3-kinase pathway 
in primary mouse cortical neurons in culture, and Kim et al. (2000b) demonstrated that 
extracellular Zn2+ activates p70 S6 kinase through PI 3-kinase signaling in Swiss 3T3 
cells.  These findings differ from our own in that PI 3-kinase activation is dependent on 
the activation of other pathways, which may be attributable to the exposure of 10 times 
higher concentrations of Zn2+ (although in the absence of ionophore), longer Zn2+ 
exposures necessary to achieve Akt phosphorylation, or varying sensitivities among cell 
types.  We did not observe that the activation of other protein kinases plays a direct role 
in the Zn2+-mediated movement effect, as inhibitors of these pathways did not protect 
against movement inhibition (data not shown).  We cannot entirely exclude the 
possibility that these kinases are either activated downstream of or in parallel with PI 3-
kinase, however, their activation did not affect Zn2+-mediated changes in mitochondrial 
trafficking or neuronal injury.  Zn2+ activates a number of other protein kinases involved 
both in pro- and anti- cell survival mechanisms.  For example, studies have demonstrated 
that [Zn2+]i can activate members of the MAP kinase family.  Zn2+ activation of the 
stress-activated p38 (McLaughlin et al., 2001), as well as its activation of the traditionally 
pro-survival ERK (Du et al., 2002), is hypothesized to contribute to neuronal injury and 
subsequent cell death.  In addition, activation of PKC in neurons plays a role in Zn2+-
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 induced oxidative neuronal injury (Noh et al., 1999).  Since signal transduction pathways 
are rarely activated in a linear fashion, it is more than likely that there is crosstalk 
between these pathways with respect to Zn2+-mediated neuronal injury.   
  
What is the role of PI 3-kinase activity during neuronal injury ?   
 PI 3-kinase activity has traditionally been associated with many key cellular 
processes, including cell growth and survival, membrane trafficking, neurite outgrowth 
and cytoskeleton reorganization (Foster et al., 2003).  Indeed, extensive literature 
demonstrates that growth factor-mediated activation of the PI 3-kinase/Akt pathway, by 
insulin (Patel et al., 1993) or IGF-1 (Dudek et al., 1997; Schubert et al., 2004), NGF 
(Chada and Hollenbeck, 2003), and BDNF (Zheng and Quirion, 2004), is neuroprotective 
against a range of cellular stresses.  In addition, Luo et al. (2003) have demonstrated that 
constitutive activation of Akt is neuroprotective in, whereas Akt deactivation promotes 
multiple models of neuronal cell death, including NMDA excitotoxicity, or NO- and 
H2O2-elicited injury.  Including the present study, however, only one other report by 
Levinthal and DeFranco (2004) recently provided an example of PI 3-kinase activity 
associated with cell death.  The authors demonstrated that glutamate-induced oxidative 
neuronal injury is mediated by activation of PI 3-kinase.  Moreover, a window of 
transient PI 3-kinase inhibition afforded protection against oxidative glutamate toxicity, 
which is consistent with our results involving Zn2+ toxicity.  We also observed that 
transient PI 3-kinase inhibition was neuroprotective, but this protection was overcome 
with sustained kinase inhibition.  This provides insight about the bipolar nature of PI 3-
 119
 kinase: short term activation may contribute to cell death, whereas long term activation is 
essential for cell survival.    
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 Chapter 5.  Discussion 
5.1 General outline 
This discussion focuses on the impact of zinc on neuronal mitochondria and is 
divided into two parts.  The first involves mitochondrial zinc transport and the direct 
impact of zinc on isolated neural mitochondria.  Here we take some effort to extract a 
long and confused history of mitochondrial-Zn2+ investigation into an accessible 
summary, to which our own findings are related.  The second part describes our novel 
findings that elevated intracellular zinc interferes with mitochondrial movement in 
primary cultures of neurons.  This part describes the relatively young but growing body 
of literature regarding the relevance of mitochondrial trafficking in normal cell function 
and during injury.  Special emphasis is given to the role of Zn2+ in cytoskeletal 
organization and Zn2+ activation of cellular signaling pathways.  The discussion 
concludes with potential therapeutic interventions into zinc-induced neuronal injury and a 
look into possible future directions for the zinc neurobiologist.      
5.2 Mitochondrial dysfunction is an early event in neurodegeneration 
Mitochondria are critical for neuronal function as they maintain energy gradients 
required for cell survival.  The mitochondrial membrane potential (∆Ψm) is necessary for 
normal ATP production, Ca2+ storage and release, and control of reactive oxygen species 
(ROS) production.  Perhaps our best understanding of the role of mitochondria in 
neuronal death comes from studies of glutamate excitotoxicity that occurs in ischemia 
(Nicholls et al., 2000).  In this scenario, high levels of extracellular glutamate cause 
massive accumulation of intracellular calcium.  As mitochondria become overloaded with 
calcium from the cytosol, membrane potential is compromised, along with the capacity to 
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 synthesize ATP production via oxidative phosphorylation.  The disruption of 
mitochondrial function eventually leads to a cell death cascade involving the release of 
pro-apoptotic molecules and accumulation of reactive oxygen species (Nicholls et al., 
2000).   
 Zn2+ is also thought to cause neuronal injury by targeting mitochondria, and it is 
useful to compare Ca2+ toxicity to Zn2+ toxicity.   However, there are significant 
differences.  For instance, it is clear that in normal healthy cells, mitochondria labor 
continuously to take up and release Ca2+, while similar regulation of zinc is only 
suspected.  Additionally, while mitochondria have calcium transport pathways that can 
accommodate zinc, it is unclear whether zinc has access to these pathways particularly 
when calcium reaches micromolar levels that occur during excitotoxic stimulation. 
5.2.1 Mitochondria can import zinc by two pathways 
 From circumstantial evidence, previous studies suggested that Zn2+ could enter 
mitochondria through the mitochondrial calcium uniporter.  Studies conducted as early as 
1967 in isolated bovine heart mitochondria observed Zn2+ accumulation in mitochondria 
by atomic absorption, which was dependent upon respiration and inhibited by uncouplers 
(Brierley and Knight, 1967).  However, the conditions used a sucrose buffer without 
other cations, and added micromolar levels of Zn2+.  Saris and Niva (1994) proposed a 
role for uniporter-mediated transport, based on ruthenium red inhibition of Zn2+-induced 
swelling in rat liver mitochondria.  However, swelling was modest even at large 
concentrations of free zinc, and interpretation of the data was further complicated by the 
use of a variety of assay conditions.  Using isolated rat brain mitochondria, Jiang and 
colleagues (2001) observed similar swelling that was inhibited by ruthenium red, and also 
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 cytochrome c release, which they claimed occurred at free zinc levels as low as 10 nM.  
Curiously, their data suggested that mitochondria take up more zinc when exposed to zinc 
and calcium combined.  In any case, none of these studies presented any conclusive 
evidence for zinc import.   
 Thus our work using FluoZin-3 in isolated, attached brain mitochondria is the first 
to directly show zinc accumulation in the matrix (Chapter 3).  Moreover, we found 
evidence for two distinct modes of zinc import.  The first is a high capacity transport 
mechanism that is consistent with a uniporter mode because it is inhibited by ruthenium 
red, and depends on ∆Ψm.  The second is a low capacity, presumably energy-independent 
mechanism that occurs in the presence of ruthenium red and in the absence of ∆Ψm.  We 
are unable to further characterize this second pathway.  Speculation might include a 
mitochondrial zinc transporter, but this seems improbable given that the heart 
mitochondria proteome revealed no ZIP or CDF-like proteins (Taylor et al., 2003).  
Because our recording conditions contained no added Na+, it is also unlikely that Zn2+ 
could be substituting for Ca2+ in the mitochondrial Na+-Ca2+ exchanger.  It might be 
argued that our isolation procedure or treatments disrupted mitochondrial membranes, 
allowing free diffusion of zinc, but if so we would also expect significant leakage of dye, 
which was not the case.  A possible mechanism is suggested by Zazueta et al. (2004), 
who found evidence for the distinct subunit localization for the inhibition and transport 
properties of the uniporter.  By reconstituting solubilized mitochondrial proteins into 
cytochrome oxidase vesicles, a bimodal calcium uptake activity was measured, where 
one pathway was sensitive to the ruthenium red and Ru360, and the other was insensitive.  
One could propose a similar explanation for Zn2+ actions, in that ruthenium red may bind 
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 to the inhibition subunit that would prevent most Zn2+ uptake, but still allows some Zn2+ 
to bind the transport subunit.  Further characterization of the calcium uniporter is required 
to elucidate this mechanism.  Our data also provide evidence for zinc efflux (Chapter 3).  
However, similar to the low capacity influx, we are unable to further characterize this 
mechanism.  We know only that it is apparently unaffected by mitochondrial phosphate 
pools and proceeds relatively slowly compared to Zn2+ influx, although the latter could 
result from buffering of Zn2+ by FluoZin-3.  
5.2.2 Where do zinc actions on mitochondria occur ? 
 Numerous groups including ours have shown that zinc depolarizes mitochondrial 
membrane potential (Sensi et al., 1999; Sensi et al., 2000; Dineley et al., 2005).  
However, it has been a matter of disagreement as to whether zinc exerts this effect from 
the inside or outside of mitochondria.  Using isolated brain mitochondria in cuvette-based 
experiments, we showed that free zinc at about 100 nM effectively depolarizes 
mitochondria, and that membrane potential could be partially or even wholly rescued by 
an impermeant chelator (Dineley et al., 2005).  This suggests that zinc is acting 
externally.  Our recent data (Chapter 3) are in agreement.  Using adherent mitochondria 
loaded with Rh123, we showed that as low as 10 µM free Zn2+ depolarized mitochondria, 
and repolarization was observed with subsequent application of an impermeant chelator 
(EDTA).  Moreover, ruthenium red, which completely blocks calcium-induced 
depolarization, only protected against Zn2+-induced depolarization at low free Zn2+ 
concentrations (10 µM) but had no effect at higher free zinc concentrations (80 µM).  We 
can not rule out a depolarizing effect of small amounts of zinc that enter mitochondria in 
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 the presence of  ruthenium red, but it seems unlikely given the robust repolarization 
achieved with EDTA.   
 With respect to Zn2+ effects on respiration, several studies in isolated 
mitochondria have delineated specific inhibitory sites on the electron transport chain 
(Kleiner and von Jagow, 1972; Kleiner, 1974; Link et al., 1995; Mills et al., 2002).  
These results support the specific actions of Zn2+ on the electron transport chain, but do 
not explicitly confirm whether Zn2+ inhibits respiration from within the matrix or by 
binding to an external site.  In some of these situations, Zn2+ inhibition was shown to be 
reversible upon membrane-impermeant Zn2+ chelation (Kleiner, 1974; Link et al., 1995; 
Mills et al., 2002), suggesting an external association between the electron transport 
chain and Zn2+.  In a recent study (Dineley et al., 2005), we specifically demonstrated 
that Zn2+ inhibits oxygen consumption in isolated brain mitochondria when mitochondria 
are supplied with substrates that feed into specific complexes.  Again, extramitochondrial 
Zn2+ chelation with EGTA restored respiration in the presence of complex I and II 
substrates, suggesting that Zn2+ inhibition of these complexes occurs in the 
intermembrane space side of the electron transport chain.  Our interpretation from Zn2+ 
effects on ∆Ψm (Chapter 3) or respiration (Dineley et al., 2005) is in agreement with 
crystallography studies that revealed zinc binding sites near the externally accessible bc1 
complex (Berry et al., 2000). 
5.2.3 Evidence for zinc effects on mitochondria in cells 
 Previous groups have demonstrated that lethal doses of [Zn2+]i in vitro result in 
general mitochondrial injury.  Specifically, Manev and colleagues (1997) observed that 
brief exposure of high micromolar Zn2+ concentrations to cultured cerebellar neurons 
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 resulted in early global mitochondrial dysfunction prior to cell injury.  A more specific 
study demonstrated that toxic levels of Zn2+ inhibit glycolysis at glyceraldehyde 
phosphate dehydrogenase (GAPDH; Sheline et al., 2000), resulting in progressive 
reduction of ATP and NAD+.  In addition, elevated nanomolar Zn2+ was also shown to 
cause mitochondrial swelling in neurons loaded with MitoTracker Green to visualize 
mitochondria (Jiang et al., 2001).  However, there were problematic issues associated 
with the results: (1) the swelling was only assessed qualitatively, employing an ill-
defined arbitrary swelling index and (2) since no zinc buffering components were used to 
establish more physiological intracellular conditions, they could not define any 
concentration dependency to their measured parameters. 
 Others have previously demonstrated that excitoxicity-induced [Zn2+]i 
accumulation dissipates ∆Ψm in cultured primary neurons (Sensi et al., 1999; Sensi et al., 
2000).  In contrast, we never observed Zn2+-mediated depolarizations in primary neurons.  
These were reasonable ionophore-mediated rapid Zn2+ elevations that were sufficient to 
cause neuronal injury (Dineley et al., 2000, Chapter 4).  Perhaps these different findings 
can be explained by the role of Zn2+ during excitotoxicity.  We know that Ca2+ by itself is 
an effective and direct mitochondrial toxin.  During glutamate stimulus, both [Ca2+]i and 
[Zn2+]i become elevated.  The question is: does Zn2+ become elevated enough in the 
presence of Ca2+ to mediate direct effects on mitochondrial function ?  In the studies by 
Sensi and colleagues, they applied high extracellular Zn2+ in the presence of depolarizing 
stimuli or kainate treatment, which would allow Zn2+ influx presumably through Ca2+-
permeable pathways.  The estimated nanomolar Zn2+ levels cannot compete as an 
excitotoxin with Ca2+.  In this case, the mitochondrial depolarization observed by others 
 126
 would be predominantly Ca2+-induced.  In our paradigm, where we attempt to elevate 
Zn2+ levels comparable to Ca2+ by introducing Zn2+ in cells with the ionophore, we do not 
see loss of ∆Ψm.  Here, it is reasonable to speculate that Zn2+-induced ROS production or 
Ca2+ mobilization is the more direct mitochondrial effect, as opposed to Zn2+ directly 
acting on mitochondria.  Together, this speculates the ancillary role of Zn2+ during 
excitotoxicity.  This proposed role is not meant to demote the importance of Zn2+ as a 
neurotoxin.  Indeed, we recently demonstrated that glutamate exposure in neurons 
stimulated large FluoZin-3 increases, which were reduced with TPEN (Dineley et al. 
2004, SFN Abstract).  We know that cellular Zn2+ elevations occur during glutamate 
excitotoxicity, however, once free inside the cell, perhaps Zn2+ is more indirectly 
involved in mitochondrial dysfunction compared to Ca2+. 
5.3 Metallothioneins and mitochondria 
5.3.1 Metallothionein modulation of mitochondrial function  
 Ye and colleagues (2001) observed that MT localized to the intermembrane space 
of isolated rat liver mitochondria, where micromolar protein levels inhibited respiration.  
Added free Zn2+ inhibited respiration to the same extent, suggesting that Zn2+ release 
from MT mediates this effect.  The apo-form of MT, thionein, was quite effective at 
reversing Zn2+ inhibition of respiration, suggesting that MT delivers Zn2+ to the 
mitochondrial inner membrane without necessary matrix entry of MT.  The primary issue 
which failed to be addressed in the study by Ye and colleagues are that micromolar 
concentrations of exogenous MT protein may artificially force MT into isolated 
mitochondria, thereby being displaced from a more physiological investigation of its 
function.  Secondly, there is no current evidence that mitochondria contain any MT-like 
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 proteins (Taylor et al., 2003).  In isolated mitochondria, we did not observe any oxidant-
induced Zn2+ signals, suggesting that MT does not serve in mitochondrial Zn2+ 
sequestration (Chapter 3).  Indeed, very few mitochondrial proteins have been identified 
as Zn2+-binding proteins (Taylor et al., 2003). 
 The only study which remotely provides a physiological link between MT and 
mitochondria comes from Sakurai and colleagues (1993), where they measured levels of 
MT protein in rat liver by radioimmunoassay.  In subcellular fractions, MT was highest in 
cytosol, followed by nucleus, mitochondria and microsomal fractions.  Although the 
authors claimed that mitochondria were the organelles with the highest MT 
concentrations, they did not analyze MT content in other organelles or cytosolic 
compartments.  Another problematic issue with this study was that strong MT staining 
was only evident in livers of rats that developed hepatitis compared to much weaker 
staining in control rats, suggesting that the disease condition may have induced protein 
expression and may not be a physiological phenomenon.  Together, there is no conclusive 
data for the endogenous presence of MT in mitochondria. 
5.3.2 Is metallothionein a mitochondrial zinc chaperone ? 
 As mentioned above, it was hypothesized that mitochondrial Zn2+ transport occurs 
via the Ca2+ uniporter.  Although we have shown that uniporter blockade partially inhibits 
direct mitochondrial Zn2+ uptake (Chapter 3) and Zn2+-induced mitochondrial 
perturbations (Dineley et al., 2005), we cannot exclude the possibility of a novel, 
uncharacterized transport mechanism.  Two recent studies by Leslie Costello and 
colleagues have demonstrated the existence of a novel mitochondrial Zn2+ uptake 
process, whereby Zn2+ ions are thought to be donated from loosely-bound zinc-ligand 
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 complexes to a putative zinc transporter on the inner membrane.  In the first study (Guan 
et al., 2003), mitochondria isolated from rat prostate were subjected to radioisotope 
labeling with 65Zn to measure uptake rates with different Zn-ligand complexes.  Prostate 
cells contain 3 to10-fold more Zn2+ compared to other cells and citrate is a prominent 
Zn2+-ligand in the prostate.  Kinetic transport assays exhibited that uptake rates from 
Zn2+-ligands, such as cysteine, citrate or aspartate were essentially the same as for free 
Zn2+.  Notably, no uptake was determined in the presence of EDTA or EGTA, indicating 
that undissociated Zn2+ is not available for transport across the inner membrane.  In 
addition, none of the Zn2+-ligands themselves were permeable across the membrane.   
 The more recent study by Costello et al. (2004) proposed MT as a chaperone for 
mitochondrial zinc uptake in rat prostate and liver.  Exogenous MT enhanced liver 
mitochondrial Zn2+ uptake as effectively as Zn2+-citrate described in the previous study.  
On the other hand, prostate mitochondria do not accumulate Zn2+ from MT sources, but 
depend on the presence of other Zn2+-ligand complexes, suggesting a novel transport 
uptake mechanism in prostate vs. liver tissues.  Although Zn2+ transport may be regulated 
differently in brain vs. prostate and liver, it is possible that this putative transporter is the 
uniporter-independent mechanism that we hypothesize in our studies (Chapter 3).   
 Several differences arise when comparing approaches of our studies vs. Costello 
et al.:  (1) Since our preparations are devoid of cytosol and we did not introduce MT, we 
are not concerned with MT acting as a donor to the transport mechanism.  (2) We used 
fluorescent indicators to directly visualize free Zn2+ accumulation inside individual 
isolated mitochondria, whereas the other studies used radiolabeling, which does not allow 
distinction between free and bound Zn2+ in isolated mitochondria in suspension.   
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 (3) When we exposed our isolated mitochondria to strong sulfhydryl oxidants we 
observed no oxidant-labile Zn2+ pool, such as MT.  In summary, perhaps mitochondria 
import Zn2+ by transporter-dependent mechanisms under basal conditions, whereas 
import is more energy-independent with elevated [Zn2+]i.    
 As one potential candidate for Zn2+ chaperone, the mitochondrial copper 
chaperone, Cox17, was recently identified and shown to deliver copper into mitochondria 
for incorporation into and activation of cytochrome c oxidase.  Interestingly, the 
molecular weight of this copper chaperone is quite similar to MT, their sequences align at 
lysine and cysteine residues critical for metal binding, and they both lack a defined 
mitochondrial localization sequence but still manage to localize to the intermembrane 
space.  A recent study by Palumaa and colleagues (2004) demonstrated through 
electrospray ionization-mass spectroscopy that purified Cox17 can bind and transfer up to 
4 copper ions and two zinc ions regardless of the redox status of the protein.  Given these 
similarities between the two proteins, it would be interesting to examine whether Cox17 
can transport Zn2+ into mitochondria.    
5.4 Measuring mitochondrial zinc pools 
5.4.1 Oxidant-labile Zn2+ exchange between the cytosol and mitochondria ?  
 One hypothesis for Zn2+-induced neurotoxicity was that perhaps Zn2+ is also taken 
up by mitochondria like Ca2+ for it to depolarize mitochondria and generate ROS as 
necessary stages leading to global cellular dysfunction (Sensi et al., 2000).  To investigate 
the hypothesis that mitochondria take up Zn2+ from oxidant-sensitive cytosolic pools and 
release Zn2+ for cytosolic Zn2+ proteins, Sensi and colleagues (2003b) sought to visualize 
Zn2+ mobilization between cytoplasm and mitochondria by treatments with 2,2’-DTDP 
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 and FCCP, respectively.  Neurons exposed to FCCP followed by 2,2’-DTDP exhibited 
increased FluoZin-3 responses, suggesting the movement of Zn2+ released from 
mitochondria to protein-bound cytosolic sites.  However, it should be noted that FCCP 
also acidifies the intracellular environment, potentially destabilizing Zn2+-protein 
complexes in the cytosol.  One would therefore expect that FCCP would alone increase 
cytosolic Zn2+.  The reverse however, 2,2’-DTDP followed by FCCP, did not exhibit 
similar increases in [Zn2+]i.  The authors claimed that this reduced response is due to the 
rapid sequestration of mitochondrially-released Zn2+ into protein-bound pools.  Given the 
highly oxidized cytosolic environment resulting from 2,2’-DTDP exposure, it is difficult 
to imagine that the redox state of MT under these conditions would allow it to quickly 
bind Zn2+.  Indeed, in previous studies of 2,2’-DTDP treatment of non-stimulated 
neurons, the Zn2+ response remains elevated and relatively stable until Zn2+ chelation 
(Aizenman et al., 2000).  This response must be relatively large since it was detected with 
the low-affinity cytosolic indicator Newport Green.  Approaches to visualize and 
distinguish mitochondrial vs. cytosolic pools of Zn2+ may provide more convincing 
evidence of intracellular Zn2+ mobilization.  Techniques that attempted to demonstrate 
this will be discussed below. 
5.4.2 Use of mitochondrial-specific zinc fluorescent indicators 
 The specific visualization of mitochondrial Zn2+ was confounded by the lack of 
Zn2+-selective mitochondrial probes.  Initial studies by Sensi and colleagues (2000) 
sought to adapt the divalent cation indicator, rhod-2, since it was used to observe 
glutamate-stimulated intramitochondrial Ca2+ accumulation in neurons (Peng et al., 
1998).  Using this dye in primary neurons, Sensi et al. (2000) observed Zn2+-dependent 
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 speckled fluorescent changes in the perinuclear region, which they concluded as 
mitochondrial Zn2+ sequestration.  However, the failure to demonstrate co-localization 
with a ∆Ψm-sensitive dye did not confirm that the speckled pattern actually corresponds 
to mitochondria.   
More recently, a novel Zn2+ indicator with nanomolar affinity, thought to localize 
to mitochondria has been used to monitor changes in intramitochondrial free Zn2+.  In a 
methods study (Sensi et al., 2002) to characterize the properties of RhodZin-3, high co-
localization was observed in neurons labeled with RhodZin-3 and MitoTracker Green.  
The staining of both dyes was predominantly in the perinuclear region and spread 
throughout the processes.  However, basal RhodZin-3 fluorescence in a resting neuron 
was observed as speckles throughout the cell body, which may or may not correspond to 
mitochondria.  In our experiments visualizing mitochondria using GFP-tagged 
mitochondrial protein (Chapter 3), the cell bodies are completely and consistently bright 
due to the high concentration of mitochondria localized within a focused region, whereas 
individual mitochondria can be distinguished in the processes as elongated structures.  
Therefore, we rarely have observed speckled or punctuate mitochondria within the cell 
body or processes of healthy neurons.  In contrast, Sensi and colleagues observed that in 
stimulated cells, only certain speckles increased modestly in fluorescence, as opposed to 
entire mitochondrial structures or the entire cell body.   
In summary, studying [Zn2+]i has been difficult because of limitations in reagents.  
However, even with recently emerging Zn2+ fluorescent indicators, detecting 
mitochondrial Zn2+ still remains a challenge, due to the indeterminate localizations of 
these probes and their uninterpretable signals.  In order to convincingly detect 
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 mitochondrial Zn2+ in living cells, perhaps designing a mitochondrially-targeted Zn2+ 
sensor (i.e. mitochondrially-targeted MT) may provide more accurate localization of 
mitochondrial Zn2+ in the absence of cytosolic noise.    
5.4.3 Detected mitochondrial zinc signals are dependent on experimental model 
 As mentioned above, currently available fluorescent indicators do not allow the 
precise separation between Zn2+ signals arising from the cytosol and mitochondria.  To 
more directly observe mitochondrial Zn2+ accumulation without confounding signals 
from the cytosol, we investigated mitochondrial Zn2+ transport in isolated mitochondria.  
Our initial studies effectively demonstrated Zn2+-induced mitochondrial dysfunction 
using ∆Ψm- and ROS-sensitive indicators (Dineley et al., 2005).  However, we were 
unsuccessful at demonstrating direct Zn2+ uptake in isolated mitochondria using 
fluorescent Zn2+ indicators in a spectrofluorimetric assay.  In loading isolated 
mitochondria with Newport Green, we observed some dye leakage.  Also, because of the 
nature of the cuvette-based assays, it was difficult to determine precise free zinc 
concentrations in the presence of chelator.  Since experiments were performed on isolated 
mitochondria in suspension, it was difficult to determine the location of Zn2+ actions on 
mitochondria; distinguishing between dye binding Zn2+ within the matrix vs. dye binding 
Zn2+ on external sites.  These problems prevented us from accurately interpreting the 
signals we detected in mitochondria upon Zn2+ exposure.   
We overcame some of these issues in using a novel experimental system, whereby 
isolated brain mitochondria were attached to glass coverslips and were capable of taking 
up FluoZin-3 to investigate mitochondrial Zn2+ transport.  The advantages this model has 
over the previous one are as follows: (i) the mitochondria retained dye fairly well and we 
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 were able to detect matrix Zn2+ changes, (ii) chelator concentrations were maintained 
relatively stable as it was present in the isolation procedure and perfused throughout the 
experiment, (iii) as opposed to cuvette-based experiments, individual attached 
mitochondria can be imaged, where solutions and treatments can be perfused over the 
sample when desired and (iv) adherent mitochondria allow direct visualization of 
mitochondrial Zn2+ uptake, since it is not possible to observe direct transport in 
mitochondrial suspensions.  Although this model is devoid of cytosolic components and 
therefore does not account for any Zn2+ mobilization between different intracellular 
pools, it presents many advantages to directly visualize mitochondrial Zn2+ uptake.    
5.5 Mitochondrial trafficking in neurons  
The concept of mitochondria as dynamic entities was described almost 90 years 
ago (Lewis and Lewis, 1915).  However, based on the availability of imaging methods, it 
has been difficult to study their movements in cells.  The recent advent of techniques to 
visualize mitochondria in living cells has revolutionized our investigations of these semi-
autonomous organelles that constantly divide, fuse, and move throughout the cell 
(Bereiter-Hahn and Voth, 1994).  Although we lack a complete understanding of the 
forces that drive mitochondrial dynamism, there are emerging suggestions for the 
necessity of their cellular distribution.  Mitochondrial motility and distribution become 
important parameters, especially when considering cellular polarity, or the presence of 
distinct subcellular domains and the demands and needs with them.  For example, 
neurons have a highly polarized morphology, consisting of processes that originate from 
a central cell body, forming the basis for directionalized signaling.  By delivering ATP to 
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 areas of high metabolic demand, mitochondria could play an important role in organizing 
neuronal polarity (Mattson, 1999).   
 The need for mitochondrial movement in neurons has been hypothesized in 
several ways:  (i) Diffusion of ATP within neurons seems inadequate to support energetic 
homeostasis.  Therefore, the positioning of mitochondria to regions where required ATP 
consumption is high appears favorable for cell survival (van Blerkom, 1991).  (ii) 
Calcium is essential for the activation of critical cellular enzymes and acts as a second 
messenger in signal transduction processes, in addition to regulating neurite growth and 
axonal development (Spira et al., 2001).  By regulating local calcium homeostasis, 
mitochondria may deliver calcium to and sequester calcium at required regions of the 
cell.  Specifically, the efflux of Ca2+ by mitochondria has been shown to enhance 
neurotransmitter release at nerve terminals, indicating that mitochondria also play a role 
in modulating local synaptic transmission (Tang and Zucker, 1997).  This emphasizes the 
need to deliver mitochondria to pre-synaptic terminals.  How mitochondrial functions 
affect mitochondrial movement in neurons has only recently been addressed.  Indeed, 
evidence has suggested that differences in metabolic properties can affect frequency and 
distance of organelle motility in axons and dendrites of primary neuronal cultures 
(Overly, 1996).   
5.5.1 Regulation of mitochondrial trafficking 
Role of the cellular cytoskeleton 
Aside from bioenergetic-associated changes in mitochondrial movement, there is 
evidence that the cytoskeleton regulates organelle distribution.  Several studies have 
addressed aspects of mitochondrial movement with respect to their interaction with the 
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 cytoskeleton.  Specifically, it is known that mitochondrial movement is microtubule-
based.  For example, Ligon and Steward (2000b) demonstrated that using cytoskeleton-
disrupting drugs that depolymerize microtubules, but not actin filaments, attenuated 
mitochondrial movement in both axons and dendrites.  An earlier study by Krendel and 
colleagues (1998) demonstrated that disassembly of actin filaments resulted in increased 
rate and frequency of mitochondrial movement along microtubules, confirming that most 
of the movement occurs along microtubules, although actin filaments may modulate 
movement by tethering mitochondria to specific regions and controlling rate of 
microtubule-based movement.  In addition, physical associations between microtubules 
and mitochondria have been identified (Price et al., 1991), further supporting the concept 
of mitochondrial movement along these cytoskeletal “tracks”.  More recently, 
mitochondria-neurofilament interactions were noted in vitro as another cytoskeletal 
component that modulates mitochondrial motility (Wagner et al., 2003).  The physical 
association was dependent on ∆Ψm and also the phosphorylation status of the 
neurofilament subunits, suggesting that neurofilament activity may also control 
mitochondrial distribution in neurons.   
Contributions of motor proteins to mitochondrial movement 
 In addition to microtubules, molecular motor proteins of the dynein and kinesin 
families also mediate mitochondrial movement.  These proteins provide the bidirectional 
movement of mitochondria (Hirokawa, 1996), specifically anterograde and retrograde 
transport in neurons, through their phosphorylation/dephosphorylation.  Anterograde 
axonal transport of mitochondria is supported by kinesin motors, driving movement 
towards the plus ends of microtubules.  In contrast, retrograde movement is supported by 
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 the dynein motors, driving movement towards the minus ends of microtubules (Schroer 
and Sheetz, 1991).  
 Although the exact properties and functions of these motor proteins are not 
completely known, evidence suggests that these motor proteins distinguish mitochondrial 
axonal movement from the axonal movement of other organelles and vesicles.  Firstly, 
the observation that mitochondria globally move slower than other organelles suggests 
that in addition to simply having a larger mass, they contain specific motors that control 
or regulate the velocity of their movement (Morris and Hollenbeck, 1993).  For example, 
both mitochondrial and vesicular movement in axons was demonstrated to be regulated 
by two distinct isoforms of kinesin (Elluru et al., 1995), suggesting that the specific 
isoform associated with the organelle may explain why vesicles move faster than 
mitochondria.  Secondly, mitochondrial movement is described as bidirectional and 
saltatory (Morris and Hollenbeck, 1993), whereas vesicular movement is generally 
unidirectional and smooth (Allen et al., 1982).  The need to constantly change direction 
in a less smooth fashion could reflect the larger responsibility of the motor proteins in 
directional transport and the overall slower mitochondrial movement in axons.  And 
thirdly, the physical association of mitochondria with motor proteins in discrete patches 
that are widely-spaced along the mitochondrial surface (Martz et al., 1984) provides the 
advantage of more precise control of cytoskeleton-based movement.  
5.5.2 Mitochondrial trafficking during cell injury 
It is thought that mitochondrial biogenesis, or the generation of new 
mitochondria, occurs in the perinuclear region (Davis and Clayton, 1996) and the 
mitochondria then move anterogradely to provide energy for growth of new processes 
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 (Ligon and Steward, 2000a).  Furthermore, it may be hypothesized that under injury 
conditions, mitochondria may be transported retrogradely or are accumulated and 
degraded in the periphery.  Although there is this notion that mitochondrial distribution 
can be regulated in part via communication with the surrounding cytoskeleton, the 
mechanisms by which this occurs have not been defined.  However, in vitro studies have 
demonstrated that targeted disruption of kinesin results in an abnormal perinuclear 
clustering of mitochondria (Tanaka et al., 1998), suggesting that these motor proteins 
may be regulators of mitochondrial distribution. 
Indeed as evidence for mitochondrial degradation near the cell body, Miller and 
Sheetz (2004) demonstrated that ~ 90% of mitochondria maintaining high potential were 
transported anterogradely towards the growth cone, whereas ~80% of mitochondria with 
reduced potentials were transported towards the cell body.  Previous studies have shown 
that depolarized or damaged mitochondria are targeted for elimination and removal by 
the process of autophagy (Xue et al., 2001).  Autophagy involves an intracellular vacuole 
composed of ER membranes and contains a lysosome used to engulf and degrade old, 
damaged mitochondria.  If damaged or non-functioning mitochondria predominantly 
return back towards the cell body, perhaps high concentrations of these autophagosomes 
reside in the perinuclear region and serve as a mitochondrial “burial ground”.  These 
notions are purely speculative and no conclusive evidence so far demonstrates that 
mitochondria are destroyed near the cell body, although it would be convenient to recycle 
old mitochondrial components in regions proximal to where new mitochondria are 
generated. 
 
 138
 Neurodegeneration models and altered mitochondrial axonal transport 
Emerging data suggest that neuronal mitochondrial distribution can change in 
response to injury, although we know relatively little about how organelle transport 
processes change under physiological conditions.  Using glutamate excitoxicity as a 
model for stroke, we demonstrated impaired mitochondrial movement and morphology in 
neurons (Rintoul et al., 2003).  A failure to transport mitochondria to peripheral cell 
compartments were observed in response to overexpression of tau protein (Ebneth et al., 
1998) or mutations in presenilin protein (Pigino et al., 2003) as a model for Alzheimer’s 
disease, and mitochondrial perinuclear clustering and fragmentation in response to 
apoptotic stimuli (De Vos et al., 1998), presumably from defective kinesin-mediated 
organelle movement.  Brownlees and colleagues (2002) demonstrated that abnormal 
neurofilament assembly perturbs mitochondrial movement and localization in a neuronal 
model of Charcot-Marie-Tooth disease, an inherited disorder of the peripheral nervous 
system.   
Hereditary spastic paraplegia (HSP) is a genetic heterogeneous condition 
characterized by selective axonal degeneration in corticospinal tracts, resulting in 
progressive weakness, spasticity, and loss of sensation in the lower limbs.  Ferreirinha 
and colleagues (2004) developed a mouse model for HSP by mutating the mitochondrial 
ATPase paraplegin, which resulted in local mitochondrial morphological and functional 
abnormalities, followed by impairment of axonal transport and consequent axonal 
degeneration.  As a classic example of a polyglutamine-related disease, Huntington’s 
disease is also associated with altered mitochondrial trafficking in motor neurons 
(Piccioni et al., 2002; Trushina et al., 2004).  These studies demonstrated that aggregation 
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 of polyglutamine tract-containing proteins confounds axonal trafficking of mitochondria, 
presumably due to disruptions of cytoskeletal interactions.  We have recently 
demonstrated that overexpression of mutant huntingtin protein creates a physical 
“roadblock” in axonal processes, thereby preventing mitochondria from getting around 
these barriers to neuronal regions where they are needed (Chang et al. 2003, SFN 
Abstract).  Such pathological alterations in mitochondrial distribution may contribute to 
the neurodegenerative process.   
Glutamate excitotoxicity 
 Glutamate excitoxicity has been extensively studied as a model for ischemia-
induced neurodegeneration.  Our earlier studies demonstrated that upon intense glutamate 
stimulation of primary neurons, mitochondria accumulate Ca2+ (White and Reynolds, 
1997).  Mitochondrial Ca2+ overload prevents the organelle from properly buffering 
cytosolic Ca2+ levels or generating necessary ATP.  Additionally, Ca2+ overload causes 
the release of apoptotic factors and subsequent cell death.  In a later study (Stout et al., 
1998) our lab demonstrated that ∆Ψm-driven mitochondrial Ca2+ uptake was necessary 
for glutamate-induced neuronal death.   
The inability of mitochondria to regulate [Ca2+]i and fulfill cellular ATP demands 
will inevitably affect neuronal viability.  One hypothesis is that mitochondria cannot 
deliver energy and nutrients to neuronal regions with high metabolic demand.  In turn, the 
failure to place mitochondria in regions of where ATP is needed may compromise 
neuronal viability.  To examine the effects of glutamate on mitochondrial trafficking in 
primary neurons, we utilized a mitochondrially-targeted fluorescent protein to visualize 
and measure mitochondrial movement (Rintoul et al., 2003).  We observed that toxic and 
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 acute glutamate exposure drastically impaired mitochondrial movement and altered 
morphology from an elongated to punctuate structure.  In elucidating a mechanism for 
these effects, we compared the actions of glutamate to FCCP to depolarize mitochondria 
and oligomycin to inhibit ATP synthesis.  Both FCCP and oligomycin impaired 
mitochondrial movement, but did not alter morphology.  We speculate that movement 
inhibition results from loss of ATP, whereas the morphological change results 
specifically from Ca2+ uptake generated by glutamate.  This is consistent with our 
observations that acute Zn2+ elevations impair movement without affecting morphology 
(Chapter 4).  In contrast, the effects of Zn2+ and Ca2+ on mitochondrial function differ, 
such that with glutamate treatment, mitochondrial undergo Ca2+-mediated ∆Ψm 
depolarizations (White and Reynolds, 1996), whereas elevated [Zn2+]i does not cause loss 
of ∆Ψm (Dineley et al., 2000, Chapter 4).  These results suggest that ∆Ψm depolarization 
does not play a role in Zn2+-induced inhibition of mitochondrial trafficking. 
Perhaps one component of the glutamate effect is associated with changes in the 
cellular cytoskeleton.  Indeed, Ackerley and colleagues (2000) demonstrated that toxic 
exposure of glutamate in primary cortical neurons generated increased phosphorylation 
and subsequent aggregation of neurofilament proteins, thereby slowing axonal transport 
of neurofilament.  Although the study did not implicate mitochondrial associations, one 
could hypothesize that glutamate stops mitochondrial movement through disrupting 
mitochondrial-neurofilament interactions.  The mechanisms behind glutamate-mediated 
modulation of mitochondrial trafficking are still under investigation. 
Although glutamate and zinc are neurotoxins, it is interesting that only glutamate 
induced a Ca2+-mediated change in morphology.  A growing body of literature indicates 
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 that mitochondria can modulate their shape by expression of specific cytoplasmic 
proteins, examples being dynamin-related protein 1 (Drp1) and mitofusin (Mfn).  
Although their physiological roles are not clear, upregulation of Drp1 and Mfn protein 
expression in neurons causes mitochondrial fission and fusion, respectively (Filiano et 
al., 2002, SFN Abstract).  With respect to cell injury, studies in non-neuronal cells 
demonstrated that apoptogen treatment induced mitochondrial fragmentation (Frank et 
al., 2001), suggesting that fission events may be upregulated during cell death.  Although 
we have not yet investigated fission mechanisms in our glutamate paradigm, we 
recognize that morphological changes may be important with respect to cell death 
mechanisms.  However, changes in morphology during cell injury will not be discussed 
further with respect to this dissertation because we did not observe it with Zn2+. 
Nerve growth factor (NGF)-induced modulation of axonal transport 
 The docking or stopping of mitochondria in certain regions of the neuronal 
process is hypothesized to be controlled by sensor molecules, which could include ions 
(such as Ca2+), metabolites (such as ATP, ADP or NADH), second messengers (such as a 
small G-protein), or a signal transduction pathway (Hollenbeck, 1996).  The sensor could 
either be freely dispersed in the cytosol or closely associated with mitochondria or the 
cytoskeleton (Miller and Sheetz, 2004).  One such example comes from a recent study by 
Chada and Hollenbeck (2003) demonstrating that nerve growth factor (NGF) signaling 
attenuates mitochondrial motility in dorsal root ganglion (DRG) neurons.  Here, the 
authors show that local application of NGF along the axons causes not only more 
mitochondria to enter these NGF-concentrated foci, but also decreases the number of 
mitochondria that leave these foci as well.  Most intriguingly, inhibitors of 
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 phosphatidylinositol 3-kinase (PI 3-kinase) prevented the mitochondrial congregation at 
these locales, suggesting that a sensor protein-induced signaling pathway that is 
mimicked by NGF mediates this docking phenomenon.     
These observations strongly support our [Zn2+]i-mediated mitochondrial 
movement inhibition that is regulated by PI 3-kinase activity (Chapter 4).  However, it is 
interesting that unlike Zn2+ or glutamate, NGF is not normally considered a neurotoxin.  
This suggests that NGF-induced mitochondrial docking may be a necessary event to 
control mitochondrial transportation within cells and may have a more global importance 
for neuronal survival (Reynolds and Rintoul, 2004).  Indeed, Kuruvilla and colleagues 
(2000) observed that NGF-mediated PI 3-kinase activation in sympathetic neurons is 
critical for neuronal viability.  It must be emphasized that the concept of mitochondrial 
docking is not well established.  Therefore, questions that remain to be addressed are: (1) 
what are the identities of these docking proteins that cause mitochondria to stop at 
specific sites and (2) what signals guide mitochondria to docking stations ?     
5.6 Associations between zinc and trafficking in neurons 
We use the term “mitochondrial trafficking” here to describe not only 
mitochondrial distribution, but also the anterograde and retrograde translocation of 
mitochondria along neuronal processes.  These properties of mitochondrial trafficking 
have only been recently addressed, and even less is known about the factors that regulate 
them during injury.  Based on the current literature, however, there is the suggestion that 
neurotoxins may affect mitochondrial trafficking in neurodegenerative conditions.  Given 
that [Zn2+]i is both a neuronal and mitochondrial toxin, we proposed that [Zn2+]i mediates 
neurotoxicity through changes in mitochondrial movement.  Through investigation of 
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 mitochondrial movement in neurons, we have identified possible mechanisms and 
consequences of toxic [Zn2+]i accumulation on mitochondrial trafficking in neurons 
(Chapter 4).  We observed that Zn2+ does not affect ∆Ψm at the exposure concentrations 
and times which inhibit mitochondrial movement.  This is similar to Miller and Sheetz 
(2004) where treatment of mannitol stopped mitochondrial movement without affecting 
∆Ψm.  This suggests that mitochondrial inhibition, which is mediated by local sensor 
molecules, and directional transport, which is determined by ∆Ψm, are events that are 
independently regulated. Topics that speculate mechanisms in zinc regulation of 
mitochondrial trafficking will be discussed below.   
5.6.1 Zinc and the cellular cytoskeleton 
The earliest evidence for Zn2+ effects on the cytoskeleton in the nervous system  
was provided by Kress and colleagues (1981) where zinc wires were implanted into adult 
rat brains for several weeks.  The exposure of zinc reduced the numbers of microtubules 
significantly in brain tissue, which was presumed to result from destabilizing tubulin 
assembly as opposed to directly interacting with microtubules.  The slow release of zinc 
ions from the wire had no affect on actin filaments or neurofilaments.  Interestingly, the 
mitochondria within the processes exposed to zinc were enlarged, swollen and started to 
disintegrate, since only remains of cristae were visible at the end of the wire implantation 
period.  This suggested that microtubule disorganization and mitochondrial disruption 
may be potential mechanisms involved in zinc-induced neuronal injury.   
We have previously demonstrated that acute exposure of cytoskeletal disrupting 
agents dramatically stops mitochondrial movement (Filiano et al. 2004, SFN Abstract).  
After drug treatment, our primary neurons display punctate and fragmented staining of 
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 tubulin (for microtubule organization) and phalloidin (for actin filament organization).  In 
our Zn2+ experiments, however, we were not able to sufficiently conclude that Zn2+ 
inhibition of mitochondrial movement was specifically associated with cytoskeletal 
components (Chapter 4, data not shown).  In contrast to the positive control using 
cytoskeletal inhibitors, the staining for cytoskeletal proteins after acute and toxic Zn2+ 
exposure produced ambiguous results, implying weaknesses in the technique that failed 
to display cytoskeletal disorganization unless the cell was grossly disrupted.          
5.6.2 Zinc activation of cellular signaling pathways 
Zn2+ has been shown to activate a number of cellular signaling pathways, which 
highly depend on the conditions and concentrations of Zn2+ exposure.  Having tested a 
number of protein kinase inhibitors for protection against our Zn2+-mediated movement 
phenomenon (Chapter 4), we identified inhibitors of the PI 3-kinase pathway as positive 
“drug hits” in our assay since (1) they did not affect mitochondrial movement by 
themselves and (2) they prevented the Zn2+-mediated movement effect in our primary 
neurons.  Therefore, we will exclude the discussion of other signaling pathways here and 
will only focus on evidence for PI 3-kinase activation by Zn2+.  
Zinc activation of phosphatidylinositol 3-kinase 
Extensive evidence exists for indirect activation of PI 3-kinase by Zn2+ in various 
cell types: (i) hundreds of micromolar Zn2+ activated PI 3-kinase in epithelial cells within 
15 minutes (Tang and Shay, 2001), (ii) low micromolar concentrations of added Zn2+ 
activated p70 S6 kinase in cell lines, which was sensitive to PI 3-kinase inhibitors (Kim 
et al., 2000b), (iii) micromolar concentrations of Zn2+ activated p70 S6 kinase, regulated 
by both PI 3-kinase and MAPK pathways in neuroblastoma cells (An et al., 2005), (iv) 
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 micromolar Zn2+ concentrations at chronic exposures induces c-Jun-N-Terminal kinase 
(JNK) through PI 3-kinase in primary cortical cells and cell lines (Eom et al., 2001) and 
(v) micromolar quantities of Zn2+ for only a few minutes robustly activated PI 3-kinase in 
primary neurons and cell lines by activating upstream tropomycin-related kinase (Trk) 
receptors (Hwang et al., 2005).  The important distinction between these studies and our 
own (Chapter 4) is that opposed to relying on inherent mechanisms for cellular Zn2+ 
uptake, we rapidly and reliably elevated [Zn2+]i using an ionophore (Dineley et al., 2000).  
Using this method for Zn2+ delivery, we consistently observed that pathological Zn2+ 
elevations increased phosphorylated Akt levels in primary neurons within 5 minutes of 
exposure, at the same time as mitochondrial movement was inhibited.  PI 3-kinase 
inhibitor prevented both Akt phosphorylation and the Zn2+-induced movement effect, 
confirming that PI 3-kinase activity modulates mitochondrial movement. 
In our mitochondrial movement paradigm, we sought the role of Akt 
phosphorylation as the most obvious downstream factor in the PI 3-kinase pathway 
(Chapter 4).  Bijur and Jope (2003) demonstrated rapid accumulation of Akt in 
mitochondria after PI 3-kinase activation, suggesting that Akt is the downstream 
mitochondrial target in the PI 3-kinase pathway in response to cellular stresses.  
However, we could not conclude that Akt phosphorylation was a downstream event in 
Zn2+-induced PI 3-kinase pathway, though we speculate that other downstream targets of 
PI 3-kinase (ARF6, TOR) may identify a Zn2+ target on mitochondria.  Apart from Akt, 
the several other downstream targets of PI 3-kinase that we investigated were also not 
involved in the Zn2+ inhibition of mitochondrial movement.  The difficulties in 
identifying the correct protein kinase target stem from the multitude of kinase substrates 
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 in the cell, as well as limitations in the available methods for detecting targets.  These 
issues will be discussed below. 
Specificity of protein kinase inhibitors 
The eight isoforms of PI 3-kinase proteins make up a kinase superfamily involved 
in key cellular functions such as cell growth and proliferation, motility, differentiation, 
survival and intracellular trafficking (Foster et al., 2003).  Therefore, nearly all important 
aspects of cellular function are regulated by the cycle of phosphorylation and 
dephosphorylation of these critical kinases.  We can specifically study these critical 
functions by blocking them in cells.  The two most commonly used, yet chemically 
unrelated, inhibitors are wortmannin and LY294002.  Unfortunately, the limited 
selectivity of these inhibitors stems from the fact that they inhibit all known PI 3-kinase 
isoforms, therefore it is difficult to dissect the involvement of distinct PI 3-kinase 
proteins.  The fungal metabolite wortmannin (isolated from Penicillium wortmanni) 
irreversibly inhibits PI 3-kinase in cell-based assays at > 100 nM (Ward et al., 2003).  It 
is also capable of inhibiting the skeletal muscle isoform (SnMLCK) and other protein 
kinases, although at several micromolar concentrations.  Derived from the bioflavanoid 
quercetin family of chromenones, LY294002 is a selective, but less potent, inhibitor of 
the PI 3-kinase family.  LY294002 completely inhibits PI 3-kinase activity at 100 µM.  
Although less potent than wortmannin, LY294002 has the advantage of being more stable 
in solution.  As mentioned above though, neither of these inhibitors is selective toward 
any PI 3-kinase isoform and may even inhibit other protein kinases outside of the PI 3-
kinase family.   
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 Developments of more selective inhibitors have utilized the structures and binding 
properties of wortmannin and LY294002.  More recently, a second generation of PI 3-
kinase inhibitors have been developed with specific selectivity towards the α, β, and δ 
isoforms, although detailed information about their structures and their commercial 
availability are unknown.   
Identifying targets of protein kinases 
The other issue involving the study of kinases is the enormous complexities of 
signaling pathways.  Approximately one-third of mammalian cell proteins can be 
phosphorylated and there are roughly 1000 protein kinases encoded by the human 
genome, each of which phosphorylates an estimated 30 proteins (Davies et al., 2000).  
This number is probably an underestimate since proteins can be phosphorylation targets 
of multiple kinases.  The identification of kinase substrates has been slow and difficult 
because the active domains of many protein kinases share a high degree of structural 
similarity.  Also as mentioned above, many of the pharmacological inhibitors lack 
specificity and often exhibit overlapping sensitivities to many different protein kinases.   
We established in primary neurons that Zn2+ attenuated mitochondrial movement 
through rapid PI 3-kinase activation (Chapter 4).  Speculating that the most direct 
downstream target is also a protein kinase, we selectively blocked the activity of that 
particular kinase to determine its role in our movement paradigm.  Of the number of PI 3-
kinase targets that we tested, none of the potential candidates provided us with positive 
evidence.  In finding this target, we contended with the following difficulties: (i) 
signaling pathways are never linear and distinct, and therefore are dependent on and 
regulate other pathways simultaneously, (ii) we are limited with a finite number of 
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 reagents which are not entirely selective and may even block multiple kinases, depending 
on concentrations applied, and (iii) many protein kinases have critical functions in several 
cell processes, therefore blocking its activity to study one aspect may compromise other 
cellular functions.  However, the PI 3-kinase inhibitors provided a direct and specific 
effect on mitochondrial movement compared to the other signaling pathway inhibitors 
tested.  Despite the inability to completely dissect this pathway from all the others 
occurring in the cell, we demonstrated that inhibition of a specific kinase prevented an 
indirect interaction between Zn2+ and mitochondria. 
5.7 Therapeutic implications of chelators in zinc-induced toxicity 
Evidence for Zn2+ contribution to neuronal death suggests potential targets for 
neuroprotection, the most logical approaches involving Zn2+ chelation or blocking 
cellular Zn2+ entry.  More specific methods of reducing Zn2+ neurotoxicity, specifically 
by chelating [Zn2+]i will be discussed below.  
5.7.1 Methods of zinc chelation 
We have demonstrated that membrane-permeant (TPEN) and membrane-
impermeant (EDTA) chelators can reverse Zn2+-mediated effects both in cells (Dineley et 
al., 2000) and isolated mitochondria (Dineley et al., 2005), respectively.  With respect to 
use of these chelating agents in vivo, Cuajungco and Lees (1996) demonstrated that the 
presence of TPEN during intrahippocamal administration of ZnCl2 completely prevented 
Zn2+-induced neuronal loss.  This is consistent with our results in primary neurons, where 
maximal cell survival was observed when elevated Zn2+ was co-administered, or applied 
within 5 minutes of TPEN (Chapter 4).  However, if TPEN was applied following a 10-
minute Zn2+ exposure, Zn2+ chelation no longer afforded protection, suggesting that 
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 TPEN has a critical window for therapeutic potential.  In other studies, administration of 
EDTA significantly protected against Zn2+-induced neurotoxicity (Frederickson et al., 
2002) in animal models of ischemia (Koh et al., 1996) and traumatic brain injury 
(Hellmich et al., 2004).  Although these lines of evidence suggest that these chelators 
may provide therapeutic value to neurodegenerative models, whether they interfere with 
physiological Zn2+-mediated processes remains unknown.  In addition, it is apparent that 
direct Zn2+ removal reduces its neurotoxic consequences.  However, the window of time 
for chelation is critical in order to prevent the cascade leading to Zn2+-mediated 
neurotoxicity (Chapter 4). 
5.7.2 Zinc and tissue plasminogen activator 
Tissue plasminogen activator (tPA) normally converts plasminogen into the active 
form plasmin and is observed to mediate neurodegeneration in vivo and in cell culture 
(Tsirka et al., 1995; Tsirka et al., 1996).  In addition, cell death is limited in tPA-/- mice, 
indicating that tPA is a potent neurotoxin (Tsirka et al., 1997).  Interestingly, in the 
context of zinc-mediated neurotoxicity, tPA can afford protection (Kim et al., 1999a).  
Siddiq and Tsirka (2004) have investigated the mechanism for tPA-mediated protection 
against Zn2+.  They show that zinc binds and inhibits tPA activity in a dose-dependent 
fashion.  In addition, tPA modulates extracellular Zn2+ by binding to it and also 
facilitating its cellular entry through voltage-sensitive calcium channels and Ca2+-
permeable AMPA/KA channels.  The presence of tPA has physiological significance for 
Zn2+ sequestration and neuroprotection, since primary neurons deficient for tPA exhibit 
increased sensitivity to Zn2+.  Based on these studies, it has been speculated that zinc and 
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 tPA may act to inhibit the neurotoxic properties of the other, although how their 
interactions are regulated is not entirely clear. 
5.7.3 Zinc and clioquinol 
One example of a potential clinical candidate for Zn2+ chelation is the oral 
antibiotic clioquinol (CQ), which selectively binds Zn2+ and Cu2+, possesses hydrophobic 
properties, and freely crosses the blood-brain barrier.  Given that one of the proposed 
mechanisms for Alzheimer’s disease development is the Zn2+-induced promotion of Aβ 
plaques, CQ presented an ideal drug candidate to solubilize the plaques.  Cherny and 
colleagues (2001) presented a study, whereby chronic CQ treatment in a transgenic 
mouse model of Alzheimer’s disease markedly improved Aβ plaque deposition compared 
to non-treated controls.  These structural brain changes were accompanied by significant 
improvement in general behavior.  These primary results suggest that CQ may be useful 
in clinical trials involving AD patients.  Indeed, a recent study by Ritchie and colleagues 
(2003) described a pilot phase 2 clinical trial in AD patients with CQ treatment to 
specifically detect cognitive changes.  According to the study, CQ provided a beneficial 
effect on AD progression seen only in the most severely affected subjects by reduction in 
plasma Aβ, enhanced zinc levels and cognitive improvements.  However, after extensive 
use for over 20 years as an antibiotic, CQ was withdrawn from oral use in 1970, primarily 
due to the safety concerns associated with it, such as risk for developing subacute myelo-
optic neuropathy, therefore long-term effects with CQ treatment remain unknown.   
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 5.8 Overall conclusions and future perspectives 
5.8.1 Source and concentrations of zinc with relevance to neuronal injury 
One of the most concerning factors with respect to investigating the toxic effects 
of Zn2+ in cell culture is determining what effects are generated under the most 
physiologically relevant conditions.  Because it presents a simplified and basic system, 
isolated mitochondria allow one to dissect the precise location of Zn2+ actions.  We have 
previously demonstrated that 5-20 µM additions of Zn2+ cause substantial ∆Ψm loss and 
also completely inhibit O2 consumption (Dineley et al., 2005).  However, the actual 
concentrations sensed by mitochondria are much lower, given that 10 µM EGTA is 
present in the suspension solution.  In contrast, in a study by Sensi and colleagues 
(2003b), picomolar concentrations of Zn2+ caused substantial ∆Ψm depolarizations in 
isolated mitochondria.  The high sensitivity of mitochondrial function to such small Zn2+ 
concentrations compared to what we observed may be accounted for by the differences in 
techniques used to measure mitochondrial depolarization – TPP+ electrode vs. Safranin O 
fluorescence, respectively.  Returning to the study by Sensi et al., the authors 
demonstrated that the same picomolar concentrations of Zn2+ increased mitochondrial 
respiration, whereas slightly higher concentrations in the nanomolar range significantly 
inhibited mitochondrial respiration.  However, these values only represent stock Zn2+ 
concentrations added to a mg of mitochondrial protein and do not reflect final 
concentrations in the suspended solution. 
In contrast to isolated mitochondria, it is much more difficult to determine precise 
[Zn2+]i in cells, given the presence of Zn2+-binding proteins and other buffering 
components in the cytoplasm.  Using the potentiometric probe JC-1, we observed only a 
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 modest mitochondrial depolarization in primary neurons exposed to 300 µM Zn2+ in the 
presence of the ionophore sodium pyrithione (Dineley et al., 2000).  Similarly, we 
observed no significant depolarization of neurons exposed up to 30 µM Zn2+ in the 
presence of pyrithione using either Rh123 or TMRM (Chapter 4).  On the contrary, Sensi 
and colleagues demonstrated in subsequent studies in 1999 and 2000, that neurons loaded 
with TMRE underwent substantial loss of ∆Ψm upon acute exposure to kainate and 100-
300 µM Zn2+.  The contrasting effects on mitochondrial function may be explained by 
variable experimental parameters: differences in [Zn2+]i accumulation achieved with 
ionophore vs. stimulus or variability in dye concentrations used.   
Although several studies have established a range of Zn2+ concentrations that 
affect neuronal function in a variety of ways, the critical question is how much [Zn2+]i is 
minimally sufficient to mediate substantial cellular and mitochondrial defects ?  From the 
studies completed in this dissertation, we have demonstrated: (1) oxidant-induced [Zn2+]i 
release in cells sufficient to induce toxicity, (2) mitochondrial transport mechanisms that 
are either uniporter-dependent or uniporter-independent based on the concentrations and 
capacities for Zn2+ uptake, and (3) a concentration-dependent effect on mitochondrial 
movement that occurs at pathophysiological levels.  Interestingly, these effects are 
sensitive to various ranges of Zn2+ concentrations, given that low micromolar Zn2+ 
concentrations do not depolarize mitochondria in cells, yet they effectively stop 
mitochondrial movement (Chapter 4).  Based on our results, it is clear that there are 
several toxic effects mediated by Zn2+ and we have demonstrated that they occur at the 
lowest, pathophysiologically relevant levels in our paradigms.  
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 5.8.2 (Patho)physiological role of synaptic vesicular zinc 
Defined in the early 1990s, the zinc translocation hypothesis claimed that 
synaptically-released Zn2+ from presynaptic vesicles that accumulates into postsynaptic 
neurons may contribute to the excitotoxic brain injury characteristic of stroke, traumatic 
brain injury, or epileptic seizures.  This hypothesis was strengthened by the use of 
extracellular metal chelators (Koh et al., 1996) and specific blockade of Zn2+-permeable 
channels on the postsynaptic membrane (Yin et al., 2002) that substantially reduced the 
Zn2+ accumulation in and subsequent cell death of postsynaptic neurons.  What 
immediately brought the Zn2+ translocation hypothesis into question was the observation 
that in transgenic mice that were deficient in ZnT-3, postsynaptic neurons still 
accumulated Zn2+ upon stimulation and the mice still suffered from kainate-induced 
seizures (Lee et al., 2000).  Interestingly, this Zn2+ accumulation was demonstrated to be 
blocked by EDTA chelation (Frederickson et al., 2002), suggesting either that the 
membrane-impermeant chelator may be able to leech Zn2+ out of the cell or there may be 
an unknown extracellular source for Zn2+ release.  Accordingly, Alan Kay (2003) 
recently demonstrated the visualization of releasable Zn2+ pools from brain slices using 
the Zn2+ fluorophore, FluoZin-3.  From these studies, very little chelatable Zn2+ (~ 2 nM) 
was detected during synaptic transmission, representing the pool released from synaptic 
vesicles into the extracellular space.  In contrast, more Zn2+ (~ 6 nM) was extruded in the 
presence of high K+, but was not seen as released from slices, suggesting that this pool is 
not synaptic, and may be part of a new extracellular pool of Zn2+ that is loosely-
associated with proteins. 
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   Although the extensive evidence described above argues against the zinc 
translocation hypothesis, recent studies have determined that synaptic zinc still has an 
important pathophysiological role during the course of neurodegeneration.  For example, 
a study by Lee and colleagues (2003) demonstrated that amyloid plaque formation was 
reduced in Alzheimer’s disease (AD) transgenic mice, which were also ZnT-3-deficient, 
suggesting that the synaptic Zn2+ is a major contributor to the progression of AD.  In a 
subsequent study by the same group (Lee et al., 2004), they hypothesized that female sex 
hormones reduced synaptic Zn2+, and diminished plaque formation and AD progression.  
The estrogen levels were also inversely related to amounts of ZnT-3 protein in the brain, 
suggesting that estrogen modulation of synaptic Zn2+ may be neuroprotective in AD.  In a 
third and most recent study, Friedlich and colleagues (2004) observed a transgenic mouse 
model for AD, whereby an exchangeable pool of Zn2+ between ZnT-3 and the 
cerebrovascular wall promotes cerebral amyloid angiopathy.  The authors claimed that 
the source of Zn2+ had to be synaptic since the angiopathy was reduced in ZnT-3-/- 
animals.  Furthermore, the condition was only present in the brain and not in peripheral 
organs, and ZnT-3 protein was only found in brain tissue and not in vessel walls or other 
blood components.   
The contradicting data in these most recent studies is comparison to previous ones 
that state an absence of physiological function of ZnT-3 stem from a number of issues.  
First, although ZnT-3 knockout animals exhibit ~ 15% reduction in total brain zinc, they 
are physiologically normal in learning and memory tasks, and are found to grow, 
reproduce and age normally as well.  Second, the absence of histochemically-stainable 
Zn2+ does not preclude the presence of other synaptic pools that cannot be readily 
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 detected.  And finally, that under excitotoxic condition, mice lacking synaptic Zn2+ still 
exhibit neuronal damage from seizures, strongly suggesting that the Zn2+ accumulation 
must be derived from other sources and thereby demoting the role of ZnT-3 as a 
physiological modulator of synaptic Zn2+. 
Given the evidence against the zinc translocation hypothesis, a new model has 
been proposed whereby Zn2+ contribution to neuronal death may be derived from 
multiple sources: (i) from presynaptic vesicles, (ii) from Zn2+-binding proteins, or (iii) 
from mitochondrial stores (Sensi et al., 2003b; Bossy-Wetzel et al., 2004) although we 
have found no evidence of this last pool (Chapter 3).  One of the most likely examples is 
metallothionein, an example of the protein-derived Zn2+ pool which has been 
demonstrated to be a stress-induced “Zn2+ fountain” after nitrosylative (Cuajungco and 
Lees, 1998; Chen et al., 2002) and oxidative (Maret and Vallee, 1998; Aizenman et al., 
2000) stresses.  The observation that MT-III knockout mice exhibit reduced neuronal 
Zn2+ staining after excitotoxic insult (Lee et al., 2002; Lee et al., 2003) suggests that MT-
III may be a major source of toxic Zn2+.  This is not surprising given that with the 
numerous Zn2+-binding proteins and enzymes in the intracellular milieu, the presence of 
oxidant-sensitive Zn2+ stores is a likely and threatening contributing factor to Zn2+-
induced toxicity under stressed conditions.  
5.8.3 Zinc and reactive oxygen species: cause or effect ? 
Oxidative stress is known to disrupt metal homeostasis, but it has also been 
hypothesized that metal release causes neuronal injury through ROS production.  This 
proverbial “chicken and egg” situation begs to question whether it is metal-induced ROS 
production or ROS-mediated metal release that causes neuronal injury.  Indeed, studies 
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 have demonstrated that elevated Zn2+ exposure in vitro mediates neuronal death by free 
radicals, since cells are protected by treatment with antioxidants, such as trolox (Kim et 
al., 1999b) or vitamin D (Lin et al., 2003).  In our isolated mitochondria experiments, we 
observed ROS production upon direct and acute Zn2+ exposure (Dineley et al., 2005).  
Interestingly, as opposed to reversal of Zn2+-induced depolarization or compromised 
respiration upon EGTA addition, we observed no reversal in ROS production with 
chelation, suggesting that ROS production occurs by a more permanent and damaging 
mechanism compared to other mitochondrial disruptions.  In our experiments involving 
Zn2+ modulation of mitochondrial trafficking, we observed that both elevated Zn2+, strong 
oxidizing agents (2,2’-DTDP) or mimicking ROS exposure (H2O2) inhibited 
mitochondrial movement at concentrations toxic to neuronal cultures (Chapter 4).  To 
determine if the effect of Zn2+ on movement was mediated primarily by ROS production, 
we followed the treatments with the reducing agent dithiothreitol (DTT).  DTT provided 
no restoration of movement, indicating that ROS exposure may contribute to the 
movement effect in an irreversible and permanent manner.   
In the reverse manner, it has been demonstrated in cultured cells that both strong 
oxidative (Aizenman et al., 2000) and nitrosylative (Bossy-Wetzel et al., 2004) stresses 
induce high [Zn2+]i in cultured neurons.  It is hypothesized that the subsequent ROS and 
RNS act on thiol bonds of MT to free disulfide linkage-bound Zn2+.  Indeed, we 
demonstrated that 2,2’-DTDP treatment in MT-expressing astrocytes rapidly generated 
[Zn2+]i elevations significantly higher than controls.  These [Zn2+]i rises were diminished 
quickly upon Zn2+ chelation, indicating that Zn2+ was directly released from MT stores 
upon oxidation (Chapter 2).  MT provides a direct linkage between oxidative stress and 
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 metal release given that (1) MT is a metal-binding and antioxidant protein, (2) MT 
mRNA is upregulated in response to both elevated Zn2+ and levels of oxygen, and (3) 
MT-deficient mice and cells exhibit increased sensitivity to oxidative stress (Lazo et al., 
1995) and enhanced apoptosis (Kondo et al., 1997), respectively.  Since mitochondria are 
the primary generators of free radicals within cells, they are another critical linkage 
between Zn2+ and ROS.  The elevated free Zn2+ released from MT then acts on 
mitochondria at specific sites of electron transport to enhance further ROS accumulation 
(Figure 5.1).  This “feed-forward loop” of metal release and oxidative stress suggests that 
regardless of which one begins the cycle, excitotoxic mitochondrial, and subsequent 
neuronal damage, stems from simultaneous potentiation of increased Zn2+ accumulation 
and oxidative stress.  What appears to be a future direction for the field is perhaps 
investigation of how drastic alterations in cellular oxygen in the brain during neurological 
conditions of stroke or cerebral ischemia, contribute to disruption of metal homeostasis 
and subsequent mitochondrial and cellular dysfunction.  
 
MT
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1  “Feed-forward loop” of zinc and reactive oxygen species 
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